Effect of anchomanes difformis extract on biochemical and histological parameters in streptozotocin-induced diabetes and diabetic complications by Alabi, Toyin Dorcas
  
 
 
EFFECT OF ANCHOMANES DIFFORMIS EXTRACT ON BIOCHEMICAL 
AND HISTOLOGICAL PARAMETERS IN STREPTOZOTOCIN-INDUCED 
DIABETES AND DIABETIC COMPLICATIONS 
 
by 
 
TOYIN DORCAS ALABI 
 
Thesis submitted in fulfilment of the requirements for the degree 
 
Doctor of Philosophy: Biomedical Sciences 
 
in the Faculty of Health and Wellness Sciences 
 
at the Cape Peninsula University of Technology 
 
Supervisor: Prof OO Oguntibeju 
Co-supervisor: Dr NL Brooks 
 
Bellville 
October 2019 
 
CPUT copyright information 
The dissertation/thesis may not be published either in part (in scholarly, 
scientific or technical journals), or as a whole (as a monograph), unless 
permission has been obtained from the University 
 
 
i 
 
DECLARATION 
 
I, Toyin Dorcas Alabi, declare that the contents of this thesis represent my own unaided 
work, and that the thesis has not previously been submitted for academic examination 
towards any qualification. Furthermore, it represents my own opinions and not 
necessarily those of the Cape Peninsula University of Technology. 
 
 
 
        26th November 2019 
   
Signed        Date 
 
 
 
 
 
 
  
ii 
 
ABSTRACT 
Diabetes mellitus is one of the major health challenges facing the world today and it is 
not restricted by age, gender, education or urbanisation. Increased oxidative stress, 
inflammation and apoptosis are implicated in the pathogenesis of diabetes mellitus. The 
progression of diabetes mellitus leads to pathological events and alterations in many 
tissues of the body, thereby causing damage to these tissues and organs. Anchomanes 
difformis is has a strong ethnopharmacological relevance and it is known for its diverse 
traditional uses against hyperglycemia, kidney damage, pain, wounds, inflammation, 
onchocerciasis and gastrointestinal pathologies amongst others. Scientific investigations 
have been performed on some of these ethnobotanical claims on Anchomanes difformis 
using animal models. While some of these claims have been established scientifically, 
others are yet to be explored. In vivo experimental study on the leaves of Anchomanes 
difformis revealed its hypoglycemic effect, however, there is no information on the 
possible effect of Anchomanes difformis on oxidative stress, inflammatory mediators and 
apoptosis in diabetes mellitus. Therefore, this study investigated the potential benefits of 
Anchomanes difformis in increased oxidative stress, inflammation and apoptosis in a 
diabetic model. The study also assessed the ameliorative effect of Anchomanes difformis 
in diabetes-induced damage in the organs such as the liver, heart, kidney, testis and 
epididymis.  
The first phase of the study compared the antioxidant capacity and phytochemical 
characterisation of three different solvent extracts; aqueous, ethanolic and methanolic 
from the leaves and rhizome of Anchomanes difformis. All these six extracts (3 extracts 
each from the leaves and rhizome) exhibited antioxidant properties, however aqueous 
extract demonstrated the highest antioxidant potential, hence it was selected for further 
experiment in the study. Furthermore, certain bioactive compounds with antioxidant, 
antidiabetic and anti-inflammatory properties were identified in Anchomanes difformis. 
The second phase of the study involved the induction of diabetes, treatment with AD and 
standard drug and euthanasia followed by biochemical investigations in male Wistar rats. 
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Type 2 diabetes was induced with two-weeks administration of 10% fructose, followed 
by a single intraperitoneal injection of streptozotocin (40mg/kgBW). Dosages of 200 and 
400 mg/kgBW of Anchomanes difformis leaves extract were administered for six weeks 
to diabetic and normal rats which served as treatment controls. The effect of 
Anchomanes difformis on glycemic indices, body weights, relative organ weights, organ 
function markers, antioxidant statuses, inflammatory biomarkers, apoptosis and 
structural integrity of the liver, kidney, pancreas, testis and the epididymis were 
conducted. The administration of streptozotocin led to hyperglycemia, hyperlipidemia, 
body weight loss, increased inflammation, oxidative stress and apoptosis, reduced 
sperm concentration, viability and distorted sperm morphology. It also induced tissue 
damage in the liver, kidney, pancreas, testis and epididymis. Treatment with both doses 
of Anchomanes difformis improved organ functions, markedly reduced and repaired 
tissue damage in a dose-dependent manner and comparable to the standard drug; 
glibenclamide. Furthermore, Anchomanes difformis distinctly lowered blood glucose, 
abnormal lipid levels, enhanced antioxidant status, modulated inflammation, reduced 
apoptosis and increased sperm functions better than glibenclamide in diabetic rats.  
In conclusion, the protective and ameliorative properties of Anchomanes difformis 
projects it as a potential new, reliable therapeutic agent that should be explored and 
considered in the management of diabetes mellitus and its associated complications. 
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PREFACE 
This thesis consists of eight chapters, and it is presented in an article-based format, the 
chapters are written according to the guidelines of the journals where they are published 
or submitted for review. 
 
 
 
Chapter one is a brief introduction of diabetes and its significance, chapter two (literature 
review) provides an overview of diabetes mellitus, oxidative stress, inflammation, 
apoptosis and diabetic complications. It also presents background information on 
Anchomanes difformis and its biological relevance. The literature review has been 
published as a book chapter in the book “Bioactive compounds of medicinal plants: 
Properties and potentials for human health”. Chapters three, four, five, six and seven are 
research articles which presents the results of the experimental investigations carried 
out in this study as shown in the chart above. Chapter three has been published in the 
“Natural Product Journal”. Chapter four is under review in the “Journal of 
Ethnopharmacology”. Chapter five has been published in “Biomedicines”. Chapter six 
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has been submitted to the “European Journal of Integrative Medicine”. Chapter seven 
has been submitted to “Andrologia” journal for publication. Chapter eight is a general 
discussion and conclusion of the study as a whole. 
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DEFINITION OF TERMS 
 
Ameliorate: to improve or make an unpleasant situation better, more bearable or more 
satisfactory. 
Antioxidant: a molecule that inhibits the oxidation of other molecules. Oxidation is a 
chemical reaction that can produce free radicals, leading to chain reactions that may 
damage cells. Antioxidantssuch as thiols or ascorbic acid (vitamin C) terminate these 
chain reactions. 
Apoptosis: is a form of cell death where the programmed cascades of events leads to 
an eventual elimination of the cells without releasing the cell content into the surrounding 
environment in the system.  
Decoction: a concentrated liquor resulting from heating or boiling a substance, 
especially a medicinal preparation made from a plant and contains the constituents or 
principles of the substance (plant) soluble in boiling water. 
Diuresis: increased or excessive production of urine.   
Folklore: the traditional beliefs, myths, tales, and practices of a people which have been 
disseminated in an informal manner from generations to genrations.  
Inflammation: is a part of the complex biological processes involved in the protective 
response of the tissues to harmful stimuli such as pathogens, damaged cells and irritants 
in or exposed to the body. 
Oxidative stress: An imbalance between the systemic manifestation of reactive oxygen 
species and a biological system's ability to readily detoxify the reactive intermediates or 
to repair the resulting damage. 
Pathogenesis: the origin and development of a disease, it involves the biological 
mechanism(s) that leads to the diseased state.  
Phytochemicals: chemicals compounds occuring in plants and have protective or 
disease-preventive properties. 
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     CHAPTER ONE 
1 INTRODUCTION 
 
1.1 Statement of Research Problem 
Diabetes mellitus is one of the most prevalent pathological conditions worldwide today. 
Constant hyperglycemia as a result of metabolic abnormalities in diabetic condition 
contributes to the development of diabetic complications such as cardiomyopathy, 
retinopathy, nephropathy, hepatic injury and infertility. Furthermore, the enhanced 
generation of reactive oxygen species in diabetes leads to increased inflammatory 
response/mediators, lipid and lipoprotein modifications, nitric oxide production and all of 
these have been implicated in diabetic complications. Conventional drugs such as 
insulin, metformin, sulfonylureas are being used in the treatment of diabetes, however, 
the cost and adverse effects as a result of the use of these drugs necessitated the need 
for alternative medicine. This drive for alternative sources of treatment has led to the 
exploration of a lot of plant reserves such as Anchomanes difformis. This study therefore 
examined in detail the potential effects of Anchomanes difformis in diabetic animal model 
and the possibility of its contributions as an effective remedy in the treatment of diabetes 
and its complications. 
 
1.2 Background 
Diabetes mellitus (DM) is a metabolic disorder that is characterized by persistent 
hyperglycemia which is either due to inadequate insulin production or impaired response 
of body cells to insulin secretion or both (Maritim et al., 2003; Johnson et al., 2019). 
Diabetes results to over 4 million deaths in a year as reported by the International 
Diabetes Federation (IDF Diabetes Atlas, 2019). Diabetes has been ranked as the 7th 
leading cause of death (WHO, 2016). An estimated increase of diabetic patient from 382 
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million (2013) to 552 million in 2030 and 700 million in 2045 has been predicted (Vos et 
al., 2012; Melmed et al., 2015; IDF Diabetes Atlas, 2019). The most prevalent types of 
DM are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM 
accounts for about 10% of all cases of DM with children being diagnosed majorly, while 
T2DM accounts for about 90% of all diabetes occurrence (IDF Diabetes Atlas, 2019). 
 
Hyperglycemia enhances the production of reactive oxygen species (ROS) which is 
highly implicated in the development of oxidative stress (Wright et al., 2006). Some of 
the mechanisms by which hyperglycemia leads to oxidative stress include the increased 
production of superoxide anion which activates nuclear factor kappa-light-chain 
enhancer of activated beta cells (NFĸB); a transcription factor that leads to the increased 
expression of inducible nitric oxide synthase (iNOS). This increased iNOS results in 
enhanced production of nitric oxide (NO). Nitric oxide rapidly reacts with superoxide 
anion when present in high concentrations to form a strong oxidant; peroxynitrite 
(Beckman & Koppenol, 1996; Ramdial et al., 2017) which exerts its toxic effects through 
oxidation of proteins, initiation of lipid peroxidation and nitration of protein. Triggering of 
the inflammatory response is another mechanism whereby hyperglycemia causes 
oxidative stress. Hyperglycemia contributes to increased glycation of proteins and lipids 
to form advanced glycation end products (AGEs) (Lyons & Jenkins, 1997). AGEs bind to 
their receptors (RAGE) on different cells and macrophages leading to intracellular 
generation of ROS which in turn activates NFĸB causing increased expression of a 
variety of cytokines such as TNF-α and TNF-ß (tumor necrosis factor alpha and beta), 
interleukins (IL-1, IL-6, IL-8, IL-18) and interferon-γ. Also, hyperglycemia causes lipid 
and lipoprotein modification which results in glycation and glyoxidation of proteins, lipid 
peroxidation and lipoxidation of lipoproteins (Wright et al., 2006; Moldogazieva et al., 
2019). 
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Severe lipid peroxidation, protein oxidation and nitration of proteins leads to oxidative 
stress which is an important risk factor in the development of diabetic complications such 
as retinopathy (Pan et al., 2008), nephropathy (Ceriello et al., 2016), cardiomyopathy 
(Miranda-Díaz et al., 2016), and liver injury (Ghanbari et al., 2016). Also, the 
overproduction of ROS leads to the inactivation of antiatherosclerotic enzymes resulting 
in atherosclerosis and ultimately cardiomyopathy (Saely et al., 2004; Svensson et al., 
2004). Oxidised lipoproteins have pro-atherogenic effects which include increased 
smooth muscle cell proliferation, increased apoptosis in endothelial cells, activation of 
protein kinase-C and transforming growth factor-beta (TGF-β), increased non bio-
availability of nitric oxide, pro-inflammatory effects and inhibition of antioxidant enzymes 
(Jenkins et al., 2004). 
 
The increased production of exogenous and endogenous ROS can be detrimental to the 
biological functions of sperm which is associated with male infertility (Sonmez et al., 
2005; Dutta et al., 2019) and it is characterized by ATP depletion leading to insufficient 
axonemal phosphorylation and lipid peroxidation (de Lamirande et al., 1997). The sperm 
plasma membrane contains a high amount of unsaturated fatty acids which makes it 
highly susceptible to peroxidative damage (Aitken, 2017). The lipid peroxidation destroys 
the structure of lipid matrix in the membranes of sperm, and it is associated with loss of 
motility and the defects of membrane integrity (Sharma & Agarwal, 1996; de Lamirande 
et al., 1997; Karunakaran et al., 2017). It is hypothesized that insulin is required in the 
initiation and continuance of spermatogenesis (Maresch et al., 2018). Also, the 
maintenance of spermatogenic process necessitates the conversion of glucose to lactate 
by the sertoli cells. Hence, the supply of glucose to the germ cells via the blood is strictly 
controlled by the blood-testis-barrier. This is however disrupted in diabetic conditions 
thereby affecting spermatogenesis (Reira et al., 2009; Alves et al., 2013). Furthermore, 
heightened ROS affects sperm viability through dysregulated apoptosis. Apoptosis can 
occur either in the germ cells during spermatogenesis or in mature cells during sperm 
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release (spermiation) (Muratori et al., 2015). However, in diabetic conditions which is 
characterized by increased oxidative stress, apoptosis is poorly regulated especially in 
the spermiation phase, resulting in the release of non-viable sperm cells and eventual 
poor sperm quality (Muratori et al., 2015). 
 
Streptozotocin (STZ); a diabetogenic agent is used to induce both IDDM and NIDDM 
(Szkudelski 2001). It is well known for its cytotoxic action mediated by ROS on beta cells 
of the rat pancreas and its characteristic alterations in blood insulin and glucose 
concentration by decreasing insulin biosynthesis and secretion (Bolaffi et al., 1987; 
Nukatsuka et al., 1990b Szkudelski, 2001) and impairing glucose oxidation (Bedoya et 
al., 1996). The pancreatic beta cells take up STZ through the glucose transporter 
(GLUT2), STZ then causes alkylation of DNA which is the main factor of beta cell death 
(Delaney et al., 1995; Elsner et al., 2000). This alkylating potency of STZ is attributed to 
its methyl-nitrosourea moiety especially at the O6 position of guanine (Schnedl et al., 
1994; Murata et al., 1999; Lenzen 2008). The transfer of the methyl group from STZ to 
the DNA molecule causes damage which subsequently results in DNA fragmentation 
(Pieper et al., 1999) and ultimately destruction of beta cells by necrosis. 
 
Various drugs are used in the treatment of diabetes in addition to insulin; these include 
sulfonylurea, metformin, alpha-glucose inhibitors, thiazolidinediones, meglitinides, D-
PP-4 inhibitors. However, these drugs have limitations due to their side effects such as 
gastrointestinal disturbances, hypoglycemia, urinary tract infection, dizziness, 
constipation and certain risks such as increased rate of lactic acidosis (Wang et al., 2003; 
Fimognari et al., 2006), liver damage (Hinterthuer, 2008) and cardiovascular risk 
(European Medicines Agency, 2009). These risks and side effects along with other 
factors such as cost have led to the search for alternative sources especially medicinal 
plants with natural anti-diabetic potentials.   
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Anchomanes difformis of the family Araceae is a large herbaceous plant that grows 
mostly in the West African forests to a height of approximately two metres (Eneojo et al., 
2011). A. difformis grows from a horizontal tuber that can measure up to 80 cm by 20 cm 
and produces one huge, much-divided leaf with a stout prickly stem (Afolayan et al., 
2012). These two parts have been used for traditional purposes such as in the treatment 
of river blindness, ulcer, dysentery and diuresis (Okpo et al., 2011). A. difformis contains 
flavonoids, glycoside, tannins (Aliyu et al., 2008b). Flavonoids have anti-inflammatory, 
anti-tumor, anti-allergy, anti-platelets, antiviral and antioxidant activities (Buhler and 
Miranda, 2000). A. difformis has been shown to possess the following medicinal 
properties such as antioxidant, anti-inflammatory (Adebayo et al., 2014), hypoglycemic 
(Adeyemi et al., 2015), gastroprotective (Okpo et al., 2011), antimicrobial (Eneojo et al., 
2011), and anti-ulcerative. However, there is very little or no reports on the mechanism 
by which AD exerts these medicinal properties especially in diabetes. Previous studies 
carried out on the anti-diabetic properties of A. difformis has been very limited and 
ambiguous, hence the need to examine in detail, its antidiabetic, antioxidant, anti-
inflammatory activities as well as the mechanisms of actions in animal model. 
 
1.3 Rationale for this study 
Diabetes mellitus is one of the most common chronic diseases in nearly all countries and 
continues to increase in numbers and significance with it taking about about 10% of the 
global health expenditure (IDF Diabetes Atlas, 2019). The prevalence of T2DM over 
T1DM and the associated complications in the management of T2DM is a strong 
motivation for this study. Also limitations in the use of current anti-hyperglycemic 
medications due to their high cost, limited action, secondary failure rates and 
accompanying side effects (Watcher, 2010, Baggio and Drucker, 2008) has necessitated 
the need for alternative therapies with the aim to discover other therapeutic agents that 
could be effective in the management and prevention of diabetes and its complications. 
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Oxidative stress and inflammatory response play a pivotal role in the development of 
diabetic complications (Pitocco et al., 2013, Ryan et al., 2009). A. difformis has been 
scientifically proven to possess anti-oxidant and anti-inflammatory capabilities (Aliyu et 
al., 2008 and Adebayo et al., 2014) and other pharmacological potentials such as 
hypoglycemic (Adeyemi et al., 2015), antimicrobial (Eneojo et al., 2011), anti-nociceptive 
(Adebayo et al., 2014) and gastroprotective (Okpo et al., 2011). However, these studies 
are limited in scope; also, to the best of my knowledge, no research has been carried 
out to demonstrate the effect of this plant in STZ and fructose-induced type 2 diabetes 
and diabetic complications such as cardiomyopathy, hepatopathy, nephropathy and 
infertility. These therefore, calls for the need to explore the effects of this plant in diabetes 
and its complications. 
 
This study wil investigate how Anchomanes difformis could ameliorate and prevent the 
development of type 2 diabetes melitus and its complications due to oxidative damage, 
inflammation, apoptosis and lipid peroxidation. It is envisaged that the findings would 
provide a better understanding and insight into the possible mechanisms of action of the 
plant extract in diabetic aninmal model. 
1.4 Aim 
This research study was conducted to investigate the antidiabetic properties of A. 
difformis administration in fructose and streptozotocin-induced type 2 diabetes mellitus. 
It also examined the potential ability of AD to prevent or ameliorate resultant diabetic 
complications such as cardiomyopathy, nephropathy, hepatopathy and reproductive 
dysfunctions as evaluated through the following: 
1. Antioxidant status 
2. Inflammatory response 
3. Apoptotic protein 
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4. Glycemic and lipidemic index 
5. Biomarkers of organ function 
6. Reproductive parameters 
7. Histological alterations in the organs 
 
1.5 Objectives 
In order to pragmatically achieve the above-mentioned aim, the following specified 
objectives were performed: 
1. Evaluation of the phytochemical characterization and antioxidant capacities of 
three solvent extracts from the leaves and rhizome of A. difformis, for 
optimization. 
2. Investigation of the hypoglycemic and hypolipidemic potential of A. difformis in 
normal and diabetic rats. 
3. Assessment of the impact of A. difformis administration on the liver and kidney 
functions in normal and diabetic rats. 
4. Measurement of the antioxidant ability of A. difformis in the serum, liver, kidney 
and heart of diabetic and normal rats. 
5. Determination of the influence of A. difformis on the inflammatory response and 
apoptosis in the liver, kidney and heart of diabetic and normal rats. 
6. Estimation of the effect of A. difformis on sperm concentration, motility, viability 
and morphology in diabetic and non-diabetic rats. 
 
1.6 Research Questions 
 What are the potential effects of A. difformis on serum lipid profile and glycemic 
parameters in diabetic and non-diabetic male Wistar rats? 
 Does A. difformis have potential effects on the oxidative status and antioxidant 
systems in diabetic and non-diabetic male Wistar rats? 
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 What are the potential effects of A. difformis on inflammatory biomarkers in the 
heart and kidney of diabetic and non-diabetic male Wistar rats? 
 Does A. difformis provide any potential effects on expression of apoptotic 
proteins in diabetic rats and non-diabetic male Wistar rats? 
 What are the potential effects of A. difformis on liver and kidney function in 
diabetic rats and non-diabetic male Wistar rats? 
 What are the potential effects of A. difformis on the reproductive system of 
diabetic and non-diabetic rats? 
 What are the concentrations of total polyphenol content and the individual 
phytochemicals present in A. difformis plant extract?  
 
1.7 Hypothesis 
H0: Aqueous leaf extract of Anchomanes difformis (200mg and 400mg) will not 
ameliorate diabetes mellitus type 2 and will not prevent the development of diabetic 
complications and infertility 
H1: Aqueous leaf extract of Anchomanes difformis (200mg and 400mg) will ameliorate 
diabetes mellitus type 2 and will prevent development of diabetic complications. 
1.8 Significance of the study 
This study provided insight into the pharmacological effects of A. difformis on 
inflammatory, oxidative and apoptotic parameters in diabetic cardiomyopathy, 
nephropathy and liver injury resulting from streptozotocin-induced damage in diabetic 
male Wistar rats. Findings of this research could contribute to the treatment and 
management of diabetes and male infertility. The research outputs from this study 
include published manuscripts in various reputable, peer-reviewed journals of high 
impact factors. Outcomes from this research was presented at local and international 
conferences, workshops and seminars which contributed immensely to the pool of 
scientific knowledge in diabetic research. 
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2.1 Diabetes mellitus 
Diabetes mellitus is strongly associated with persistent hyperglycemia and other 
metabolic disorders including insulin resistance, impaired glucose tolerance 
dyslipidemia, obesity and hypertension (American Diabetes Association, 2017). 
Diabetes mellitus is associated with the partial or complete destruction of pancreatic β-
cells which consequently leads to insulin deficiency which may further result in insulin 
resistance (American Diabetes Association, 2010).  
 
2.2 Types of Diabetes mellitus 
There are two major types of diabetes mellitus; type-1 which occurs when the body 
does not produce insulin and it is referred to as insulin-dependent diabetes mellitus 
(IDDM), type-2 which occurs when the body does not secret enough insulin or the cells 
does not respond properly to insulin, this is referred to as non-insulin dependent 
diabetes mellitus (NIDDM) or insulin resistance diabetes (DeFronzo et al., 1997; 
Zimmet et al., 2004). There are other classes of diabetes mellitus which are less 
prevalent, these include gestational diabetes, monogenic diabetes and secondary 
diabetes (Hu & Jia, 2018).  
 
2.2.1 Type 1 diabetes 
T1DM is an autoimmune disease where the beta cells of the pancreas are being attacked 
and destroyed by the body’s immune system, leading to little or no production of the 
insulin. The mechanisms underlying the destruction of the beta cells are not fully 
understood, however, genetic susceptibility and environmental factors have been 
implicated (Maahs et al., 2010; Atkinson et al., 2014). Although, T1DM is prevalent in 
children and young people, it can occur in any age group or be diagnosed in adults. 
T1DM can be effectively managed with daily dose of insulin which delays and prevent 
the development of diabetic complications (Alberti et al., 1998). Due to the involvement 
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of auto-immune reactions in the pathogenesis of T1DM, a preventive control is yet to be 
unraveled. 
 
2.2.2 Type 2 diabetes 
T2DM is uniquely characterized with insulin resistance, unlike T1DM which is majorly 
triggered by autoimmune responses, T2DM has multifactorial aetiology ranging from 
obesity, increasing age, heredity, sedentary lifestyle and environmental factors (Basu 
et al., 2013). The increased production of hepatic glucose, reduced secretion of insulin 
and or impaired response to insulin secreted (also known as insulin resistance) are 
fundamental defects in the development of T2DM (Stumvoll et al., 2005). In the course 
of insulin resistance, the insulin secreted is ineffective and the beta cells make efforts 
to overcome it by increased production of insulin (Kumar, 2020). A prolonged demand 
for increased insulin secretion in turns weakens the beta cells of the pancreas and 
eventually leads to decreased production of insulin. Insulin resistance is highly 
implicated in the development of the metabolic, cardiovascular, and endocrine 
disorders in T2DM (Kumar, 2020). 
 
2.3 Oxidative stress in Diabetes  
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced in 
the body, during normal metabolism and energy production (Mayi et al., 2004). They are 
produced to help the normal healthy tissues perform physiological roles such as 
signaling, regulation of signal transduction and gene expression, activation of receptor 
and nuclear transduction (Valko et al., 2007). Oxidative stress occurs as a result of 
imbalance between the systemic production of these free radicals; (ROS and RNS) and 
the antioxidant capacity of the system to readily detoxify and eliminate the reactive 
intermediates or to repair the resulting damage (Aliyu et al., 2013). Constant 
hyperglycemia is one of the major factors leading to oxidative stress. Hyperglycemia 
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enhances the production of reactive oxygen species which is highly implicated in the 
development of oxidative stress (Wright et al., 2006).  
 
Some of the molecular mechanisms by which hyperglycemia leads to oxidative stress 
and subsequently diabetes includes the increased activation of the hexosamine 
pathway, polyol pathway, and the protein kinase C (PKC) pathway and the formation 
of AGEs (Rolo & Palmeira, 2006). During persistent hyperglycemia, overproduction of 
free radicals occurs, and this leads to DNA damage (Styskal et al., 2012). A DNA repair 
enzyme: Poly-ADP-ribose polymerase 1 (PARP-1) is subsequently activated and 
impedes the activity of glyceraldehyde-3-phophate dehydrogenase (GAPDH). GAPDH 
is an important enzyme in the breakdown of glucose and it catalyzes the oxidation of 
glyceraldehyde-3-phosphate (GAP) (Giacco et al., 2010; Ighodaro, 2018). The 
inhibition of GAPDH leads to the accumulation of GAP which further activates the PKC, 
hexosamine, polyol and AGEs pathways (Rolo and Palmeira, 2006). 
 
Furthermore, hyperglycemia is strongly associated with glycation and glycoxidation of 
lipoproteins, ROS resulting from hyperglycemia contribute to initiation of lipid 
peroxidation (Cosentino et al., 1997) and ultimately lipoxidation to yield advanced 
lipoxidation end products (ALEs) (Esterbauer et al., 1992; Esterbauer et al., 1991; 
Spiteller, 1998). Severe lipid peroxidation, protein oxidation and nitration of proteins 
leads to oxidative stress, increased inflammation and apoptosis which are important 
factors in the development of diabetic complications such as retinopathy (Pan et al., 
2008), nephropathy, liver injury, and cardiovascular diseases (Januszewski et al., 
2003). Figure 2.1 shows the relationship between hyperglycemia, oxidative stress, 
inflammation and apoptosis and their importance in the progression of diabetes.  
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Figure 0.1: The involvement of hyperglycemia, oxidative stress, inflammation and apoptosis in 
the progression diabetes mellitus and complications. 
 
2.4 Diabetic Complications 
Chronic hyperglycemia affects almost all organs of the body. This is probably due to its 
presence in the blood which is supplied to almost all parts of the body (Dang, 2012). 
Scientific evidences show that complications result later after the onset of diabetes. 
These complications with etiology linked to diabetes are referred to as diabetic 
complications (DCM) (Resnick and Howard 2002; Singh et al., 2013). DCM present 
structural pathologies in the organs such as kidney, retina, nerves, heart and blood 
vessels. The severity of DCM has been strongly correlated with the duration of the 
disease and the degree of glycemic control (Resnick and Howard 2002). DCM is the 
principal cause of morbidity and mortality in diabetic patients (Nicholson 2006; Koulis 
et al., 2015), with etiology linked to multifaceted mechanisms (Pop-Busui et al., 2006).  
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2.4.1 Classification of Diabetic Complications 
DCM can be broadly categorized into two, microvascular and macrovascular 
complications. Microvascular complications stem from alterations in the small vessels 
and capillaries and are generally reported in people living with diabetes (Kulkarni et al., 
2016; Gæde et al., 2003;). It could be caused by several risk factors such as 
hyperlipidemia, hyperglycemia, hypertension. However, hyperglycemia seems to be 
the chief cause of microvascular complications (Solini et al., 2012). Microvascular 
complications are significant in diabetes mellitus as its progression can lead to visual 
impairment (retinopathy), kidney damage (nephropathy), nerves dysfunctions 
(neuropathy) and dementia among others (Avogaro & Fadini, 2019). These 
microvascular modifications are strongly connected to macrovascular complications as 
they are observed in other organs including the heart (Paulus & Tschöpe, 2013; 
Avogaro & Fadini, 2019). 
 
Macrovascular complications arise from defects in the large vessels such as the 
arteries and the veins (Kulkarni et al., 2016). Atherosclerosis is the major mechanism 
involved in the development of macrovascular complications, and it is a resultant effect 
of chronic inflammation and injuries to the walls of the arteries (Fowler, 2008). 
Macrovascular pathologies usually end in cardiovascular diseases and related 
conditions, which is highly associated with diabetes (Laing et al., 2003; Fowler, 2008). 
 
2.4.2 Diabetic Cardiomyopathy 
Constant hyperglycemia is a key factor in the progression of diabetic cardiomyopathy 
(Fuentes-Antras et al., 2015); a pathological condition that alters structure and function 
of the heart muscle in diabetic subjects (Wang & Hill, 2015). Persistent high glucose 
levels in the blood can lead to mitochondrial impairment, hypertrophy and degradation 
in the cardiac muscle cell, as well as myocardial dilatation and eventual dysfunction of 
21 
 
the systolic and diastolic function of the left ventricle (Yue et al., 2017). Other factors 
implicated in the pathogenesis of diabetic cardiomyopathy include oxidative stress and 
inflammation. Oxidative stress caused by constant hyperglycemia triggers the 
production of AGEs which affects the structural functions of proteins in the heart 
(Nishikawa et al., 2000). Also, increased recruitment of cytokines disrupts homeostasis 
of the myocytes thereby affecting the contractility and remodeling of the heart muscle 
(Shi et al., 2018). 
  
2.4.3 Diabetic Nephropathy 
Diabetic nephropathy (DN); also referred to as diabetic kidney disease is an 
heterogenous condition in which many pathologies may exist alongside and it has been 
majorly implicated in end-stage renal disease (Rivero-González et al., 2017; Avogaro 
and Fadini, 2019). The presence of hyperglycemia with inflammation affects the 
structure of the glomerular endothelium. This leads to alteration in the permeability and 
selectivity of the glomeruli and subsequently apoptosis of the glomerular cells. 
Abnormalities in angiogenesis are also observed in DN (Jeansson et al., 2011). 
Maladaptive expression of growth factors such as vascular endothelial growth factor 
(VEGF) as a result of irregular angiogenesis further leads to albuminuria (Avogaro and 
Fadini, 2019). Pathological features seen in DN include thickening of the glomerular 
basement membrane, albuminuria and loss of podocytes (Wharram et al., 2005). DN 
can be managed by effective glycemic control and amelioration of dyslipidemia (John, 
2016). 
 
2.4.4 Reproductive Complications of Diabetes 
Diabetes mellitus adversely affects spermatogenesis and lead to male infertility through 
oxidative stress and endocrine disorder (Johnson et al., 2019). Also, impaired 
spermatogenesis and DNA damage are linked to insulin resistance; a typical 
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characteristics of diabetes mellitus (Glazer et al., 2017). Oxidative stress has been 
highly implicated in male infertility, it leads to altered protein expression in the seminal 
plasma which is a source of antioxidant defense of the spermatozoa (Agarwal et al., 
2014). Increased oxidative stress also leads to lipid peroxidation of the poly unsaturated 
fatty acids of the sperm membrane (Tremellen, 2008), mitochondrial DNA mutations 
and damage (Agarwal et al., 2014) resulting in apoptosis (Wang et al., 2003). Nuclear 
DNA fragmentation is also a resultant effect of oxidative stress in the spermatozoa 
(Henkel et al., 2005). Diabetes also have impact on the sexual functions due to its 
influence on the endocrine system, which in turn affects spermatogenic processes 
(Sexton & Jarrow, 1997). Glycolysis and oxidative phosphorylation are major supplies 
of energy in the spermatozoa. The deficiency of insulin causes endocrine disturbances 
(Omolaoye & du Plessis, 2018), thereby altering glucose homeostasis in the gonads. 
Reports show that Leydig cell function and reproductive hormones such as 
testosterone, follicle stimulating hormone, luteinizing hormone are reduced in diabetes 
mellitus (Condorelli et al., 2018). 
 
2.5 Medicinal Plants and the Management of Diabetes Mellitus  
Medicinal plants are plants with potency to prevent and ameliorate specific ailment and 
pathological conditions (Nwachukwu et al., 2011; Nwachukwu et al., 2012). Apart from 
the well-known fact that plants serve as a source of food, it is also used for medicinal 
purposes (Obi, 2011). Many of these plants are used as spices and local remedies and 
sometimes added to foods for supplementation or as treatment regimens (Okwu and 
Ibeawuchi, 2005). 
 
Medicinal plants are of great importance to the health of individuals and communities 
(Edeoga et al., 2005). The medicinal value of plants is attributed to certain bioactive 
chemical substances present in those plants, which produce definite physiological 
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actions in the human body (Edeoga et al., 2005). Some of the bioactive constituents in 
plants that are of high importance include alkaloids, tannins, flavonoids and phenolic 
compounds (Soetan and Oyewole, 2009) and they elicit antioxidant, anticancer, anti-
inflammatory, antimalarial properties amongst many others (Buhler and Miranda, 
2000). These bioactive constituents are often referred to as phytochemicals. 
 
2.6 Anchomanes difformis; its medicinal properties and potentials  
Anchomanes difformis is a plant with many reported therapeutic properties (Adebayo 
et al., 2014; Oghale and Idu, 2015b; Okpo et al., 2011; Osho and Adetunji, 2010) and 
it is commonly used in traditional medicine to treat diseases with pathogenesis linked 
to oxidative stress among other factors (Oyetayo, 2007). A. difformis (Blume) is a 
specie of flowering plants in the family Araceae, an herbaceous plant with prickly stem 
(up to 2 cm high) having huge divided leaf and spathe that arise from a horizontal tuber 
(which could be up to 80cm long and 20cm wide) growing as wild yam in the moist and 
shady places of tropical African forest (Afolayan et al., 2012). It is prevalent in West 
African countries such as Ghana, Ivory Coast, Nigeria, Togo, Sierra Leone, Senegal 
and Guinea (Adebayo et al., 2014) and also found in southern-tropical Africa; Zambia, 
and Angola, (Boudet et al.,1986) Tanzania and Uganda. 
 
A. Difformis have a wide range of  local names which is based on the location; in Nigeria 
it is called ìgo lángbòdó, ògìrìòsákó (YORUBA), oje, olumahi (IGBO), chakara, hántsàr 
gàdaá, hántsàr giawaá (HAUSA), eba enàη (EFIK); in Zambia, Kabaka-kachulu 
(LUNDA); in Ivory Coast, niamé kwanba (BAULE), eupé, niamatimi (AKAN-ASANTE),  
kohodié (ABURE), alomé (AKYE), tupain (ANYI); in Sierra Leone, a-thoηbothigba 
(TEMNE), kalilugbo (MENDE-KPA), alatala-kunde-na (SUSU-DYALONKE), in Ghana, 
atõe, nyame kyin (FANTE),  lukpogu (DAGBANI); in Senegal, éken (DIOLA); in Togo,  
nau (TEM) (Eneojo et al., 2011). 
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Figure 0.2: Plate 1 is the Leaves of A. difformis and Plate 2 is the Rhizome of A. difformis. 
 
2.7 Folkloric Uses of A. difformis 
Medicinal plants have been used for various traditional purposes varying from one 
community to another. Majority of people especially from the underdeveloped and 
developing countries, rely on traditional plant usage for their day-to-day health care 
needs (Eneojo et al., 2011; Gurib-Fakim, 2006), mostly due to the high cost of 
conventional health care or side effects of drugs used. A. difformis has been reported for 
its wide range of traditional uses, some of which have been scientifically proven and 
confirmed. Different parts of the plants (leaves, stem and tuber) are used to treat diverse 
complications and ailments (Fongod et al., 2014; Olawale et al., 2013). 
 
The decoction from the leaves of A. difformis is traditionally used as an anti-bacterial 
agent particularly against Staphylococcus aureus in northern Nigeria (Aliyu et al., 
2008a); to ameliorate pain and inflammation (Adebayo et al., 2014), in the treatment of 
cough, ulcer and asthma in southern Nigeria, (Idu et al., 2003). The rhizome has been 
used for the treatment of many disease conditions in various parts of the world, 
commonly Africa. In Ivory Coast, it is considered to be a powerful purgative and it is used 
to treat oedema, control complications during child delivery, as an antidote to poison as 
well as a strong diuretic for treating urethral discharge, jaundice and kidney pains (Akah 
and Njike, 1990). In Nigeria, the peeled tuber soaked in water is used in treating cases 
Plate 1 Plate 2 
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of dysentery and diarrhea (Eneojo et al., 2011). In some part of Africa such as Tanzania, 
the juice from the root tuber is used as eye drop in the treatment of river blindness (Gills, 
1992). The decoction from the tuber is used to treat cough, diabetes, dysentery and 
throat-related problems (Oyetayo, 2007).  Most of the ethno-medicinal uses of A. 
difformis has been scientifically proven and established (Table 2.1). 
 
Table 0.1: Scientific confirmation of some folkloric uses of A. difformis 
Folklore (scientifically 
proven) 
Parts Used Reference 
Anti-diabetes leaf (ethanolic extract) 
rhizome (ethanolic extract) 
Adeyemi et al., 2015  
Aderonke and 
Ezinwanne, 2015 
Anti-inflammation leaf (ethanolic extract) Adebayo et al., 2014 
Pain killer/analgesic leaf (ethanolic fraction) 
rhizome (ethanolic fraction) 
Adebayo et al., 2014  
Gabriel et al., 2013 
Anti-ulcer & gastro-
protective 
rhizome (ethyl acetate extract) 
leaf and rhizome (ethanol:methanol:water) 
Okpo, 2011 
Eneojo et al., 2011  
Anti-asthma rhizome (aqueous fraction) Oghale and Idu, 2015b 
Dysentery and diarrhea leaf and rhizome (ethanol:methanol:water) Eneojo et al., 2011  
Anti-malarial rhizome (methanolic, aqueous 
and dichloromethane fractions) 
Bero et al., 2009 
Anti-onchocercal  
(river blindness) 
rhizome (methanolic extract) Nkoh et al., 2015 
Anti-trypanosomal rhizome (dichloromethane extract) 
aqueous and methanolic fractions 
Bero et al., 2011 
Atawodi, 2005 
Anti-microbial  
 
leaf and rhizome (ethanol:methanol:water) 
leaf and rhizome extracts 
Eneojo et al., 2011  
Agyare et al., 2016 
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2.8 Nutritive value of A. difformis 
The leaves of A. difformis are consumed as vegetables in some states in Nigeria (Obi, 
2011; Olawale et al., 2013 and some other West African countries. Proximate analysis 
carried out on the leaves revealed that it contains carbohydrate 58.63%, crude protein 
30.55%, crude fiber 14.77%, fat and oil 0.49%, ash 11.71% and moisture content 12.39% 
(Oyeyemi and Tadela, 2014). The crude protein content (30.55%) of A. difformis leaves 
when compared with some other vegetables such as Momordica balsamina (11.29%), 
Moringa oleifera (20.72%), Lesianthera africana leaves (13.10-14.90%), Ocimum 
gratissimum (8.00%) and Hibiscus esculentus (8.00%) is found to be relatively higher 
(Akindahunsi and Salawu, 2005; Oduro et al., 2008).  The high protein value in the leaves 
of A. difformis suggests a potential source of plant protein and therefore, can be used as 
protein supplement in diet. 
 
A. difformis is also considered to be rich in essential minerals (Aliyu et al., 2008b). 
Essential mineral elements play significant roles in human nutrition and metabolism 
(Soetan et al., 2010), and their deficiencies could lead to anemia (iron), low glucose 
tolerance and liver necrosis (selenium), hypersensitivity (chloride) and reduced fertility 
(lithium) (Turan et al., 2003). Certain macro elements play physiological roles such as 
structural (calcium in bones, iron in heme, phosphorus in phospholipids and nucleic 
acids), catalytic (magnesium) and signal transduction; calcium in nerve and muscular 
cells (O'Dell and Sunde, 1997). Potassium, Sodium and chlorine are essential for the 
maintenance of osmotic balance between cells and the interstitial fluid (Turan et al., 
2003; Soetan et al., 2010). 
 
Other micro elements such as manganese and copper serve as co-factors of certain 
enzymes and are indispensable in numerous biochemical pathways that are essential 
for the normal functioning of the cell (Soetan et al., 2010). These include protein 
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synthesis, carbohydrate metabolism, cell growth and cell division. The mineral analysis 
of A. difformis (leaves) showed the presence of essential minerals; potassium 1.74%, 
calcium 0.26%, phosphorus 157.11 parts per million (ppm), magnesium 24525 ppm, iron 
81.5 ppm, manganese 95.5 ppm, sodium 0.026% and copper 8.0 ppm (Oyeyemi and 
Tadela, 2014). This was supported by the output of mineral analysis carried out on the 
same plant by (Aliyu, 2008b). The appreciable concentrations of minerals such as 
sodium, potassium, calcium and phosphorus obtained from the plant showed that the 
plant has the potential of providing various secondary metabolites and mineral supply 
that could enhance the curative process of ill- health (Aliyu, 2008b; Oyeyemi and Tadela, 
2014). Another study (Arigbede et al., 2010) compared the nutritive value of the leaves 
and tuber of A. difformis and also used it as a feed supplement to basal diet of West 
African dwarf sheep. The proximate analysis conducted, indicates that the leaves contain 
more crude protein than the tuber, and non-fiber carbohydrate is higher in the tuber than 
in the leaves. The results illustrated that 10% inclusion of A. difformis into ruminant 
animal concentrate diet, increased nutrient digestibility coefficient in the animals 
(Arigbede et al., 2010). 
 
2.9 Phytochemical Constituents of A. difformis 
Phytochemicals are bioactive, non-nutrients compounds found in plants (Liu, 2004). 
Medicinal plants contain numerous phytochemicals which are responsible for the plants’ 
therapeutic potentials.  Phytochemicals have been associated with amelioration of 
diseases and pathological conditions given that they possess several properties such as 
antioxidant, antidiabetic, anti-cancer, antimicrobial, anti-inflammatory and gastro-
protective (Surh et al., 2001; Loew and Kaszkin, 2002; Liu, 2004; Hausteen, 2005; 
Aggarwal et al., 2008; Nandakuma et al., 2008; Li-Weber, 2009). The knowledge of 
phytochemical constituents of plants helps in the discovery of therapeutic agents and 
exploring new resources of such active chemical agents (Mojab et al., 2003).  
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Ethanolic and methanolic leaf extracts of A. difformis contain phytochemicals such as 
flavonoids, tannins, phlebotannins, cardiac glycosides, saponins and reducing sugars 
(Aliyu et al., 2008b; Aderonke and Ezinwanne, 2015). Conversely, aqueous extract from 
leaves indicates the presence of flavonoids, alkaloids, phenolics, and terpenoids while 
cardiac glycosides and anthraquinones are absent (Oghale and Idu, 2015b). A 
comparative study on the total phenolics content of root extract using three different 
solvents was done by Aliyu et al (2013). The results showed that n-butanol extract has 
significantly higher phenolics content than the methanol and acetone extracts. Other 
studies compared the presence of phytochemicals in the tuber and leaves of A. difformis 
(Eneojo et al., 2011; Agyare et al., 2016).  
 
2.10 Medicinal Benefits of A. difformis 
2.10.1 Anti-diabetic Activities 
Diabetes mellitus (Type I and II) is an endocrinological and metabolic disorder arising 
from insulin deficiency or impaired response of the body cells to insulin production 
(Maritim et al., 2003; Rahmatullah et al., 2012). Diabetes mellitus is characterized by 
persistent hyperglycemia.  Anti-hyperglycemic and anti-diabetic properties of numerous 
plants have been explored, among which is Anchomanes difformis (Saxena and 
Vikram, 2004; Aderonke and Ezinwanne, 2015). Ethanolic extract of A. difformis tuber 
significantly reduced blood glucose concentration in alloxan monohydrate-induced 
diabetes in Wistar rats (Adeyemi et al., 2015). Similar result was found when the 
ethanolic extract of the leaves were used (Aderonke and Ezinwanne, 2015). 
Conversely, a study carried out on aqueous extract of leaves of A. difformis revealed 
that it does not reduce blood glucose in normoglycemic rats (Lustigman et al., 2007). 
This was supported by (Adeyemi et al., 2015). The mechanism underlying the anti-
hyperglycemic and anti-diabetic effect of A. difformis has not been reported.  
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2.10.2 Antioxidant Activities 
Antioxidants and other bioactive components in plants, have received much attention 
especially in the medicinal field and food industry in recent years (Reddy and Grace, 
2016). Natural antioxidants may function as reducing agents, free radical scavengers, 
complexers of pro-oxidant metals, or as quenchers of the formation of singlet oxygen 
(Hernández et al., 2009). The most common natural antioxidants are flavonoids 
(flavanols, isoflavones, flavones, catechins, flavanones), cinnamic acid derivatives, 
coumarins, tocopherols, and polyfunctional organic acids (Lee et al., 2000). 
 
The free radical scavenging activity, total antioxidant capacity, and reducing power 
assay were measured in the acetone, n-butanol and methanolic extracts of A. difformis 
tuber (Aliyu et al., 2013). From the report, all the extracts displayed strong radical 
scavenging activity, but n-butanol extract has the strongest reducing ability which is 
comparable to that of gallic acid at all the concentrations tested (Aliyu et al., 2013). 
Similar antioxidant studies were carried out on methanolic leaf and root extracts of A. 
difformis by Agyare et al. (2016). The report of the study revealed that the methanolic 
root extract has more antioxidant capacity than the leaves and this is directly 
proportional to the total phenolic content. A study on the in vivo antioxidant capacity of 
A. difformis as reported by Oghale and Idu (2015b) confirmed the plant as a potent 
inhibitor of free radicals and lipid peroxidation in guinea pigs. Aqueous fraction of A. 
difformis leaves was used for the study. 
 
2.10.3 Anti-inflammatory Activities 
Inflammation plays a key role in the pathogenesis of certain disease-conditions such as 
asthma, diabetes, arthritis and cardiovascular diseases (Adebayo et al., 2014). Elevated 
markers of inflammation are implicative of oxidative stress (Wright et al., 2006). During 
oxidative stress, resident T-lymphocytes and activated macrophages around the β-cells 
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releases cytokines; particularly interleukin-1 (IL-1) which have been tagged as 
immunological molecules that inhibit secretion of insulin by the pancreatic β-cells and 
causes destruction of the β-cells (Hohmeier et al., 2003; Meares et al., 2013). Many 
inflammatory diseases are associated with the synthesis of prostaglandins, which are 
responsible for a sensation of pain (Loew and Kaszkin, 2002). The primary enzyme 
responsible for prostaglandins synthesis is the membrane-associated cyclooxygenase 
(COX), which occurs in two isoforms, COX-1 and COX-2. COX-1 is constitutively 
expressed while COX-2 is induced in the inflamed tissue. Modulation of the activity of 
the enzyme implies that the inflammation process can be modified. 
 
Adebayo et al (2014) conducted a study to demonstrate the anti-inflammatory activity 
of A. difformis. This was done by inducing oedema; injecting raw egg albumin (0.1ml) 
on the left paw of the rats after thirty minutes of administration of A. difformis leaves 
(ethanolic extract). Oedema size was measured and evaluated at intervals using a 
digital letica plethysmometer. The results showed that administration of A. difformis 
showed significant inhibition of oedema in the paw. 
 
The anti-inflammatory studies performed by Agyare et al (2016) on leaf and tuber 
extracts of A. difformis in chicks revealed that it possesses significant anti-inflammatory 
activity and inhibitory effects on preformed mediators such as histamine and serotonin 
which are involved in the initial phase of the acute inflammatory process. Both extracts 
at all the doses tested, demonstrated higher anti-inflammatory activity than aspirin. The 
anti-inflammatory activity could be due to the presence of steroids in the extracts which 
exert their effects through switching off multiple activated inflammatory genes and 
repressing NF-κB-regulated inflammatory genes, it may also activate several anti-
inflammatory genes and increases the degradation of mRNA encoding certain 
inflammatory proteins (Barnes, 2005).  
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2.10.4 Anti-nociceptive Activities 
Nociception which is the causing of pain and injury or reacting to pain stimuli (Cammack 
et al., 2006), can be induced by various methods such as tail-flick, hot plate, writhing, 
injection of formalin among others depending on the nociceptors to be investigated 
(Björkman, 1994). In this study, 0.25% injection of formalin on the hind paw was used 
to induce pain in Wistar rats following the administration of ethanolic extract of A. 
difformis leaves and a standard drug; aspirin (Adebayo et al., 2014). The result 
indicated that formalin-induced paw nociception was significantly reduced, and this was 
dose-dependent. Therefore, A. difformis possesses anti-nociceptive ability as 
displayed by its inhibition of formalin-induced pain.  
 
2.10.5 Anti-microbial Activities 
Microorganisms especially pathogens are of great medical and economical value 
(Postgate and Abdollahi, 1982; Mc Neil and Brown, 1994). Due to the side effects of 
antibiotics and the resistance built up by pathogenic microbes (Monroe and Polk, 2000; 
Parekh et al., 2006) against these drugs, much attention has been shifted to plant 
extracts and the biological active components in them (Cordell, 2000; Essawi and Srour 
2000). Anti-microbial of plant origin show great therapeutic potentials (Parekh et al., 
2006). Medicinal plants have been explored for their anti-microbial properties (Atawodi 
and Atawodi, 2009; Bero et al., 2009; Eneojo et al., 2011; Nkoh et al., 2015). 
 
Reports on investigations of anti-microbial activities of A. difformis vividly showed that 
it is potent against common and drug-resistant microorganisms (Agyare et al., 2016; 
Atawodi, 2005; Eneojo et al., 2011). A comparative study on anti-microbial activities of 
the leaves and rhizome extracts of A. difformis using a ratio of different solvent was 
reported by Eneojo and his colleagues (2011). The microorganisms tested against 
were of public health importance; Salmonella paratyphi, Salmonella typhi, Candida 
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albican, Proteus vulgaris, Staphylococcus aureus, Shigella flexneri, Shigella 
dysenterae, Pseudomonas aeniginosa and four different strains of Escherichia coli. 
The result revealed that A. difformis leaf and rhizome extracts demonstrated inhibition 
against all the microorganisms except for Shigella flexneri and Pseudomonas 
aeniginosa which conferred resistance against leaf and rhizome extracts respectively 
(Eneojo et al., 2011; Agyare et al., 2016). Another assessment of aqueous and 
methanolic extract of A. difformis against trypanosoma brucei presents trypanocidal 
activities of the plant (Atawodi, 2005).  
 
In vitro antiplasmodial activity of A. difformis rhizome was tested against chloroquinne-
sensitive strain of plasmodium falciparum (3D7). Roots of A. difformis exhibited 
moderate antiplasmodial activities when compared with other plants used in the study 
(Bero et al., 2009). In vivo study of antiplasmodial activities of A. difformis has been 
recommended giving that inhibition or other mechanisms of action may take place at 
other stages of plasmodium cycle such as the pre-erythrocytic development in the liver 
(Bero et al., 2009). 
 
2.10.6 Gastro-protective Activities 
Experimental peptic ulcer models can be induced using the following; acetic acid, 
ethanol, indomethacin, histamine, reserprine, pylorus ligation, ischemia-reperfusion, 
stress (hypothermic restraint, water-immersion) and diethyldithiocarbamate among 
others (Rodrı́guez et al., 2003; Zayachkivska et al., 2005; Adinortey et al., 2013). 
Investigations carried out on Sprague-dowley rats to assess the gastro-protective effect 
of ethyl acetate extract of A. difformis rhizome using different gastric ulcer models 
showed a positive result (Okpo et al., 2011). Ulcer conditions were induced using 
ethanol, indomethacin and pylorus ligation in the animals after pre-treatment with 
ranitidine. Although the mechanism through which it exerts its effect is not clear, the 
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ethylacetate fraction of A. difformis extract was shown to possess a clear anti-ulcer 
activity in all three, tested models of ulcer (Okpo et al., 2011). The gastro-protective 
ability of A. difformis can be associated with the presence of flavonoids which have been 
proven to be gastro-protective (Zayachkivska et al., 2005). It was discovered that 
flavonoids obtained from different plants were gastro-protective against ethanol-induced 
damage by causing increase in gastric microcirculation. 
 
2.10.7 Anti-asthmatic Activities 
Bronchial asthma is one of the common syndromes of the several respiratory diseases 
affecting humans (Parmar et al., 2010). Anti-asthmatic evaluation was carried out on 
the leaves (aqueous extract) of A. difformis using guinea pigs as experimental animals 
(Oghale and Idu, 2015b). The experimental groups were first sensitized with ovalbumin 
intraperitoneal administration; 100mg/kg body weight, intramuscular administration; 
50mg/kg body weight, 24 hours later.  A. difformis leaf extract was administered for 
seven days after which the animals were exposed to 0.2% histamine aerosol 
(bronchioconstrictor).  The effect of A. difformis was assessed on the tracheal fluid 
volume and the tracheal fluid viscosity against salbutamol; a standard drug for treating 
asthma (Oghale and Idu, 2015b). The results of the study showed that A. difformis is 
effective against asthma as revealed by its bronchodilator properties similar to the 
effect of the standard drug used. Similar results were reported by Boskabady and his 
colleagues (Boskabady et al., 2010), who assessed the effect of Nigella sativa on 
airways of asthmatic patients.  
 
2.10.8 Anti-onchocercal activities of A. difformis 
Onchocerciasis or subcutaneous filariasis, popularly known as river blindness, is 
caused by the filarial worm Onchocerca volvulus and transmitted by the black fly, 
Simulium damnosum (Lustigman and McCarter, 2007). Onchocerciasis is one of the 
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leading causes of blindness due to infections. It is prevalent in 37 countries of the world 
among which 30 of these countries are in Africa (Boatin and Richards, 2006) and these 
account for 99% of the global burden of onchocerciasis and its related maladies while 
the other 1% is confined to Yemen and some countries of Central and South America 
(Tanya et al., 2011). 
 
Mass drug administration (MDA) and vector control programs have been the major 
approaches to control the disease (Wanji et al., 2012). Although onchocerciasis control 
in Africa has lasted more than forty years, the disease is still a public health concern in 
many African countries. Ivermectin which is the main chemotherapeutic agent currently 
used has limited microfilaricidal efficacy (Richards et al., 1998). Also, the fear of side 
effects and the duration of treatment (15-18 years) in order to terminate parasite 
transmission have led to a reduction in the ivermectin intake with serious 
epidemiological consequences (Tanya et al., 2011). These factors and the potential 
development of resistance to Ivermectin have necessitated the need for new drugs in 
the treatment of onchocerciasis to achieve elimination of transmission. The search for 
an efficient microfilaricide has led to exploration of certain plants such as Cyperus 
articulates Craterispermum laurinum, Morinda lucida and Anchomanes difformis (Cho-
Ngwa et al., 2010; Metuge et al., 2014). A study on the anti-onchocercal ability of A. 
difformis was performed on the methanolic extracts and on different fractionated 
extracts obtained at varying polarity using column chromatography (Nkoh et al., 2015). 
The extracts and fractions were tested against O. ochengi; a strain very similar to O. 
volvulus. The methanolic extract and the four fractions obtained exhibited 100% 
inhibition against the microfiliariae (Nkoh et al., 2015) and this lends credence to its 
ethno-botanical use in the treatment of river blindness. 
 
A. difformis has been clearly shown to possess antioxidant and anti-inflammatory 
properties (Adebayo et al., 2014); essential factors that minimize oxidative stress and 
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ultimately ameliorate diabetes (Aderonke and Ezinwanne, 2015; Adeyemi et al., 2015) 
and possibly diabetic complications. 
 
2.11 Future prospective and research opportunities 
Further investigations should be performed extensively on A. difformis to be able to 
understand the molecular mechanisms involved in its therapeutic abilities against 
diabetes and associated factors. It will be of importance to identify the bioactive 
constituents present in the leaves and rhizome, and to investigate comprehensively the 
antioxidant potentials of A. difformis. 
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ABSTRACT 
Background: Anchomanes difformis (ENGL: Blume) is specie of flowering plants in the 
family Araceae. Anchomanes difformis is commonly reported for ameliorating 
hyperglycemia, inflammation, ulcer, malaria, and inhibiting microbial growth.  
Objective: This study evaluated total yields of phytochemicals present, measured 
antioxidant capacities and identified bioactive compounds in the leaves and rhizome 
extracts of A. difformis using solvents of different polarity (ethyl acetate, ethanol and 
water).  
Methods: Total polyphenolic, flavonoid content and alkaloids were measured, ORAC, 
TEAC and FRAP were performed as antioxidant capacity indices, and identification of 
bioactive compounds was done using UPLC-MS and HPLC.  
Results: All extracts contained polyphenols, flavonols, flavanols, and alkaloids in varying 
concentrations. All extracts exhibited antioxidant properties. However, aqueous leaves 
extract had highest antioxidant properties and polyphenols with significance (p<0.05). 
Thirty-four compounds were identified altogether in the leaves and rhizome.  
Conclusion: A. difformis leaves and rhizome are potential sources of natural 
antioxidants and can serve as potential therapeutic agents against diseases linked with 
oxidative stress. Presence of health-promoting compounds indicates possible 
ameliorative potentials of A. difformis. 
 
Keywords: Anchomanes difformis, antioxidant, bioactive compounds, medicinal plant, 
phytochemicals 
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3.1 Introduction 
Free radicals are generated in the body during normal biological processes such as 
oxidative phosphorylation, and respiratory burst; phagocytosis1. The body has its own 
antioxidant mechanisms2, but there is the need for dietary supplementation of 
antioxidants. This is because overproduction of free radicals leading to imbalance in free 
radical production and antioxidant levels results in oxidative stress1. Oxidative stress has 
been implicated in several disease conditions such as diabetes mellitus, arthritis, 
cardiovascular diseases, cancer, cognitive impairment and gastrointestinal 
dysfunctions3,4. Antioxidants have multiple biological effects such as anti-inflammatory, 
anticarcinogenic and anti-atherosclerotic properties5. This is due to their capacity to 
protect cells and bio-macromolecules from oxidative damage by neutralizing free 
radicals or upregulating antioxidant enzymes thereby preventing oxidative degradation 
and neoplastic processes4. 
 
Phytochemicals are groups of non-nutrient substances, mostly present in fruits, 
vegetables, nuts and teas. They are biologically active and have high health-promoting 
impacts5. Phytochemicals are secondary plant metabolites that elicit biological properties 
such as antioxidant activity, modulation of detoxification enzymes, antimicrobial effect, 
stimulation of the immune system, modulation of hormone metabolism, decrease of 
platelet aggregation, and anticancer property6. Phytochemicals have also been widely 
promoted for the prevention and treatment of diabetes, muscular degeneration, 
hypertension and other pathological conditions. Several compounds in this group of 
phytochemicals are antioxidants and scavengers of free radicals. Examples of 
phytochemicals that act as antioxidants are polyphenolic compounds, alkaloids, 
tocopherols and carotenoids4. These groups of phytochemicals also act against lipid 
peroxidation4,8. 
 
51 
 
Polyphenols are the largest group of phytochemicals; they have gained more attention 
in recent years especially flavonoids, in reference to their anti-diabetic properties9. 
Polyphenols possess free radical scavenging potentials10. Polyphenols are strong 
antioxidants that can independently or in synergy with other antioxidant enzymes and 
vitamins, to act as a defense against oxidative stress4. Polyphenols also elicit their 
antioxidant ability by inducing antioxidant enzymes such as catalase, glutathione-S-
transferase, superoxide dismutase, and glutathione reductase11. Polyphenols further 
protect cells from apoptosis and other oxidative damage induced by xanthine oxidase. 
This is revealed by the effect of catechin and proanthocyanidin on cardiomyocytes 
exposed to xanthine oxidase11.  
 
Flavonoids are naturally occurring polyphenolic compounds. They comprise of flavonols, 
flavanols, flavones, flavanones isoflavonoids and anthocyanidins. Examples of flavonols 
include; quercetin, kaempferol, myricetin, galangin and fisetin, while catechin, 
epicatechin and gallate are examples of flavanols12. The study conducted by Wang and 
his colleagues,13 revealed that intake of foods with high content of flavonoids reduced 
the risk of cardiovascular diseases in human. Flavonols protect against neuronal 
excitotoxicity and mitochondrial dysfunction14. 
 
Alkaloids act as antibacterial and antifungal in plants, against insects and herbivores15,16. 
Alkaloids have many pharmacological activities including, antiarrhythmic effect, 
antihypertensive effects, antimalarial activity, antioxidant activity and anticancer 
actions7,17. Berberine; an alkaloid has been shown to be effective as an analgesic and 
antimalarial therapeutic agent17. Medicinal plants have shown to contain lots of 
phytochemicals; hence they possess antioxidant activities. They play important roles in 
the management of diseases especially those with aetiology linked to oxidative 
stress18,19.  
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Anchomanes difformis (Blume); a tropical plant found mostly in African forests, is rich in 
phytochemicals20,26 and have been reported in ameliorating pathological conditions. A. 
difformis (AD) reduced blood glucose in alloxan-induced diabetes21, pain and 
inflammation in rats and chicks22, ameliorates ulcer and asthma20,23. AD has also shown 
to have a positive effect on female sex hormones and activity against microbes24.  
Studies on the qualitative phytochemical analysis of AD reported the presence of 
flavonoids, tannins, saponins, phlebotannins, cardiac glycosides, and reducing 
sugars21,25. Investigations on the phytochemical contents of AD have mostly been limited 
to qualitative studies20,25, which were carried out to determine the presence or absence 
of certain groups of phytochemicals in AD leaves and rhizome26. The current study 
carried out the quantification of the polyphenols, flavonols, flavanols and alkaloids 
present in the leaves and rhizome of AD. Furthermore, literature review on AD shows 
that no study has reported the determination and identification of active compounds in 
the leaves.  
 
Different methods have been developed and recommended to standardize the 
measurement of antioxidant capacities in food, dietary supplements and nutraceuticals27. 
These include; oxygen radical antioxidant capacity (ORAC), trolox equivalent antioxidant 
capacity (TEAC), and Folin-Ciocalteu (for polyphenols) methods. Ferric reducing 
antioxidant power (FRAP) have been widely used to investigate the total antioxidant 
power of biological samples. These assays have underlying principles that are based on 
either single electron transfer (SET) reaction or hydrogen atom transfer (HAT) reaction 
between an antioxidant and a free radical.  
 
This study measured total polyphenols, flavonols, flavanols and alkaloids of aqueous, 
ethanol and ethyl acetate fractions of AD leaves and rhizome. It also evaluated 
antioxidant capacities on these six extracts and identified some of the compounds 
present in them.  
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3.2 Experimental section 
3.2.1 General Experimental Procedures 
All chemicals and reagents used were of grade quality. The reagents were supplied by 
Merck, South Africa, while chemicals were purchased from Sigma Aldrich, South Africa. 
The following equipment were used: rotary evaporator and vacuum filter to concentrate 
extracts, Spectrophotometric readings were taken using a computer-assisted UV-VIS 
Multiskan Spectrum (Thermoscan Electron Corporation, USA) and Fluoroscan Ascent 
plate reader (Thermo Fischer Scientific, Waltham, MA, USA) was used for ORAC assay. 
HPLC analysis was performed using Agilent Technology (1200 series, Bellefonte, USA). 
UPLC-MS was carried out in a Waters Synapt G2 Quadrupole time-of-flight (QTOF) 
mass spectrometer (MS) and a Waters Acquity ultra performance liquid. 
 
3.2.2 Plant Collection and Authentication 
A. difformis leaves and rhizome were collected from a farm in Abeokuta, Ogun state, 
Nigeria, between August and December 2015. This was authenticated at the Herbarium, 
University of Lagos, Nigeria with herbarium number: LUH6623. A specimen voucher was 
deposited at the herbarium.  
 
3.2.3 Preparation of Plant Extracts 
Six different extracts of AD were extracted using cold-stirred extraction method. The 
extracts investigated were aqueous, ethanol and ethyl acetate extracts of the leaves and 
rhizome. The harvested plant parts were dried under shade and blended to increase the 
surface area. The blended leaves and rhizome were soaked in the solvent (water, 
ethanol and ethyl acetate separately) in the ratio 1:10 of plant material and solvent. The 
mixtures were then filtered using vacuum filtration method and the solvent evaporated. 
Ethanol and ethyl acetate were evaporated under reduced pressure using rotary 
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evaporator and later left to dry in the fume extraction hood. Aqueous mixture was 
evaporated to dryness using the lyophilizer.  
 
3.2.4 Phytochemical Analysis 
Quantitative measurement of polyphenols, flavonols, flavanols, alkaloids and 
carotenoids were performed using spectrophotometry and colorimetry techniques. 
 
3.2.4.1 Determination of Total Polyphenols 
Total polyphenols were determined by adapting the method of Waterhouse55. This 
involved the use of Folin-Ciocalteu reagent and sodium carbonate. 25µl of samples 
followed by 125µl of 200mM Folin reagent was dispensed into each well. After 5 minutes, 
100µl of 7.5% aqueous sodium carbonate was added. A blue colour complex was formed 
from the reaction between phenolic compounds and Folin’s reagent. The plates were 
incubated at room temperature for 2 hours. The absorbance was measured at 765 nm. 
The intensity of this colour-complex measured is directly proportional to the 
concentration of phenolic compounds present in the sample. Gallic acid (0, 20, 50, 100, 
250 and 500mg/L) in 10% ethanol was used to prepare the standard curve. Results were 
expressed as mg gallic acid equivalents per gram dry mass of the plant (mgGAE/g DM). 
 
3.2.4.2 Determination of Flavonol Content 
Flavonol content was determined using quercetin (0, 5, 10, 20, 40, and 80mg/L) in 
distilled water as a standard. 50mg of the extracts were weighed and dissolved in water 
(for the aqueous extract) or 95% ethanol (for ethanolic and ethyl acetate extracts). 12.5µl 
of samples were pipetted into the 96-well plates. 12.5µl of 0.1% HCl was added to each 
well, followed by 225µl of 2% HCl. This was left to incubate for 30 minutes at room 
temperature56. Readings were taken at 360nm and results expressed as mg quercetin 
equivalent per gram dry mass of the plant (mgQE/g DM).  
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3.2.4.3 Determination of Flavanol Content 
Spectrophotometric determination of flavanols was done using 4-(dimethylamino)-
cinnamaldehyde (DMACA) reagent. DMACA reacts with flavanols to form a 
characteristic light blue colour. 1mM Catechin hydrate was used to prepare caliberation 
curve at the following concentrations; 0, 5, 10, 25, 50, 100µM. DMACA reagent was 
prepared by dissolving DMACA in a solvent-mixture of methanol-HCl (in the ratio 3:1 
respectively) to a final concentration of 10µg/ml. 25µl of sample was dispensed into each 
well, 275µl of DMACA reagent was added to each well. Plates were incubated for 30 
minutes at room temperature. Readings were taken at 640 nm. The intensity of the 
coloration is directly proportional to the concentration of flavonols in the sample. Results 
were expressed as mg catechin equivalent per gram dry mass of the plant (mgCatechin/g 
DM). 
 
3.2.4.4 Determination of Total Alkaloids 
Total alkaloids was determined using spectrophotometric method described by Fadhil, 
et al57. The assay is based on the reaction of Bromocresol green (BCG) with alkaloids 
which produces a yellow-coloured complex. 5mls of 2M sodium phosphate buffer (pH 
4.7) was added to 500µl of AD extracts, followed by 5mls of BCG solution. The mixture 
was vortexed, and the yellow complex formed was extracted with 12mls of chloroform 
and strongly vortexed. Two layers were formed; the lower layer which contains the 
alkaloid (yellow complex in chloroform) is pipetted (300µl) into 96 wells-plate, 
absorbance read at 470nm against blank. 0.1mg/ml Atropine of varying concentrations 
(8, 12, 16, 20, and 24µg/ml) in 2M sodium phosphate buffer (pH 4.7) was used as a 
standard reference. 
 
 
56 
 
3.2.5 Antioxidant capacities   
3.2.5.1 ORAC Assay 
The ORAC assay kinetically measured the peroxyl-radical absorbing potential of the 
antioxidants present in the plant extracts according to the method of Ou et al58. Trolox; 
a water-soluble analogue of vitamin E, was used as the antioxidant standard reference. 
The change in fluorescence of the reaction mixture was monitored over a period of 2 
hours and recorded every minute (excitation = 485 nm and emission = 535 nm). Results 
were determined with a regression equation, that relates trolox concentrations with the 
net area under the kinetic fluorescein decay curve (y = ax2 + bx+ c). The ORAC values 
were expressed in micromoles of trolox equivalents per gram of sample (μmol TE/g 
sample).  
 
Working solutions were 1.2mM fluorescein solution, 75mM phosphate buffer (pH 7.4) 
and 2,2’-Azobis (2-methylpropionamidine) dihydrocholide (AAPH) solution. Samples 
were diluted (x10) using phosphate buffer. 12µl of samples were pipetted into the wells, 
followed by 138µl of fluorescein solution. 50µl of AAPH was added and readings were 
taken. 12µl of samples, followed by 138µl of fluorescein solution and 50µl of AAPH were 
pipetted into the wells, readings were taken.  
 
3.2.5.2 FRAP Assay 
The ferric-reducing power of the plant extracts was determined using spectrophotometry 
according to the method of Benzie and Strain59. The stock solution (FRAP reagent) was 
prepared with acetate buffer (300mM, pH 3.6), TPTZ solution, Iron (III) chloride 
hexahydrate solution and distilled water. The solution mix was in a ratio of 10:1:1:2 
respectively. 10µl of sample followed by 300µl of FRAP reagent was pipetted into the 
microplate. After 30 min of incubation at room temperature, the absorbance was 
determined at a wavelength of 593 nm. Ascorbic acid was used as the reference 
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standard and results expressed as milligram of ascorbic acid per gram of extract 
(mgAAE/g sample).  
 
3.2.5.3 TEAC Assay 
TEAC was used to measure the antioxidant capacity of the plant samples using ABTS 
(2,2’-azino-bis (3-ethylbenz-thiazoline-6-sulphonic acid)) decolorization assay. This was 
carried out by assessing the ability of the sample to scavenge/reduce ABTS radical, 
converting the solution (blue-green) to a colourless product. The extent of decolorization 
by the sample is proportional to the concentration of the antioxidant present and it is 
compared to that of trolox; thereby giving TEAC value. The TEAC value was expressed 
as milligram of trolox equivalent per gram of sample (mgTE/mg sample). 25μl of sample 
was pipetted into the 96-well plate, and 275μl of ABTS reagent (prepared with 150mM 
potassium persulfate (K2S2O8) and ABTS in distilled water and placed in the dark room 
overnight) was added. This was incubated for 30 minutes at room temperature and the 
readings were taken at 734nm. 
 
3.2.6 Identification of active compounds 
Bioactive compounds preseent in the leaves and rhizome were determined using liquid 
chromatographic methods, as discussed below. 
 
3.2.6.1 High Performance Liquid Chromatography (HPLC) 
HPLC analysis was performed on the six extracts. Water (solvent A) and methanol 
(solvent B) were used for the mobile phase. The gradient program ran from 100% water 
at 0 minute to 100% methanol at 35 minutes for each sample, after which the column 
was washed and reconditioned. The sample injection volume was 20 µl, a flow rate of 1 
ml/min and a temperature of 25oC was maintained throughout the analytical run. The 
diode array detector was controlled at a wavelength between 200nm and 700nm. The 
58 
 
detection wavelengths were 260, 320, 360 and 520nm. Individual compounds were 
identified by comparing their retention time and UV spectrum with those obtained from 
their respective standards injected under the same HPLC conditions. Concentration of 
each compound was calculated using the area of standard, area of sample, injection 
volume, weight of sample (mg) and extraction volume. Results were expressed as µg/mg 
of sample. 
 
3.2.6.2 Ultra-Performance Liquid Chromatography and Mass 
Spectrophotometry 
Ultra-performance liquid chromatography and mass spectrophotometry (UPLC-MS) was 
carried out by connecting a Waters Synapt G2 Quadrupole time-of-flight (QTOF) mass 
spectrometer (MS) to a Waters Acquity ultra performance liquid chromatograph to 
achieve high resolution. Electrospray ionization was used in negative mode with a cone 
voltage of 15 V, desolvation gas at 650 L/hr and desolvation temperature of 275°C. The 
rest of the MS settings were optimized for best resolution and sensitivity. Scanning from 
m/z 150 to 1500 in resolution mode as well as in MSE mode was done for data 
acquisition. The data acquired in the MSE mode were in two channels, one at a low 
collision energy (4 V) and the second using a collision energy ramp (40 to 100 V) to 
obtain fragmentation data. Sodium forbate was used to calibrate the instrument and 
leucine enkaphalin was used as a lock mass (reference mass) for accurate mass 
determination. The mobile phase consisted of 0.1% formic acid (Solvent A) and 
acetonitrile containing 0.1 % formic acid as solvent B. The gradient started at 100% 
solvent A for 1 minute and changed to 28 % B over 22 minutes in a linear way.  This 
further changed to 40% B over 50 seconds, a wash step of 1.5 minutes at 100% B 
followed and re-equilibration to initial conditions for 4 minutes. An injection volume of 2 
µL was used and a flow rate of 0.3 mL/min. The column (Waters HSS T3, 2.1 x 100 mm, 
1.7 μm) temperature was maintained at 55 ºC. 
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3.2.7 Data Analysis 
All data were expressed as mean ± standard deviation (SD) of triplicate determinations. 
The data were analyzed by ANOVA using GraphPad Prism 5 software and SPSS. 
Differences were considered significant at 5% level of significance. Multiple correlation 
analysis was done on secondary plant compounds vis a vis their antioxidant capacity 
using bivariate correlation to estimate the Pearson correlation coefficient. 
 
3.3 Results  
3.3.1 Phytochemical Analysis and Antioxidant capacities 
Polyphenols, flavonols and alkaloids were present in all the extracts of AD leaves and 
rhizome used in this study. The aqueous and ethanol extracts of A. difformis leaves had 
higher concentrations of polyphenols, flavonols, flavanols and alkaloids than their 
respective rhizome extracts (Figures 3.1 & 3.2). Consequently, this is expressed in the 
higher antioxidant capacity of ethanol and aqueous leaves extract when compared to 
their respective rhizome extracts (Figure 3.3). Conversely, ethyl acetate of the rhizome 
contained higher concentration of polyphenols and flavonols and lower concentrations 
of alkaloids and flavanols when compared with the ethyl acetate leaf extract (Figures 3.1 
& 3.2). This may be related to its higher antioxidant capacity for FRAP and TEAC assays 
(Figure 3.3). AD does not contain high amount of flavanols (Figure 3.2), when compared 
with other phytochemicals investigated. Very low concentrations of flavanols were 
obtained in the leaves and rhizome extracts of AD with exception to ethanol leaf extract. 
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Figure 0.1: (A) Total polyphenol and (B) flavonol content of AD leaves and rhizome. Bars with 
different letters are significantly (p<0.05) different from each other. Aq- aqueous, EtOH- ethanol, 
Ethyl A- ethyl acetate. 
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Figure 0.2: (A) Flavanol, and (B) alkaloid content of AD leaves and rhizome. Bars with different 
letters are significantly (p<0.05) different from each other. Aq- aqueous, EtOH- ethanol, Ethyl 
A- ethyl acetate. 
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Figure 0.3: Antioxidant capacities; (A) ORAC, (B) FRAP and (C) TEAC of leaves and rhizome 
extracts of AD. Bars with different letters are significantly (p<0.05) different from each other. Aq- 
aqueous, EtOH- ethanol, Ethyl A- ethyl acetate. 
 
3.3.2 Relationships between Antioxidant Capacity and Plant Secondary 
Compound 
The plant parts and extraction-solvent type influenced the relationship between the 
secondary compounds and antioxidant capacity of AD.  Aqueous leaves extract showed 
a highly significant correlation between ORAC and total alkaloids (r = 1.0, p<0.009). A 
significant, positive correlation was observed between total polyphenols and flavanols (r 
= 0.998, p<0.044), and with alkaloids (r = 0.999, p<0.022) in aqueous extract of AD 
rhizome. Ethanol extraction of AD rhizome resulted in a significant correlation between 
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FRAP and total polyphenols (r = 0.997, p<0.048). A significant, inverse relationship (r = 
-0.998, p<0.044) is observed between TEAC and total polyphenols, in the ethyl acetate 
extract of AD rhizome. 
 
3.3.3 Identification of Bioactive compounds 
The HPLC analysis revealed the presence of phenolic acids; cinnamic acid, ferulic acid, 
chlorogenic acid. Flavonols present include quercetin, kaempferol, and rutin. Catechin 
was the only flavanol identified, and it was present in the aqueous leaves extract only 
(Table 3.1). There are other polyphenols present in the extracts as revealed by the 
wavelength scan spectra of the peaks in the chromatogram, these could not be identified 
in this study due to unavailability of their standards.  
 
Table 0.1: Phenolic compounds identified in AD leaves and rhizome using HPLC 
 
Compounds 
investigated 
 
AD Extracts 
Aqueous 
(µg/mg sample) 
Ethanol 
(µg/mg sample) 
Ethyl acetate 
(µg/mg sample) 
Leaves Rhizome Leaves  Rhizome Leaves Rhizome 
Chlorogenic acid 0.1626 - -  - - 
Rutin 0.3652 0.0004 0.9062 0.0004 - 0.0009 
Kaempferol - 0.0023 0.0602 0.0013 - 0.0031 
Quercetin - - 0.0215 0.0080 - - 
Cinnamic acid 0.0220 - 0.3064 0.0340 0.3374 0.0010 
Ferulic acid 0.0865 - 0.0680 - - - 
       
Catechin 1.7797 0.0072 - - - - 
Coumaric acid - 0.0007 - 0.0980 - 0.0030 
Epigallo-catechin 
gallate 
- - - - - - 
Hesperidin - - - - - - 
Hesperitin - - - - - - 
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Myricetin - - - - - - 
Epicatechin - - - - - - 
Mangiferin - - - - - - 
Luteolin - - - - - - 
Protocatechuic 
acid 
- - - - - - 
Apigenin - - - - - - 
Sinapic acid - - - - - - 
Isorhannetin - - - - - - 
Caffeic acid - - - - - - 
Syringic acid - - - - - - 
Naringenin - - - - - - 
*compound not detectable in the extract (-) 
 
Thirty-five (34) phenolic compounds were identified (22 known and 12 unknown 
compounds), when the extracts were subjected to UPLC-MS. It is important to note that 
no research has been conducted before now to the best of our knowledge, on 
identification and quantification of compounds in AD leaves. Our study is therefore the 
first to identify and quantify active compounds in AD leaves, while report showed that 3 
compounds were recently isolated from AD rhizome28. Compounds identified in in the 
leaves and rhizome of AD are shown in Table 3.2 while Table 3.3 shows the 
characteristics of the unknown compounds identified Tentative assignment of names 
was given to each peak (each peak depicts the elution of a compound at characteristic 
wavelength and time), based on Single Mass Analysis (SMA), fragmentation of parent 
ion. SMA revealed the elemental composition, the calculated mass, the chemical 
formula, and the PPM error. The choice of name is also based on the compound with 
the lowest PPM error. Certain peaks have more than one compound with the same 
above-mentioned features on the SMA; these are referred to as isomers (Table 3.2).  
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The result obtained when HPLC was used, showed that some compounds were not 
detectable in the extracts (Table 3.1). This is probably due to their low concentrations in 
the extracts. However, some of these compounds were further identified when the 
extracts were analysed using UPLC-MS (Table 3.2). These include; apigenin, luteolin, 
and hesperidin. In addition, due to unavailability of standards, some phenolic compounds 
could not be identified using HPLC; however, UPLC-MS revealed the presence of these 
compounds in the extracts. 
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Table 0.2: Further identification of bioactive compounds using UPLC-MS 
 
Compounds 
(mg/mg dry mass) 
Extracts 
Aqueous 
Leaves 
Ethanol 
Leaves 
Ethyl acetate 
Leaves 
Aqueous 
Rhizome 
Ethanol 
Rhizome 
Ethyl acetate 
Rhizome 
1. Luteolin 
Scutellarein 
Kaempferol 
0.008267 0.096017 0.095664 0.009789 0.004862 0.003153 
2. Vicenin_2 0.165466 0.008687 - 0.003526 0.007592 - 
3. Chryosoeriol 0.102627 0.968536 1.247479 0.083549 0.035016 0.041105 
4. Vitexin 0.043549 0.062865 0.078313 0.053169 0.06839 0.065452 
5. Phloridzin 0.539154 0.444256 0.412962 0.174422 0.115476 0.087471 
6. Rutin 0.019947 0.000625 0.000338 0.000424 0.000289 - 
7. Orientin - 0.003004 - 0.002949 0.01439 - 
8. Luteolin-7-O-
glucoside 
- 0.005031 0.002332 0.002295 0.009057 - 
9. Catechin 0.000521 - - - - - 
10. Hesperedin 0.003414 0.004686 0.003728 0.003759 0.004769 0.002225 
11 p-Coumaric acid 
m-Coumaric acid 
o-Coumaric acid 
0.012879 0.018938 0.019564 0.004058 0.012482 0.027696 
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12. 4-HBA 0.003496 - 0.00896 0.00338 0.056935 0.080544 
13. 4-HBA_2 - 0.021755 0.02005 0.003369 0.041509 0.07447 
14. Luteolin-6,8-di-C-
hexoside 
0.012534 - - - - - 
15. 4-Vinylsyringol 0.180939 0.254919 0.121674 0.031925 0.068379 0.026668 
16. Chrysoeriol-7-O-
glucoside 
Or  
Isorhamnetin-3-O-
rutinoside 
0.146249 0.357013 0.308613 0.011774 0.012807 0.038917 
17. Apigenin 0.272873 0.011578 0.000807 0.009025 0.024645 0.000713 
18. Apigenin-6,8-di-C-
glucoside,  
Chrysoeriol-7-O-
apiosyl-glucoside, 
Luteolin-7-O-
rutinoside, 
Kaempferol 3-O-
rutinoside, 
0.103761 0.00703 - - 0.001743 0.000996 
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Kaempferol 3-O-
galactoside 7-O-
rhamnoside 
19. Hispidulin 0.104893 0.953434 1.248529 0.087445 0.035437 0.040733 
20. Hispidulin_2 0.104792 0.923351 1.236589 0.085448 0.036455 0.040839 
21. Kaempferol 0.008554 0.00421 - 0.007822 0.001313 - 
22. Quercetin 0.000635 0.008628 0.014729 0.000141 0.022195 0.012004 
23. AD-A  0.051546 0.022319 0.019931 0.011598 0.008724 0.002833 
24. AD-B  2.399537 2.933177 3.904022 2.71322 2.007623 2.392479 
25. AD-C  0.03819 - 0.044156 0.01228 0.01553 0.03332 
26. AD-D  0.897766 1.643279 1.003963 0.648098 0.480378 0.798512 
27. AD-E  0.865262 1.653133 2.140938 0.989202 0.837193 0.919322 
28. AD-F  - - 0.013349 0.034143 0.051478 - 
29. AD-G  - 0.008238 0.021818 0.007299 0.284961 0.532973 
30. AD-H  0.443833 1.618828 1.848603 0.023327 0.037872 0.509491 
31. AD-I  0.111219 0.47024 0.567598 0.217556 1.069945 0.829917 
32. AD-J 0.015344 0.054942 0.03207 0.034796 0.085547 0.027386 
33. AD-K - 0.002255 0.003026 0.007617 0.036329 0.005365 
34. AD-L 0.007748 0.016227 0.015851 - - - 
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Table 0.3: Characteristics of the unknown compounds 
S/N Compound Measured mass 
(grams) 
Molecular formula Retention time 
(minutes) 
1. AD-A  265.1440 C15H22O4 25.69 
2. AD-B  267.0716 C9H16O9 6.19 
3. AD-C  309.1913 C14H30O7 25.96 
4. AD-D  311.2222 C18H32O4 24.72 
5. AD-E  313.2379 C18H34O4 24.85 
6. AD-F  326.2120 C 21H29O2 24.16 
7. AD-G  327.2171 C18H32 O5 24.32 
8. AD-H  329.2328 C18H34O5 24.37 
9. AD-I  431.1917 C20H32O10 14.32 
10. AD-J 447.1863 C20H32O11 10.12 
11. AD-K 451.2543 C21H40O10 12.86 
12. AD-L 737.2293 C34H42O18 5.99 
 
 
Figure 0.4: Mass spectra showing the overall elution of the compounds in the leaf and rhizome extracts 
of AD, with the mass/charge and retention time on the major peaks. 
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Figure 0.5: Structure of certain compounds identified in AD leaves and rhizome. 
 
3.4 Discussion 
Quantitative phytochemical analysis performed on the plant extracts revealed the presence of 
health promoting phytoconstituents; polyphenols, flavonols and alkaloids. This is in line with 
previous findings which documented the presence of alkaloids, flavonoids, phenolics and other 
groups of phytochemicals in the leaves of AD20. Similarly, qualitative screening of AD plant for 
phytochemicals by Aliyu and his team,25 showed that flavonoids are present in AD, this 
corroborates with findings in this study. 
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The groups of phytochemicals contained in the leaves and rhizome of AD have been shown 
to possess medicinal abilities. Flavonols are well researched for their activity against 
hypertension, insulin resistance, inflammation, obesity, cancer, and atherosclerosis29,30 in 
animal models. This suggests that all the three extracts of leaves and rhizome have medicinal 
potentials. Aqueous and ethanolic extracts of A. difformis leaves may have more medicinal 
potentials than that of the rhizome. This is because aqueous and ethanolic extracts contains 
higher concentrations of phytochemicals and showed more antioxidant capacity. Results from 
HPLC analysis showed that chlorogenic acid is present only in the aqueous leaves extract, 
while catechin is present in the aqueous leaves and rhizome extract only, with a very significant 
concentration in the leaves (Table 3.1). This is like the LCMS output, but with further 
identification of other compounds such as luteolin-6,8-di-C-hexoside present only in the 
aqueous leaves extract (Table 3.2). This suggests that chlorogenic acid, catechin and luteolin-
6,8-di-C-hexoside may have conferred antioxidative properties on aqueous extract of AD 
leaves. It is challenging to specify which compounds are responsible for the antioxidant ability 
of ethanolic leaves extract, has it contained high concentration of polyphenols (especially 
flavonoids) and alkaloids. However, HPLC results revealed that ferulic acid which is present in 
ethanolic and aqueous leaves extract only (Table 3.1), might have enhanced the antioxidant 
capacity of ethanolic leaves extract when compared with its rhizome or ethyl acetate extracts. 
Conversely, ethyl acetate extracts of AD rhizome may show more medicinal potency than that 
of the leaves seeing that it demonstrated higher antioxidant power and contained more 
phytochemicals. Rutin, kaempferol and coumaric acid was detected in the ethyl acetate extract 
of the rhizome while they were lacking in the corresponding leaves extract (Table 3.1). These 
compounds may have increased the antioxidant quality of ethyl acetate rhizome extract over 
the leave extract. 
 
Secondary compounds that were identified in the leaves and rhizome of AD are 
pharmacologically active and have broad spectrum of biological activities and health-promoting 
abilities. Studies revealed that quercetin is a strong antioxidant and it possesses anti-
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inflammatory, anti-hypertensive, anti-cancer, and anti-thrombotic potentials29,30,31. Kaempferol 
has anti-bacterial, antioxidant, neuro-protective abilities32. Investigations on rutin revealed its 
strong antioxidant power and ameliorative capacity when treated against cancer, diabetes, 
hypertension and pathogens13. Studies suggest that cinnamic acids may be potent against 
diabetes33. Chlorogenic acids are cinnamic acid derivatives with antioxidant and anti-
inflammatory effects. Caffeoylquinic acids are naturally occurring chlorogenic acids and 
exhibits bioactivities against neuronal damage and obesity34,35. They also act as analgesic 
through inhibition of histamine36,37.  Caffeoylquinic acids are potential agents of transferrin-
mediated drug delivery for targeted cancer therapy38. Ferulic acid is a derivative of curcumin, 
it possesses the unique pharmacokinetic properties which makes it retained in the body 
circulation for several hours.  Ferulic acid is neuroprotective; inhibits neuro-inflammation and 
attenuates damage of macrovascular endothelia cells of the brain39. It demonstrated cardio-
protection against ischaemia reperfusion through up-regulation of HSP70 via NO-ERK1/2 
pathway40,41. It has been used as a therapeutic agent against epilepsy and it was effective42. 
Ferulic acid also exhibit other biological activities such as anti-apoptotic, cardioprotective, anti-
diabetic, and anti-inflammatory properties43,44,45. Catechins possess strong antioxidant 
properties, they have been reported to reduce incidence of cancer46,47. Low concentrations of 
catechins have demonstrated the ability to increase the motility and viability of sperm cells 
thereby improving the semen quality48. Catechins also lower the risk of type II diabetes by 
regulating insulin resistance49. Treatment with catechins minimizes pro-inflammatory 
cytokines50. In addition, catechins ameliorate cardiac failure by improving the endothelial 
function via up-regulation of Akt-eNOS pathway51. The active principles present in the leaves 
and rhizome of AD may be responsible for its medicinal abilities as treatment with AD leaves 
and rhizome have also shown to exhibit most of these properties26. 
 
The biological properties of natural antioxidants have been widely attributed to phenolic 
compounds52,53. Interestingly, there is a strong correlation between alkaloids and ORAC in the 
aqueous leaf extract; which exhibited the highest antioxidant ability. This suggests that 
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alkaloids present in the aqueous leaf extract, may be more responsible for its high oxygen 
scavenging ability when compared to other secondary compounds present in the extract. This 
is supported by antioxidant analysis carried out by Koolen and colleagues7. From his research, 
certain isolated alkaloids indicated high scavenging ability for oxygen radical relative to trolox. 
Total polyphenolic compounds present in the ethanol extract of AD rhizome showed a strong 
and positive correlation with the ferric reducing power of the extract. This reveals that phenolic 
acids appear to have more antioxidant potential in the ethanol extract of AD rhizome than other 
compounds present. In contrast, total polyphenols inversely and strongly correlated with TEAC 
revealing that polyphenols in AD were not involved in the trolox-reducing activity of the plant. 
This is similar to the findings of Locatelli and his colleagues53, where the phenolic compounds 
from garlic samples showed a strong and negative correlation with its antioxidant activity. 
Correspondingly, some polyphenolic compounds have redox potentials4. This agrees with 
Block’s finding54 who reported that depending on specific conditions, compounds containing 
sulphur may act as antioxidants or pro-oxidants. The significant correlation between total 
polyphenols, flavanols, and alkaloids in the aqueous extract of AD rhizome shows that there 
could be a synergetic effect of these phytochemicals in conferring antioxidant ability on the 
extract. 
 
3.5 Conclusion 
The leaf and the rhizome extracts demonstrated free radical scavenging activity on highly 
reactive hydroxyl radical, oxygen radical and ABTS radical. Hence, leaves and tuber of A. 
difformis are potential sources of natural antioxidants. A. difformis may be a therapeutic agent 
targeted at treatment of diseases linked with oxidative stress, and prevention of complications 
that might arise from such diseases. Thirty-four (34) compounds were identified in the leaves 
and rhizome extracts of A. difformis, which is the first report on identification of compounds in 
the leaves of A. difformis. Presence of active compounds in the leaf and rhizome extracts of 
A. difformis, may confer possible preventive and ameliorative potentials during pathological 
conditions.  
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3.6 Recommendation 
Further research work could be done to isolate and characterize the identified compounds for 
structural elucidation. Furthermore, these isolated active compounds with little or no scientific 
knowledge, present in A. difformis can be extensively investigated for their medicinal 
potentials. 
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ABSTRACT 
Ethnopharmacological relevance: The liver is an important organ involved in metabolism 
of xenobiotics and their metabolites and it is vulnerable to oxidative damage. Hyperglycaemia 
is highly implicated in the progression of diabetes mellitus, and adversely affects the liver. 
Though conventional hypoglycaemic drugs may be effective in reducing blood glucose, they 
do not appear to be effective in attenuating the progression of diabetes and its complications. 
Anchomanes difformis have been used traditionally to treat diabetes, pain and other related 
conditions.  
Aim of the study: This study evaluated the ameliorative effects of Anchomanes difformis on 
hyperglycaemia and hepatic injuries in type 2 diabetes. 
Materials and methods: Type 2 diabetes was induced in male Wistar rats with a single 
intraperitoneal injection of streptozotocin (40mg/kgBW) after two weeks of fructose (10%) 
administration. Aqueous extract of A. difformis (200 and 400mg/kgBW) and gilbenclamide 
(5mg/kgBW) were administered orally for six weeks. Blood glucose concentrations were 
measured. Serum levels of liver dysfunction markers (ALT, AST, and ALP), total cholesterol, 
triglycerides, HDL- and LDL-cholesterol were investigated. Total protein, albumin, and 
globulin were also assessed. Antioxidant parameters: ORAC, GSH, GSSG, SOD, CAT and 
FRAP were evaluated in the liver while ORAC, FRAP and lipid peroxidation was determined 
in the serum. Histological examination of the liver tissue was carried out. 
Results: Treatment with aqueous extract of A. difformis significantly (p<0.05) reduced the 
blood glucose and reversed steatosis in the diabetic-treated rats. The antioxidant status of 
diabetic-treated rats was significantly (p<0.05) improved. Serum levels of liver dysfunction 
markers were significantly (p<0.05) reduced in diabetic-treated rats.  
Conclusion: Anchomanes difformis ameliorated hyperglycaemia and hyperlipidaemia, 
improved antioxidant status, and protected against hyperglycaemia-induced hepatopathy in 
a diabetic animal model.  
Keywords: anchomanes difformis, antioxidants, diabetes, hyperglycaemia, hyperlipidaemia, 
liver  
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ABBREVIATIONS 
T2D  Type 2 diabetes 
TP  Total protein 
ROS  Reactive oxygen species 
SOD  Superoxide dismutase 
CAT  Catalase 
GSH  Glutathione 
GSSG  Glutathione disulphide/oxidized glutathione 
ORAC  Oxygen radical absorbing capacity 
FRAP  Ferric reducing antioxidant power 
AD  Anchomanes difformis 
STZ  Streptozotocin 
SRC  Standard rat chow 
FBG  Fasting blood glucose 
ALT  Alanine transaminase 
ALP  Alkaline phosphatase 
AST  Aspartate transaminase 
TBA  Thiobarbaturic acid 
TBARS Thiobarbaturic acid reactive substances 
MDA  Malondialdehyde 
FAS  Fatty acid synthetase 
HDL  High-density lipoprotein 
LDL  Low-density lipoprotein 
H&E  Hematoxylin and eosin 
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4.1 Introduction 
Sedentary lifestyle and nutritional overload have been directly implicated in the increased 
prevalence of type 2 diabetes (T2D) (Anhê et al., 2013). T2D which is shown by constant 
hyperglycaemia and insulin resistance leads to various organs dysfunction, such as the 
kidneys, livers, heart, blood vessels, reproductive system and the eyes (Lüscher et al., 2003). 
Persistent hyperglycaemia results in an increased production of free radicals and ultimately 
oxidative stress. Oxidative stress is an important factor in most pathological conditions. 
Oxidative damage in the structure and functions of cellular biomolecules including lipids, 
nucleic acids, and proteins, is highly implicative in the progression of diabetes and the 
development of its complications (Ghanbari et al., 2016). 
 
The liver is highly essential in glucose and lipid homeostasis (Bora et al., 2016; Sivajothi et 
al., 2007). Diabetes mellitus leads to severe damage in the liver such as necrosis, cirrhosis, 
hepatic steatosis, inflammation (Guven et al., 2006). This is usually depicted by abnormal 
levels of serum hepatic enzymes due to leakage from the damaged hepatocytes into the 
bloodstream. Increase in the serum levels of the hepatic enzymes may lead to reduced 
concentrations of total protein (TP) and albumin in the serum (Kaysen et al., 2002). Poor 
glycaemic control during diabetes mellitus causes hyperlipidaemia, which is associated with 
an increased flux of free fatty acid due to insulin resistance (Biradar et al., 2018; Sirsikar et 
al., 2016). 
 
The body has its own antioxidant defence mechanisms by which it combats reactive oxygen 
species (ROS) generated from metabolic and environmental sources. The antioxidant 
defence mechanisms prevent the initiation of free radical chain reactions (Turk et al., 2002). 
These defence mechanisms may be enzymic or non-enzymic (Vertuani et al., 2005). The 
antioxidant enzymes include superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase and they act as free radical scavengers by donating electrons to react with the 
ROS (Ghanbari et al., 2016). Glutathione (GSH) and glutathione disulphide (GSSG) are small 
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non-enzymic molecules used in fighting oxidants in the body. Other factors used to determine 
antioxidant status in the body are oxygen radical absorbing capacity (ORAC) and ferric 
reducing antioxidant power (FRAP). These antioxidant mechanisms that safeguard the body 
against oxidative damage is compromised in diabetic conditions (Ghanbari et al., 2016; Valko 
et al., 2006).  
 
Fructose is majorly metabolised in the liver and its consumption disturbs glucose metabolism 
and uptake. This results in a significantly increased rate of de novo lipogenesis and 
triglyceride synthesis, which contributes to decreased insulin sensitivity and hepatic insulin 
resistance. This appears to be the underlying mechanism of insulin resistance.  Furthermore, 
fructose, is preferentially metabolized to lipids in the liver compared with glucose (Basciano 
et al., 2005). Fructose consumption therefore induces insulin resistance, impairs glucose 
tolerance, causes hyperinsulinemia and hypercholesterolemia in animal models (ter Horst et 
al., 2016). A study on commonly consumed fruit juices revealed that natural fructose can alter 
lipid and protein oxidation biomarkers in the blood, and mediate oxidative stress responses in 
vivo (Breinholt et al., 2003).  Also, the short-term consumption of fructose was demonstrated 
to promote insulin resistance in the liver of non-diabetic adults (ter Horst et al., 2016). 
Administration of 10% fructose for two weeks, followed by a single intraperitoneal or 
intravenous injection of streptozotocin (40 mg/kg body weight) has been shown to result in a 
persistent diseased state characterized by hyperglycaemia (high blood glucose) with major 
clinical signs of T2D such as insulin resistance (Wilson and Islam, 2012). 
 
Anchomanes difformis (AD); a tropical plant found mostly in African forests, is rich in 
phytochemicals and has been reported for its biological activities (Ahmed, 2018). Folkloric 
uses of AD include the intake of the its decoction to treat coughs, diabetes, dysentery and 
throat related problems (Oyetayo, 2007). Some of these ethno-medicinal uses of A. difformis 
has been established through scientific evidences (Udje et al., 2018). Previous in vitro studies 
carried out in our research group on the six different extracts of AD revealed its free radical 
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scavenging property and antioxidant ability, while the aqueous leaf extract demonstrated the 
highest antioxidant (Alabi et al., 2019).  We further investigated the phytochemical 
characterization of AD extracts using HPLC and LC-MS (Table 4.1), and we identified 
nineteen bioactive compounds from the aqueous extracts of AD (Alabi et al., 2019) (Alabi et 
al., 2019). Three compounds were also isolated from the rhizome of AD by Nkoh and 
colleagues (Nkoh et al., 2015).  
 
Table 0.1: compounds identified in aqueous extract of AD after characterization using UPLC-MS (Alabi 
et al., 2019)  
 Compounds Concentration (mg/mg dry mass of sample) 
   
1. Luteolin 
Scutellarein 
Kaempferol 
0.008267 
2. Vicenin_2 0.165466 
3. Chryosoeriol 0.102627 
4. Vitexin 0.043549 
5. Phloridzin 0.539154 
6. Rutin 0.019947 
7. Catechin 0.000521 
8. Hesperedin 0.003414 
9. p-Coumaric acid 
m-Coumaric acid 
o-Coumaric acid 
0.012879 
10. 4-HBA 0.003496 
11. Luteolin-6,8-di-C-hexoside 0.012534 
12. 4-Vinylsyringol 0.180939 
13. Chrysoeriol-7-O-glucoside 
Or  
Isorhamnetin-3-O-rutinoside 
0.146249 
14. Apigenin 0.272873 
15. Apigenin-6,8-di-C-glucoside,  0.103761 
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Chrysoeriol-7-O-apiosyl-
glucoside, 
Luteolin-7-O-rutinoside, 
Kaempferol 3-O-rutinoside, 
Kaempferol 3-O-galactoside 7-O-
rhamnoside 
16. Hispidulin 0.104893 
17. Hispidulin_2 0.104792 
18. Kaempferol 0.008554 
19. Quercetin 0.000635 
 
A study reported only the hypoglycemic effect of ethanolic extract of AD rhizome in alloxan-
induced diabetes using Wistar rats (Adeyemi et al., 2015), however the hepatoprotective 
ability and antioxidative properties of AD extracts in vivo diabetic model has not been 
investigated. This study therefore explored the hypoglycaemic property of aqueous leaves 
extract of AD in fructose-streptozotocin induced T2D in male Wistar rats, focusing on its role 
in ameliorating liver injury, hyperlipidaemia and restoring structural liver architecture. This is 
the first study to evaluate the antioxidant effect of aqueous leaf extract of AD in diabetes and 
diabetic complications. The potentials of AD were measured in comparison to a standard 
anti-diabetic drug; glibenclamide. 
 
4.2 Materials and methods 
4.2.1 Plant Preparation 
4.2.1.1 Collection and Registration 
The leaves of Anchomanes difformis (Engl: blume) were harvested from a farm in Abeokuta, 
Ogun state, Nigeria. The authentication was conducted at the Herbarium, University of 
Lagos, Nigeria (LUH6623) and a specimen voucher was deposited at the herbarium. The 
plant’s name has been checked with http://www.theplantlist.org. (ID: kew-8734). Some of the 
local names of A. difformis include Ògìrìòsákó (Yoruba); Kabaka-kachulu (Lunda); Niamé 
kwanba (Baule). 
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4.2.1.2 Extraction 
Aqueous extraction of AD leaves was done using cold-stirred extraction method. The leaves 
were dried under shade and blended to increase the surface area. The blended leaves were 
defatted using n-hexane (10%W/V) for 48 hours. The leaves were further soaked in water for 
48 hours in the ratio 1:10 of plant material and solvent at 2-4oC. A vacuum filtration method 
was used to filter off the debris and the filtrate was lyophilized. The pulverized extract was 
stored at -20oC for further analysis. 
 
4.2.2 Ethical Approval 
The experimental protocols described in this study was approved by the Faculty of Health 
and Wellness Sciences, Research Ethics Committee (REC) of Cape Peninsula University of 
Technology (CPUT), Bellville, South Africa.  Ethical approval was granted for this study with 
REC approval reference number: CPUT/HW-REC 2016/A4. Also, ethical clearance was 
obtained (REF. 04/17) from the Ethics Committee for Research on Animals from South 
African Medical Research Council where the animal study from acclimatization to euthanasia 
was carried out.  
 
4.2.3 Animals  
Male Wistar rats (180 ± 10g, 8 weeks old) were obtained from the Animal facility, 
Stellenbosch University, South Africa. This study was carried out at the Primate Unit & Delft 
Animal Centre (PUDAC), South African Medical Research Council (SAMRC), Cape Town, 
South Africa. Animal handling, care and other procedures were done in accordance to the 
standard operating procedure of SAMRC PUDAC (SOP No: 2016-R01) which conforms to 
the internationally accepted, revised, South African National Standard for the Care and Use 
of Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008).  
The animals were acclimatized for 3 weeks. The rats were housed under controlled, standard, 
laboratory conditions; humidity between 45% to 55%, and an ambient temperature between 
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22oC to 26oC. Standard rat chow (SRC) and water was fed to all the rats ad libitum and they 
were exposed to the normal photo period (12hour dark/12hour light).  
 
4.2.4 Experimental Design 
Sixty-four (64) male, Wistar rats with weights ranging from 270-300g were used for this study. 
The rats were randomly grouped into one of seven (7) groups with a minimum of eight rats 
in each group (8 rats in normal groups and 10 in diabetic groups) as summarised in Figure 
4.1. Water served as the vehicle for fructose and AD administration, while citrate buffer was 
the vehicle for streptozotocin. Animals in group 1 served as the normal control (NC) and 
received vehicle only. Animals in group 2 and 3 are normal rats who received only 200 and 
400mg/kgBW of AD aqueous extract respectively (N+AD 200 and N+AD 400), these served 
as the treated control. Groups 4 to 7 consisted of animals that were placed on 10% fructose 
for 2 weeks followed by streptozotocin (STZ). Group 4 received vehicle only (DC), group 5 
and 6 were given 200 and 400mg/kgBW of AD aqueous extract (D+AD 200 and D+AD 400) 
respectively while group 7 received 5mg/kgBW of gilbenclamide; an antidiabetic drug (D+G).  
 
 
Figure 0.1: Experimental design. Animals were randomly assigned into 7 groups (n≥8). 14 days 
administration of 10% fructose preceded a single-dose injection of STZ (40mg/kg). Animals confirmed 
diabetic after 5 days. Normal rats were administered the vehicle; water. 
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4.2.5 Induction of Type 2 Diabetes 
A 10% fructose solution was administered to the rats ad libitum (150mls/per day) for 2 weeks 
followed by a single dose intraperitoneal injection of STZ; 40 mg/kg body weight (Wilson and 
Islam, 2012). Diabetes was confirmed after 5 days of STZ administration, rats with fasting 
(overnight; 16 hours) blood glucose level greater than 15mmol/l were considered diabetic. 
Treatment commenced immediately with aqueous extract of AD which was delivered via oral 
gavage. 
 
4.2.6 Blood and Tissue Collection 
After the treatment, the rats were weighed and anaesthetized with 2% isoflurane per oxygen 
(1L/min flow rate) via inhalation. Blood was collected from the portal vein into Z-serum clot 
activator tubes. Blood samples were centrifuged at 4,000g for 10 min at 4oC. Aliquots of the 
supernatant were stored at -800C for biochemical analysis. The liver was excised 
immediately, washed in ice-cold phosphate buffered saline (PBS), dabbed and weighed. The 
liver was then frozen using liquid nitrogen and later stored at -800C for further analysis.  
 
4.2.7 Measurement of Fasting Blood Glucose and Oral Glucose Tolerance Test 
Fasting blood glucose (FBG) levels were measured weekly for 10 weeks, this period spans 
from fructose administration, induction of diabetes, treatment with AD to euthanasia. Rats 
were fasted overnight (16 hours), blood glucose concentrations were taken using ACCU-
CHEK glucometer (Roche, South Africa). Oral glucose tolerance test was done over a period 
of 2 hours, readings were taken at 0, 30, 60, 90 and 120 minutes immediately after an oral 
administration of 0.5g/kg body weight of glucose.  
 
4.2.8 Determination of Biomarkers for Organ Function 
In this study, biochemical and histological parameters were assessed for organ integrity.  
Alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), 
albumin, total protein and lipid profile; total cholesterol, HDL-cholesterol, LDL-cholesterol and 
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triglycerides were measured in the serum. Serum AST and ALT levels were estimated using 
optimized ultraviolet test (340 nm), ALP was measured in the serum at 405 nm by a kinetic 
photometric procedure. HDL cholesterol was determined using an enzymatic colorimetric 
test; accelerator selective detergent method, while LDL cholesterol was estimated with 
Friedewald equation (Friedewald et al., 1972). Total cholesterol and triglycerides were 
measured by an enzymatic photometric assay. The analyses were carried out using Horiba 
kits (Montpellier, France) and performed on an ABX Pentra 400 Chemistry Analyzer (Horiba) 
according to manufacturer’s instructions. 
 
4.2.9 Tissue Preparation 
A 200mg sample of the liver was homogenized on ice in 2mls of 50mM phosphate buffer with 
0.5% triton and centrifuged at 10,000x gravitational force for 15 minutes at 40C. The 
supernatants were aliquoted and stored at -80 °C. 
Enzymic and non-enzymic antioxidant indices; superoxide dismutase (SOD), catalase (CAT), 
oxygen radical absorbing capacity (ORAC), Ferric reducing antioxidant power, (FRAP), total 
glutathione (GSH), oxidized glutathione (GSSG) were measured in the liver homogenates. 
Lipid peroxidation (TBARS), ORAC and FRAP were also measured in the serum to estimate 
the antioxidant levels of the serum. 
 
4.2.10 Lipid Peroxidation  
Lipid peroxidation, a major indicator of oxidative stress was measured using thiobarbituric 
acid (TBA) reaction according to the modified methods of Matsunami et al. (2010) and 
Wasowicz et al. (1993). A 100 µL of sample was pipetted into a 2mL Eppendorf tube followed 
by the addition of 12.5 µL of 4mM BHT (butylated hydroxy toluene) in ethanol. Approximately 
100 µL of 0.2M O-phosphoric acid was added and the solution vortexed for 10 seconds. This 
was followed by the addition of 12.5 µL of 0.11M TBA reagent and the mixture was then 
vortexed. The solution was incubated at 900C for 45 minutes, left on ice for 2 minutes, and 
further allowed to cool at room temperature for 5 minutes. The reaction of malondialdehyde 
92 
 
(MDA) present in the sample with TBA forms a pink colored chromophore. The thiobarbituric 
reactive substances (TBARS) were extracted with n-butanol, followed by the addition of 100 
µL of saturated NaCl for better separation and the samples were then vortexed. The solution 
was centrifuged at 15000x g at 4OC for 2 minutes and the solution separated into two layers. 
The butanol solution formed the top layer of which 300 µL of the butanol-TBARS layer was 
pipetted into the microplate and absorbance read at 532nm.   
 
4.2.11 ORAC and FRAP 
ORAC and FRAP were used to evaluate the antioxidant capacity of the serum and liver using 
a fluorescence Multiskan Spectrum plate reader (Thermoscan Electron Corporation, USA). 
The ORAC assay was performed following a modified method of Prior et al., (2003) which 
measured the potential of the antioxidants present in the sample to quench peroxyl radicals 
in comparison to Trolox; the standard reference. FRAP was assayed according to the method 
described by Benzie and Strain (1999), where the ability of a sample to reduce Iron (III) to 
Iron (II) was measured at a wavelength of 593nm using L-Ascorbic acid as the standard 
reference. 
 
4.2.12 Superoxide Dismutase 
The activity of SOD was determined by measuring the auto-oxidation of 6-hdroxydopamine 
(6-HD) and the amount of the enzyme needed to exhibit dismutation of the superoxide 
radicals (Ellerby and Bredesen, 2000). This assay quantifies all the three types of SOD 
(CU/Zn-, Mn-, and Fe-SOD) that could be present in the sample. A 15 µL sample was placed 
into wells containing 170 µL of 0.1mM DETAPAC (Diethylenetriaminepentaacetic acid), 
followed by the addition of 15 µL of 6-HD (1.6mM) to kick off the reaction. The absorbance 
was read at 490nm for 4 minutes in 1-minute intervals. The activity of SOD present in the 
sample was calculated from the equation obtained from the linear regression of the SOD 
standard curve. 
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4.2.13 Catalase 
The activity of catalase was assessed by the method of Ellerby and Bredesen (2000) where 
the rate of conversion of hydrogen peroxide to water and oxygen by catalase was measured 
at 240nm. A sample of 10 µL was added to 170 µL sodium phosphate buffer (50mM, pH 7.0) 
and 75 µL of hydrogen peroxide (30%V/V) was added to initiate the reaction. The absorbance 
was read over a minute at 15 seconds intervals. The activity of catalase present in the sample 
was extrapolated from the activity of the standard, the catalase enzyme. 
 
4.2.14 Total Glutathione and Glutathione disulphide (GSH/GSSG) 
This assay is based on the enzymatic recycling process of GSSG to GSH catalysed by 
glutathione reductase (GR) in the presence of DTNB (5,5’-dithiobis-2-nitrobenzoic acid). The 
sulfhydryl group of GSH reacts with DTNB to form a yellow coloured compound; TNB and 
GS-TNB. GS-TNB is further reduced by GR and more TNB is produced. The assay measured 
the rate of TNB production which is directly proportional to the recycling reaction and the 
concentration of GSH. A sample of 200mg of the liver was homogenized in 2mls of ice-cold, 
50mM sodium phosphate buffer containing 1mM EDTA. For GSSG, liver samples were 
homogenized in the same phosphate buffer containing 1mM EDTA and 3mM M2VP. 
Homogenates were then centrifuged at 15,000x g for 5 minutes, the supernatant was used 
for the analysis. A sample of 50 µL of the supernatant, 50 µL of GR (0.02U/µL) and 50 µL of 
0.3mM DNTB were added to each of the wells of the microplate. To this, 50 µL of GSH (3µM) 
was added, the reaction was initiated by the addition of 50 µL of 1mM NADPH. A change in 
absorbance over 5 minutes was measured at 412nm.  
 
4.2.15 Histological Examination of Liver Tissues 
Liver tissues were harvested from all the animals and fixed in 10% buffered formalin solution 
for 24 hours. Tissues were placed in small cassettes, dehydrated using ethyl alcohol series 
ranging from 50% to 100% and cleared in xylene. Embedding of tissues in paraffin was done 
at 56oC and paraffin blocks were sectioned at 5µm using a rotatory ultra-microtome. Sections 
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were deparaffinised, rehydrated and stained with haematoxylin and eosin (H&E) dyes and 
mounted. The slides were examined under a light microscope at 10x and 40x magnification. 
Observations of any changes in the structural architecture, portal or lobular inflammation, 
sinusoidal dilatation and congestion, oedema, degeneration, necrosis and fatty change were 
noted, and photomicrographs taken with Motic camera (MOTICAM BTU10) using a 
Moticonnect Image Plus 2.0 software. 
 
4.2.16 Statistical Analysis 
Values were expressed as mean ± standard error of mean (SEM). Statistical analysis of 
results was performed using one-way or two-way analysis of variance (ANOVA) to find 
differences between groups. Bonferroni test was used for all pair-wise comparisons. 
Differences (F values) were considered statistically significant at p values less than 0.05. All 
statistical calculations were done using GraphPad Prism Version 5.00 for Windows, 
GraphPad Inc., San Diego, California USA. 
 
4.3 Results 
4.3.1 Hypoglycemic effect of AD in diabetic rats 
The administration of 10% fructose for two weeks and 40 mg/kgBW of STZ led to a significant 
(p<0.05) increase in the blood glucose concentration in the diabetic rats when compared to 
normal rats (Figure 4.2A). However, treatment with 200mg and 400mg/kgBW of AD brought 
about a significant (p<0.05) reduction in the glucose levels of treated diabetic rats when 
compared to the untreated diabetic rats. Interestingly, both concentrations of AD were able 
to lower glucose concentrations more than the standard drug; gilbenclamide throughout the 
treatment period. The oral glucose tolerance test (OGTT) is a derived measure of insulin 
resistance and this was done to confirm constant hyperglycemia and insulin resistance in the 
rats administered with 10% fructose and injected with STZ in comparison with normal rats. 
The result revealed a constant significant (p<0.05) increase in the blood glucose 
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concentration of rats administered fructose and STZ when compared to normal rats. There 
was no significant (p<0.05) reduction in the glucose concentrations for 2 hours of observation. 
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Figure 0.2: Effect of AD on weekly blood glucose concentrations (A) and oral glucose tolerance test 
(B) in normal and diabetic rats. Points are indicative of mean values ± SEM of blood glucose 
concentrations. Bars with different letters are significantly (p<0.05) different from each other. 
 
4.3.2 Treatment with A. difformis abated serum levels of hepatic enzymes  
The administration of AD for six (6) weeks significantly (p<0.05) lowered biomarkers of 
hepatic injury in treated diabetic rats as illustrated in Figure 4.3. Induction of type II diabetes 
with STZ caused a significant (p<0.05) increase in the serum levels of ALT, AST and ALP. 
Treatment with 400mg/kgBW of AD extract and Gilbenclamide significantly reduced ALT 
levels in diabetic rats to normal levels (Figure 4.3A), while treatment with the 200mg/kgBW 
AD extract showed a non-significant decrease (p<0.05). A similar trend was observed in the 
levels of AST (Figure 4.3B), however, treatment with both 200mg/kgBW and 400mg/kgBW 
AD extract significantly (p<0.05) lowered AST levels in diabetic treated rats when compared 
to normal rats. It is interesting to note that AST levels in diabetic rats treated with 
gilbenclamide were significantly reduced (p<0.05) when compared with normal rats. ALP 
activity declined significantly (p<0.05) in diabetic rats treated with 400mg/kgBW AD extracts 
when compared with non-treated diabetic rats, while an observable decrease was observed 
in the diabetic rats treated with 200mg/kgBW of AD extract and gilbenclamide (Figure 4.3C). 
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Figure 0.3: Effect of AD administration on biomarkers of hepatic injury; (A) ALT (B) AST and (C) ALP 
in the serum of normal and diabetic rats. Bars with different letters are significantly (p<0.05) different 
from each other. 
 
4.3.3 Regulation/Modulation of lipid Profile by AD treatment in type II diabetes 
The concentrations of total cholesterol, HDL-cholesterol and triglycerides increased 
significantly (p<0.05) in the serum of diabetic rats (Figure 4.4(A, C and D)). Likewise, the 
serum concentration of LDL-cholesterol also increased in diabetic rats, but not significantly 
(Figure 4.4B). Treatment with 200mg/kgBW and 400mg/kg BW of AD extracts significantly 
(p<0.05) lowered the concentration of total cholesterol and HDL-cholesterol to normal when 
compared with normal control rats and diabetic rats treated with gilbenclamide (Figures 4.4A 
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and 4.4C). Triglycerides was significantly (p<0.05) reduced only in the diabetic rats treated 
with 400mg/kgBW of AD extract as illustrated in Figure 4.4D. Similarly, only diabetic rats 
treated with gilbenclamide (5mg/kgBW) showed a significantly (p<0.05) decrease in serum 
levels of LDL-cholesterol (Figure 4.4B).  
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Figure 0.4: Effect of treatment with AD on the lipid profile; (A) Total Cholesterol (B) LDL-cholesterol 
(C) HDL-cholesterol and (D) Triglycerides in the serum of normal and diabetic rats. Bars with different 
letters are significantly (p<0.05) different from each other. 
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4.3.4 Impact of AD treatment on protein synthesis in STZ-induced type II 
diabetes 
Figures 4.5A to D illustrate the concentrations of total proteins, albumin, and globulin in the 
serum. The figures indicate that total protein, albumin and LDH concentrations were affected 
by induction of diabetes as their concentrations were significantly (p<0.05) lowered. 
Inversely, albumin levels as illustrated in Figure 4.5B were restored to normalcy in the 
diabetic rats placed on 400mg/kgBW of AD extracts and gilbenclamide (5mg/kgBW).  Total 
protein level was increased to normal in diabetic rats treated with gilbenclamide only as 
presented in Figure 4.5A. Treatment with 200mg/kgBW of AD significantly (p<0.05) reduced 
globulin levels in the serum of diabetic rats when compared with non-treated diabetic rats as 
exhibited in Figure 4.5C. 
 
Total Protein
N
C
N
+A
D
 2
00
N
+A
D
 4
00 D
C
D
+A
D
 2
00
D
+ 
A
D
 4
00 D
G
0
20
40
60 a a a
b b b
a
A
Treatment Groups
C
o
n
c
e
n
tr
a
ti
o
n
g
/L
Albumin
N
C
N
C
+A
D
 2
00
N
C
+A
D
 4
00 D
C
D
+A
D
 2
00
D
+ 
A
D
 4
00 D
G
0
10
20
30
40
a a a
b b
a a
Treatment Groups
C
o
n
c
e
n
tr
a
ti
o
n
g
/L
B
Globulin
N
C
N
C
+A
D
 2
00
N
C
+A
D
 4
00 D
C
D
+A
D
 2
00
D
+ 
A
D
 4
00 D
G
0
10
20
30
a
a
Treatment Groups
C
o
n
c
e
n
tr
a
ti
o
n
g
/L
C
 
Figure 0.5: Effect of treatment with AD on (A) Total protein (B) Albumin and (C) Globulin in the serum 
of normal and diabetic rats. Bars with different letters are significantly (p<0.05) different from each 
other. 
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4.3.5 AD Intervention ameliorated lipid peroxidation, oxidative stress in type II 
diabetes 
Constant hyperglycaemia significantly (p<0.05) contributes to the increased levels of TBARS 
in the serum of diabetic rats (Figure 4.6A). This significantly (p<0.05) declined in diabetic rats 
that were administered 200mg/kgBW of AD. Lipid peroxidation decreased (though not 
significant at p<0.05) in rats treated with 400mg/kgBW of AD when compared to diabetic 
untreated. Gilbenclamide administration did not reduce lipid peroxidation in diabetic rats. 
Furthermore, antioxidant capacity measured using FRAP diminished in diabetic rats as 
illustrated in Figure 4.6B. Administration of AD extracts and gilbenclamide had no significant 
(p<0.05) influence on the ferric reducing ability in the serum. Diabetes led to a significant 
reduction in the oxygen radical absorbance capacity of the serum of rats as exhibited in 
Figure 4.6C. Furthermore, groups treated with different concentrations of AD was able to 
restore this capacity compared to normal rats. However, gilbenclamide did not have any 
effect on the ORAC in the serum of diabetic rats. 
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Figure 0.6: Effect of AD administration on biomarkers of lipid peroxidation and antioxidant activity; (A) 
TBARS, (B) FRAP and (C) ORAC in the serum of normal and diabetic rats. Bars with different letters 
are significantly (p<0.05) different from each other. 
 
4.3.6 AD administration enhanced antioxidant status in the liver of diabetic 
rats 
Hyperglycaemia resulted in a significant (p<0.05) reduction in the total glutathione levels 
(tGSH), glutathione to oxidized glutathione (GSH/GSSG) ratio and ORAC concentration in 
the liver of diabetic rats (Figure 4.7A to 4.7E). Diabetic rats who received 200mg/kgBW 
showed a significant (p<0.05) increase in the tGSH. There was an observed increase in tGSH 
levels and GSH/GSSG in diabetic rats that were administered 400mg/kgBW and the groups 
given gilbenclamide (5mg/kgBW), but not significant (p<0.05), this is presented in Figure 
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7.7A. ORAC concentrations were significantly (p<0.05) elevated in treated diabetic rats in 
response to AD administration as illustrated in Figure 4.7D. However, treatment with 
gilbenclamide did not have any positive effect on ORAC concentration in diabetic rat liver. 
There were no significant (p<0.05) changes in the FRAP concentration in normal rats, 
diabetic rats, and treated rats as exhibited in Figure 4.7E. Diabetes did not have a significant 
(p<0.05) effect on SOD levels in the liver as shown in Table 4.2. In addition, SOD activity was 
not influenced by the administration of AD and gilbenclamide. Conversely, the activity of CAT 
significantly (p<0.05) increased in diabetic rats when compared with the normal rats as 
presented in Table 4.2. Treatment with AD significantly (p<0.05) induced the activity of CAT 
in normal and diabetic rats in a dose dependent manner, gilbenclamide had the same effect 
in diabetic rats. 
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Figure 0.7: Effect of treatment on non-enzymic antioxidant indices; (A) total GSH, (B) GSH-GSSG 
ratio, (C) total GSH and GSSG, (D) ORAC, and (E) FRAP in the liver of diabetic and normal rats. Bars 
with different letters are significantly (p<0.05) different from each other. Letters with asterisk are 
significantly different from the normal control at p<0.001. 
 
Table 0.2: Effect of treatment on antioxidant enzymes in the liver of diabetic and normal rats 
  
 
 
 
 
 
 
 
 
*Values with different letters are significantly (p<0.05) different from each other 
 
4.3.7 Treatment with AD reversed pathologies and improved the histological 
structure of the liver in T2D. 
Findings from the histological examination of the liver from various treatment groups are 
shown in Figure 4.8. The normal control, non-diabetic rats showed normal histology, 
sinusoids are well divergent, the nucleus and nucleolus are clearly seen. Diabetic control 
Treatment Groups SOD (U/mg) CAT (U/mg) 
NC  53.31 ± 5.81 2683 ± 206.2a 
N+AD 200 50.98 ± 5.61 3147 ± 142.0a 
N+AD 400 40.85 ± 1.73 6201 ± 401.2b 
DC 36.53 ± 2.91 6010 ± 694.7b 
D+AD 200 40.41 ± 1.80 5937 ± 734.7b 
D+AD 400 36.34 ± 4.33 6202 ± 621.7b 
D+G 38.46 ± 4.41 6511 ± 772.2b 
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revealed enlarged sinusoids due to oedema, distorted sinusoidal arrangement, an area of 
focal necrosis exemplified by nuclear degradation (arrow ‘B’) and palour in the cytoplasm. 
Macro-vesicular steatosis can also be seen in the diabetic control rats, this was completely 
reversed in the diabetic rats treated with AD 200mg and 400mg/kgBW compared to normal 
rats. Mild centilobular necrosis and widened sinusoids were observed in the liver of diabetic 
rats treated with 200mg/kgBW of AD. Rats treated with 400mg/kgBW of AD showed normal 
histology in the liver. Steatosis and necrosis can be observed in the rats treated with 
gilbenclamide. The different pathologies that were observed in the hepatic tissues of different 
treatment groups were scored and graded as displayed in Table 4.3. 
 
Table 0.3: Hepatic injury score in the various treatment groups 
Histologic 
feature 
NC N+AD 
200 
N+AD 
400 
DC D+AD 
200 
D+AD 
400 
D+
G 
Portal  
inflammation 
0 0 0 1 1 0 1 
Steatosis 0 0 0 2 0 0 2 
Sinusoidal 
dilatation  
0 0 0 2 1 0 1 
Sinusoidal 
Distortion 
0 0 0 2 1 0 1 
Centrilobular 
necrosis 
0 0 0 3 1 0 2 
 
The hepatic injury score was graded from 0 to 3, where 0 represents <5% damage and 
categorised as ‘none’, 1 represents 5%-33% damage and categorised as ‘mild’, 2 represents 
damage between 34%-66% and categorised as ‘moderate’ and 3 represents damage >66% 
of the tissue and categorised as ‘severe’.   
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Figure 0.8: Light micrographs from liver sections of normal and diabetic rats stained with hematoxylin–
eosin (x400). The black thick arrows lettered ‘A’ points at the sinusoids, arrows lettered ‘B’ points at 
the nucleus of the hepatocytes, and arrows lettered ‘C’ shows fatty droplets in the hepatocytes. 
Magnification 10x (left) and 40x (right). CV- central vein, PT-portal triad. 
 
4.4 Discussion 
The present study demonstrates the hypoglycaemic effect of AD aqueous leaves extract in 
T2D. AD showed a higher potential in lowering blood glucose in diabetic rats than the 
standard drug; gilbenclamide. Ethanolic extracts obtained from the roots of AD has been 
reported to possess hypoglycaemic effect (Adeyemi et al., 2015). Constant hyperglycaemia 
is associated with distortion in lipid metabolism, this results in hyperlipidemia and subsequent 
hepatic steatosis (Adeyemi et al., 2015). The data showed that treatment with AD and 
gilbenclamide significantly reduced total cholesterol to normal levels. Significant increase in 
HDL-cholesterol of diabetic untreated rats may be in response to the increased LDL-
cholesterol in the blood, as HDL-cholesterol does reversed-cholesterol transport to get rid of 
excess cholesterol from the blood (Khera et al., 2011). LDL-cholesterol and triglycerides were 
reduced in diabetic rats with the administration of AD. This result is in agreement with a 
previous study which reported that root extract of AD was able to reduce plasma cholesterol 
in alloxan-induce diabetes (Adeyemi et al., 2015).   
 
Abnormalities in glucose metabolism leads to an overproduction of free radicals. The 
presence of excess free radicals results in the oxidation of biomolecules such as lipids, 
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leading to breakdown of lipids especially in the cell membrane; which is majorly made up of 
lipids (Farombi et al., 2015). Lipid peroxidation plays an important role in the progression of 
diabetes and diabetic complications such as atherosclerosis which increases the risk of 
coronary heart disease (Ayepola et al., 2014; Ekstedt et al., 2006). Lipid peroxidation 
significantly increased in diabetic rats which is suggestive of cell membrane damage due to 
an increased production of free radicals. Treatment with AD significantly lowered lipid 
peroxidation in the serum of diabetic rats. Previous studies carried out in our research group 
shows that AD contains bioactive compounds that have antioxidant properties (Alabi et al., 
2019). 
 
Loss of cell integrity due to membrane damage results in the leakage of hepatic enzymes in 
diabetic rats. Hepatic enzymes have been shown to be elevated in diabetic conditions and 
are associated with liver pathologies (Bora et al., 2016; Chen et al., 2017). Our findings are 
consistent with these studies as demonstrated by the significant increase in hepatic enzymes 
in the serum of diabetic rats. This was however abated by the intervention with AD. Hepatic 
enzymes have also been used as indices of accumulation of liver fat, which was observed in 
the diabetic controls (Figures 4.4 and 4.8). Reports shows that increased hepatic enzymes 
with liver fat accumulation leads to progression of fibrosis which constitutes a clinically 
significant risk factor in developing end-stage liver disease (Ekstedt et al., 2006). The potency 
of AD in restoring elevated hepatic enzymes and total cholesterol to normalcy suggests its 
strong capacity to ameliorate or prevent diabetic complications associated with obesity and 
insulin resistance.   
 
Proteins play a key role in cell functioning and structure. The amount of protein present in 
circulation is dependent on the balance between the rate of synthesis and the rate of 
catabolism or loss (Hamad et al., 2009). Therefore, the depletion of serum proteins may be 
due to increased catabolism or decreased synthesis. Abnormalities in serum proteins are 
observed during pathological conditions, especially diabetes mellitus (Hasan and 
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Abdulsattar, 2015; Suzuki, 2006). STZ-induced diabetes demonstrated a decreased 
concentration of total proteins and albumin in the serum. The liver is a major site of protein 
synthesis, therefore pathological conditions that adversely affect the liver can lead to a 
reduced production of proteins, hence the low concentration of total proteins observed in the 
diabetic groups. The observed low protein in the diabetic groups may also be as a result of 
an increased supply of amino acids for gluconeogenesis (Adeyemi et al., 2015). The ability 
of AD to restore protein levels to normalcy in diabetic rats placed on 400mg/kgBW, is 
suggestive of its involvement in enhancing protein synthesis. Albumin is one of the most 
abundant proteins in the serum (Wang et al., 2015) with numerous functions such as 
maintaining the colloidal osmotic pressure, acts as a source of amino acids, and in binding 
and transporting of substances. Low concentration of serum albumin may cause a decline in 
the antioxidant status of diabetic rats and is a risk factor for the development of diabetic 
complications (Obia et al., 2017; Park et al., 2014). The current study indicated a significant 
elevation in the albumin concentrations of diabetic rats treated with AD, this may have 
promoted the antioxidant capacity and delayed the progression of diabetic complications in 
the treated rats.  
 
The oxygen radical absorbing capacity and ferric reducing antioxidant power of the diabetic 
rats were significantly (p<0.05) reduced. This is associated with the increased production of 
ROS as depicted by the significantly increased lipid peroxidation. However, AD significantly 
(p<0.05) elevated ORAC levels back to normal, whereas there was no effect on the FRAP 
levels. Administration of gilbenclamide was not able to improve the antioxidant status in the 
serum of rats Furthermore, there was an observable increase in the antioxidant indices in 
normal rats placed on AD in a dose-dependent manner, though not significant. AD increased 
the ORAC and FRAP levels in the serum and GSH in the liver of normal rats. This indicates 
the antioxidant ability of AD over gilbenclamide.  
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AD caused a dose-dependent induction of catalase in normal rats. The increased activity of 
catalase in the un-supplemented diabetic rats were likely due to the increased hydrogen 
peroxide and a compensatory response to the oxidative damage. Certain studies have 
reported a reduction in catalase activity in diabetic conditions (Erejuwa et al., 2010; Ghanbari 
et al., 2016). Contrarily, our findings corroborate with those of El Barky and colleagues (2016) 
who observed a significant increase in catalase activity in the liver of STZ-induced diabetic 
rats. Furthermore, this trend was also reported by Maritim  and co-workers (Maritim et al., 
2003). The activity of SOD in the liver of diabetic rats was not affected and administration of 
AD did not significantly influence SOD levels in normal and diabetic rats. Very similar 
observations were reported by Turk et al., (2002). Glutathione is an important inhibitor of free 
radical-mediated lipid peroxidation.  Diminished tGSH levels and increased concentrations of 
TBARS are consistently observed in diabetes (Maritim et al., 2003) and our findings 
corroborate with these. AD was able to significantly increase tGSH levels in treated rats when 
compared to normal rats. The decreased tGSH levels in the liver of diabetic rats may be due 
to an increased utilisation in trapping the oxyradicals produced. AD administration restored 
antioxidant capacity in the liver of diabetic rats as expressed by the significantly increased 
ORAC levels in diabetic treated rats when compared to normal levels. This signifies the ability 
of AD to ameliorate oxidative stress-induced hepatic injuries in T2D. 
 
T2D affected the normal histoarchitecture of the liver as shown by necrosis, macro-vesicular 
steatosis, dilatated sinusoids due to oedema. Treatment with AD markedly improved the 
histology of the liver as some of the pathologies such as steatosis were completely reversed. 
The observations were dose-dependent, as 400mg of AD restored the overall 
histoarchitecture of the liver in diabetic rats back to normal. Steatosis reflects an impairment 
of the normal processes of synthesis and elimination of triglycerides. Insulin resistance is a 
major factor that contributes to hepatic steatosis by inhibiting lipase thereby gaining control 
over free fatty acid release into the hepatocytes from the adipocytes (Hickman et al., 2002; 
Samuel and Shulman, 2016). This stimulation may be responsible for the observed significant 
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increase in triglyceride levels in the serum of diabetic rats, which was significantly reduced in 
response to treatment with AD. Also, LDL-cholesterol delivers cholesterol to the cells and this 
was significantly elevated in the serum of diabetic rats as was the case with total cholesterol 
levels. These were reversed with administration of AD. 
 
A summary of the likely pathways involved in the antioxidant and hepatoprotective activity of 
AD is illustrated in Figure 4.9. The administration of fructose and STZ led to the damage of 
beta cells in the pancreas, this resulted into insulin resistance and hyperglycaemia. Insulin 
resistance brought about disturbed lipid and protein homeostasis which translated to 
hyperlipidaemia and decreased protein synthesis. Lipids were transported from the blood 
system to the hepatocytes causing steatosis. Persistent hyperglycaemia generated more 
ROS and caused increased lipid peroxidation which in turn resulted into oxidative damage of 
the cell membrane and leakage of hepatic enzymes. AD was able to attenuate these 
resultants effects of STZ by preventing or reducing oxidative stress, hyperglycaemia, insulin 
resistance, blocking fat mobilisation, and lipid peroxidation. 
 
 
Figure 0.9: Proposed pathways involved in the antioxidant and hepatoprotective effect of Anchomanes 
difformis. 
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4.5 Conclusion  
A. difformis ameliorated hepatic injury in fructose and STZ-induced diabetes in male Wistar 
rats. A. difformis exerts its hepatoprotective effects by demonstrating good glycaemic control, 
regulating lipid homeostasis, improving the antioxidant status, and restoring hepatic enzymes 
to normal levels. Treatment with A. difformis displayed a more antidiabetic ability than 
gilbenclamide. Administration of A. difformis in diabetes may be a potential therapeutic agent 
in the management of diabetes and resulted hepatic injuries. 
 
Future Prospects 
This study establishes the ability of AD aqueous extract to ameliorate hyperglycemia, 
hyperlipidemia, oxidative stress, liver steatosis and other pathologies in the liver. The findings 
will be helpful in the management of T2D using AD. However further molecular studies on 
the mechanisms by which AD exerts its hypolipidemic, hypoglycemic and antioxidant 
potentials in T2D can be explored, this will be a great tool in exploiting the full potentials of 
AD. Studies investigating the effect of AD on the expression of glucose transporters and other 
proteins involved in glucose transport and uptake, and insulin signalling is also essential. It 
is hoped that the current study will encourage further research on the effect of AD in other 
diabetic complications such as cardiomyopathy, nephropathy and reproductive dysfunctions. 
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ABSTRACT  
Background 
Persistent hyperglycemia has been known to cause enhanced generation of reactive oxygen 
species in diabetes. Several inflammatory cytokines are induced by oxidative stress, and their 
release also leads to increased oxidative stress, this makes oxidative stress one of the 
important factors in the development of chronic inflammation and other immune responses. 
These have been implicated in the development of diabetic complications such as nephropathy 
and cardiomyopathy. Anchomanes difformis has been shown to possess antioxidant and anti-
inflammatory potentials. The present study investigated the immunomodulatory potential and 
antiapoptotic ability of Anchomanes difformis to ameliorate heart toxicity and injury in type 2 
diabetes.  
Methods 
Two weeks of fructose (10%) administration, followed by single intraperitoneal injection of 
streptozotocin (40mg/kg) were used to induce type II diabetes in male Wistar rats. Leaf extract 
(aqueous) of Anchomanes difformis (200 and 400mg/kg) was administered orally for six 
weeks. Blood glucose concentrations and body weights before and after interventions were 
determined. Interleukin (IL)-1β, IL-6, IL-10, IL-18, MCP-1 and TNFα were measured in the 
heart homogenates. CAT, SOD, total protein, ORAC, FRAP, TBARS and H-FABP levels were 
determined. Expressions of transcription factors (Nrf 2 and NFkB/p65) and apoptotic markers 
were also investigated in the heart. 
Results 
Anchomanes difformis administration reduced pro-inflammatory cytokines, increased anti-
inflammatory markers and enhanced antioxidant defense in the heart of diabetic treated 
animals.  
Conclusion 
Anchomanes difformis is a new, promising therapeutic agent that can be explored for the 
treatment of pathological conditions associated with immune responses and will be a useful 
tool in the management of associated diabetic complications. 
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ABBREVIATIONS 
AD  Anchomanes difformis 
ARE  Antioxidant response elements  
Bcl2  B-cell lymphoma 2 
CAT  Catalase 
FRAP  Ferric reducing antioxidant power 
H-FABP Heart fatty acid binding protein 
IL  Interleukin 
KEAP-1 Kelch-like ECH-associated protein 1 
MDA  Malondialdehyde 
MCP-1  Monocyte chemoattractant protein 1 
Nrf2  Nuclear factor-erythroid 2-related factor 2 
NFkB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
ORAC  Oxygen radical absorbance capacity 
PBS  Phosphate buffer saline 
ROS  Reactive oxygen species 
SOD  Superoxide dismutase 
STZ  Streptozotocin 
TBARS Thiobarbituric acid reactive substances 
TNF-α  Tumor necrosis factor alpha 
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5.1 Introduction 
Constant hyperglycemia: a major characteristic of diabetes mellitus (DM) has been linked to 
overproduction of ROS. Excessive generation of ROS activates cytokines production, 
apoptotic proteins and transcription factors, resulting in chronic inflammation and increased 
apoptosis; an underlying factor in the development of diabetic complications (Miranda-Díaz et 
al., 2016). Evidence suggest that oxidative damage, pro-inflammatory responses and 
apoptosis are key players in pathological conditions relating to diabetic cardiomyopathy [1,2]. 
Diabetic cardiomyopathy (DCM) is a pathological condition of the heart observed in subjects 
with diabetes, and it is independent of other cardiovascular pathologies such as hypertension, 
ischemic heart injury, coronary artery disease, and congenital heart diseases. DCM is a major 
cause of heart failure [3,4]. The progression of diabetes mellitus to diabetic cardiomyopathy 
involves the interplay of several mechanisms; oxidative damage, inflammation, apoptosis, 
mitochondrial dysfunction and overactivation of Raas (Renin-angiotensin aldosterone system) 
as illustrated in Figure 5.1 [5,6]. 
 
 
Figure 0.1: The pathophysiological pathway in the progression of diabetic cardiomyopathy. 
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Inflammation is a form of defense and protection from infections and tissue damage, however 
the uncontrolled regulation of immune responses can lead to excessive tissue damage [7,8].  
Pro-inflammatory cytokines with other indices of inflammation have been shown to be elevated 
in the hearts of T2D subjects [9,10]. Diabetes triggers lower levels of systemic inflammation in 
the cardiomyocytes as an early response to myocardial injury due to the overproduction of 
mitochondrial ROS. This systemic inflammation triggers the recruitment of leukocytes and 
cause the secretion of pro-inflammatory cytokines and chemokines such as interleukin (IL)-1β, 
IL-6 and TNF-α [5,11]. Further exposure to high concentrations of glucose results in increased 
production of advanced glycation end products (AGEs). AGEs are regulators of endothelial cell 
permeability, migration of monocytes, and ultimately activates nuclear factor kappa-light-chain 
enhancers of activated B cells (NFkB) [12]. NFkB primarily stimulates the expression of more 
pro-inflammatory cytokines (TNF-α, IL-6, IL-18) in the heart which are associated with 
hypertrophy, fibrosis and left ventricular dysfunction. This cascade of reactions is repeated 
severally, leading to a sustained immune response thereby causing further injury and hence, 
cardiomyopathy [6,13]. 
 
The significance of maintaining homeostasis in multicellular organisms is pivotal and having a 
balance between cell death and proliferation plays a key role in homeostasis. Cell death could 
occur in the form of necrosis, apoptosis, autophagy. Apoptosis is a programmed cell death that 
serves as natural barrier against uncontrolled proliferation of cells and prevent injury that may 
be caused by damaged or stressed cells [14]. Excess cellular level of ROS cause damage to 
biomolecules, membranes and organelles which activates cell death processes such as 
apoptosis [15]. However, increased apoptosis has been implicated in the development of 
diabetic complications (DCM). Recently, Nunes and co-workers reported the influence of MCP-
1 on apoptosis in cardiomyocytes. This substantiates the link between inflammation, apoptosis 
and DCM. [16].  
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During increased oxidative stress, the body system augments its antioxidant capacities to 
combat elevated oxidative stress. The nuclear factor E2-related factor 2 (Nrf2) is a transcription 
factor that is associated with mitigating oxidative stress [17]. Nrf2 is activated in the cytosol to 
counteract increased oxidative stress and maintain homeostasis. This is done by enhancing 
the expression of AREs such as CAT, SOD, GSH and GPx that will mop up the reactive oxygen 
and nitrogen species.  Keap1 which is bound to actin in the cytosol, interacts with Nrf2, 
promotes ubiquitination, and eventually degrades Nrf2. This process is rapid, making the half-
life of Nrf2 around 13-21 minutes [18,19]. This, however, keeps Nrf2 at relatively low basal 
levels. Conversely, during increased intracellular ROS which leads to cellular stress, Keap1 
loses its effectiveness in degrading Nrf2. This extends the half-life of Nrf2 to about 100-120 
minutes, thereby stabilizing Nrf2 levels [18,19]. Nrf2 then enters the nucleus and triggers the 
transcription of AREs and other cytoprotective genes [20]. Investigation on the protective role 
of Nrf2 showcased its significance in the regulation of inflammation and apoptosis. Nrf2 is 
involved in enhancing the expression of survival inflammatory markers which in turn 
suppresses pro-apoptotic proteins. Hematopoietic stem cells with their Nrf2 gene knocked off, 
showed increased oxidative stress, apoptosis and reduced expression of pro-survival genes 
[21]. It has recently been established that Nrf2 directly inhibits the transcription of pro-
inflammatory genes coding for pro-inflammatory proteins (IL-1α, IL-1β IL-6) therefore 
ameliorating increased inflammation and apoptosis [22]. 
 
Streptozotocin (STZ) is a glucose analogue that is cytotoxic to the beta cells of the pancreas. 
It is a diabetogenic compound that is produced naturally in Streptomyces achromogenes; a 
soil bacterium. The effect of STZ administration is usually seen within 3 days depending on 
the dosage. STZ exhibits its selective toxicity on beta cells in rats by DNA fragmentation of the 
beta cells and causes death, leading to diabetic conditions which further progresses to diabetic 
complications if uncontrolled [23]. High dosage of STZ has been reported to result in complete 
destruction of the beta cells; a model of type I diabetes. Recent studies report the effective use 
of low dose of STZ to induce insulin resistance; a model of type II diabetes (T2D) and 
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subsequently, diabetic complications [24–26]. Administration of 10% fructose for two weeks, 
followed by 40 mg/kgBW of STZ was demonstrated by Wilson and Islam to cause partial 
destruction of the beta cells and insulin resistance in rats; which are typical of T2D [27].  
Anchomanes difformis (AD) is a plant with numerous ethno-botanical uses in Africa for 
conditions such as inflammation, diabetes, asthma, microbial infections, pain, ulcerations and 
gastrointestinal disturbances. Some of these folkloric uses have been scientifically established 
while others are still indigenous claims [28]. The anti-inflammatory ability of the leaf and 
rhizome extracts of AD was revealed by its inhibitory activity on histamine and serotonin which 
are mediators in the initial phase of acute inflammation. AD showed more anti-inflammatory 
potential than the standard drug used; aspirin [29]. Similarly, Adebayo and colleagues also 
demonstrated the anti-inflammatory property of AD. The plant inhibited oedema (paw volume) 
in raw-egg albumin induced inflammation in chicks [30]. Studies showed that AD is effective 
against hyperglycemia in alloxan-induced diabetes [31,32], however the potential of AD 
against inflammation and apoptosis in diabetic mellitus has not been explored. This study 
therefore investigated the anti-inflammatory and anti-apoptotic ability of AD leaves extract on 
increased inflammatory response and cell death in STZ-induced diabetic cardiomyopathy in 
male Wistar rats. We carried out phytochemical characterization and profiling of six different 
extracts of AD, and 32 compounds were identified. Furthermore antioxidant capacities of the 
extracts were measured using ORAC, FRAP and TEAC assays, and the aqueous extract 
exhibited the highest antioxidant capacity [33], hence its choice for this study. 
 
5.2 Materials and methods 
5.2.1 Chemicals and reagents 
STZ was purchased from Biocom Africa, South Africa. H-FABP (Cat. No: FB 4025) was 
obtained from Randox Laboratories (South Africa). The interleukins and TNF-α were supplied 
by Biorad, while MCP-1 by Merck (South Africa). Anti-Nrf2, Anti-NFkB/p65, Anti-Bcl2, Anti-
Caspase-3, Anti-mouse IgG H&L and Anti-rabbit IgG H&L were bought from BiocomAfrica 
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(South Africa). Bicinchoninic Acid Protein Assay kit was purchased from Thermo Fisher 
Scientific, South Africa. 
 
5.2.2 Plant Preparation 
The harvested leaves of A. difformis was authenticated (LUH6623) and a specimen deposited 
at the herbarium, University of Lagos, Nigeria. The leaves were dried under shade, blended, 
de-fatted with n-hexane. Aqueous extract was from the dried leaves of AD were extracted via 
cold extraction (2-8oC). The extract was pulverised and stored at -20oC for further analysis. 
 
5.2.3 Ethical Approval 
This study was approved by the Faculty of Health & Wellness Sciences Research Ethics 
Committee (REC) of the Cape Peninsula University of Technology, Bellville, South Africa 
(CPUT/HW-REC 2016/A4). It was also approved (REF.04/17) by the Ethics Committee for 
Research on Animals at the South African Medical Research Council (SAMRC), South Africa, 
where the animal experiment was performed. 
 
5.2.4 Animals  
Wistar rats (male) weighing approximately 180 ± 10 g (male) were obtained from Stellenbosch 
University (animal facility), South Africa. The animals were acclimatized for 3-4 weeks and 
housed at the Primate Unit & Delft Animal Centre (PUDAC), SAMRC, Cape Town. Housing 
conditions were controlled: humidity- 45% to 55%, temperature between 22oC to 26oC. 
Standard rat chow (SRC) and water was fed to all the rats ad libitum and they were exposed 
to normal photo period (12hour dark/12hour light). Animal handling, care and other procedures 
were done in accordance with the standard operating procedure of SAMRC PUDAC (SOP No: 
2016-R01) which conforms to the revised South African National Standard for the Care and 
Use of Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 
2008).  
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5.2.5 Experimental Design 
Sixty-four (64) male, Wistar rats with weights ranging from 270-300 g were used for this study. 
The rats were randomly assigned into seven (7) groups with a minimum of eight rats in each 
group (8 rats in normal groups and 10 in diabetic groups) as summarised in Figure 3.2. Water 
served as the vehicle for fructose and AD administration, while citrate buffer was the vehicle 
for streptozotocin. Animals in group 1 served as the normal control (NC) and received the 
vehicle only. Animals in group 2 and 3 are normal rats who received 200 and 400 mg/kgBW of 
AD aqueous extract only (N+AD 200 and N+AD 400), these served as the treated control. 
Groups 4-7 consisted of animals that were placed on 10% fructose for 2 weeks followed by 
streptozotocin (STZ). Group 4 rats received vehicle only (DC), rats in group 5 and 6 were given 
200 and 400 mg/kgBW of AD aqueous extract (D+AD 200 and D+AD 400) respectively while 
group 7 rats received 5 mg/kgBW of glibenclamide; an antidiabetic drug (D+G).  
 
 
Figure 0.2: Experimental design. Animals were randomly assigned into 7 groups (n≥8). 14 days’ 
administration of 10% fructose preceded a single-dose injection of STZ (40mg/kg). After 5 days, 
animals with fasting blood glucose of 15mmol/L or greater were considered diabetic. OGTT was 
conducted to confirm insulin resistance. Normal rats were administered the vehicle; water and citrate 
buffer (CB) accordingly. Treatment commenced immediately for 42 days via oral gavage. Animals 
were euthanized on the 43rd day (red bar). 
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5.2.6 Blood and Tissue Collection 
The rats were anaesthetized before euthanasia, with 2% isoflurane per oxygen (1L/min flow 
rate) via inhalation. Blood was collected into Z-serum clot activator tubes from the abdominal 
vein. Blood samples were centrifuged at 4,000 g for 10 min at 4oC. Aliquots of the supernatant 
were stored at -80 oC for biochemical analysis. Under euthanasia, the heart was extracted and 
immediately washed in ice-cold phosphate buffered saline (PBS), dabbed and weighed. This 
was then frozen using liquid nitrogen and later stored at -80 oC for further analysis.  
 
5.2.7 Tissue Preparation 
The heart samples for histological examination were fixed in 10% buffered formalin solution 
immediately. Samples that will be used for immunofluorescence assays were fixed with a 
freezing media, froze in the liquid nitrogen and further stored at -80 oC. Homogenization of the 
heart tissues was done subsequently for assays requiring tissue lysate. A 200mg sample of 
the heart was homogenized on ice in 2mls of 50mM phosphate buffer with 0.5% triton and 
centrifuged at 10,000x gravitational force for 15 minutes at 4 oC. The supernatants were 
aliquoted and stored at -80 oC. 
 
5.2.8 Determination of organ function and toxicity markers 
The body weights of all the animals were measured weekly throughout the animal study. The 
relative heart weight was derived from the weight of the heart and the body weight of the same 
rat. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 ℎ𝑒𝑎𝑟𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 =  
𝐻𝑒𝑎𝑟𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 × 100 % 
  
Heart-type fatty acid-binding protein (H-FABP) was quantified in the serum and the 
determination was carried out according to the standard operating procedure provided by the 
manufacturer. The principle of the assay was based on immunoturbidimetry.   
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5.2.9 Analysis of antioxidant status and lipid peroxidation indices 
Activities of catalase, superoxide dismutase and levels of thiobarbituric acid reactive 
substances (TBARS) were assayed in the heart of normal and diabetic rats. In addition, ORAC 
and FRAP were also measured to evaluate antioxidant capacity in the heart. The method of 
Ellerby and Bredesen [33] was used to determine catalase activities in the hearts, where the 
rate of conversion of hydrogen peroxide to water and oxygen by catalase was measured at 
240nm. SOD levels were also measured by the method of Ellerby and Bredesen [33], which 
measures the amount of the enzyme needed to exhibit dismutation of the superoxide radicals 
produced from the auto-oxidation of 6-hydroxydopamine (6-HD). TBARS levels were evaluated 
using the modified methods of Matsunami et al. and Wasowicz et al. [34,35]. ORAC levels 
were assessed according to the method of Prior et al., [36] while FRAP was measured using 
the method described by Benzie and Strain [37]. Total protein present in the heart was 
quantified using Bicinchoninic Acid Protein Assay kit, and manufacturer’s procedures were 
duly followed.  
 
5.2.10 Estimation of pro- and anti-inflammatory biomarkers  
Interleukins (IL)-1β, IL-6, and IL-10 were measured, and other chemokines including MCP-1 
(monocyte chemotactic protein-1) and TNF-α (tumor necrosis factor-α) were also measured in 
the heart lysates of normal and diabetic rats. These inflammatory markers were measured 
using Bioplex Promagnetic bead-based assays (Bio-Rad Laboratories, Hercules, USA) on the 
Bio-plex platform (Bio-Rad). Assays were performed according to the manufacturer’s 
instructions (BioRad and Merck Millipore). Bead acquisition and analysis of median fluorescent 
intensities was done using Bio-Plex Manager software, (version 6.0). 
 
5.2.11 Evaluation of apoptotic and transcriptional proteins expression 
To explore the effect of AD on Nrf2, NFkB/p65, Bcl2 and caspase-3 expression in increased 
oxidative stress and inflammatory process induced by hyperglycemia, we carried out an 
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immunohistochemical fluorescence staining on the heart tissue. The process was carried out 
according to the manufacturer’s procedures. 
 
5.2.11.1 Antibodies 
Optimization of primary antibodies were carried out on the heart tissues, to determine the 
optimal staining concentrations and conditions for each antibody. Single and double stains 
were done for each antibody at varying dilutions and diluents. The combination that showed 
the highest specificity and sensitivity on positive and negative control samples was considered 
as the optimal staining concentration. This was done with the help of an experienced 
pathologist. The details of each antibody used, and their optimal concentration is presented in 
Table 5.1.  
 
Table 0.1: The descriptions of the antibodies used for detection of protein expression levels, stating 
the host, supplier and the optimization factor 
No  Marker Antibody Host Source Dilution 
1. Nrf2  Anti-Nrf2 Mouse ABCAM, UK 1:200 
2. NFkB/p65 Anti-NFkB/p65 Rabbit  ABCAM, UK 1:250 
3. Bcl2 Anti-Bcl2 Mouse BioLegend, SA 1:125 
4. Caspase-3 Anti-Caspase-3 Rabbit ABCAM, UK 1:150 
5. Alexa Fluor 488 Anti-mouse IgG H&L Goat ABCAM, UK 1:400 
6. Alexa Fluor 594 Anti-rabbit IgG H&L Goat ABCAM, UK 1:400 
 
5.2.11.2 Tissue Preparation and Staining 
Heart tissues were fixed with freezing media (Leica, South Africa) and stored at -80oC. 10µm 
of the tissues were sectioned using a Leica CM 1860 UV Cryostat and permeabilized with PBS 
plus 0.025% Triton X-100 (PBS-T). Tissues were blocked with 10% normal goat serum in PBS 
containing 5% bovine serum albumin (BSA) for 2 hours. Incubation with respective primary 
antibodies (see details in Table 5.1) were done overnight at 4oC, followed by 2 washes in PBS-
T. Tissues were incubated with secondary antibodies for 1 hour at room temperature, in the 
dark and washed thrice with PBS. Mounting was done using Dako mounting medium (Agilent 
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Technology Inc, South Africa). The argon multiline laser at 488nm and DPSS 561-10 laser at 
561nm was used to excite the Alexa Fluor 488 (green) and Alexa Fluor 594 (red) respectively.  
 
5.2.11.3 Imaging 
Images were acquired on a Zeiss LSM780 ELYRA PS1 super-resolution, confocal microscope 
with a 10x/0.3 M27 objective (EC “Plan-Neofluar”).  Zen 2.6 imaging software (blue and black 
edition, Zeiss Germany) were used for image analysis and to obtain mean fluorescent 
intensities (MFI) on 4 images acquired in each experimental condition. This was repeated 
thrice.   
 
5.2.12 Data Analysis 
Values were expressed as mean ± standard error of mean (SEM). Statistical analysis of results 
was performed using one-way or two-way analysis of variance (ANOVA) to find differences 
between groups. Bonferroni test was used for all pair-wise comparisons. Differences (F values) 
were considered statistically significant at p values less than 0.05. All statistical calculations 
were done using GraphPad Prism Version 5.00 for Windows, GraphPad Inc., San Diego, 
California USA. 
 
5.3 Results 
5.3.1 AD reduced weight loss and organ toxicity in STZ-induced diabetes 
Induction of diabetes led to significant reduction in the mean body weight of the diabetic rats 
(Figure 5.3A). There was 24.1% weight loss in the untreated diabetic rats, while diabetic rats 
treated with glibenclamide experienced 11.2% weight loss. Body weight results of the rats 
treated with 200mg and 400mg of AD revealed 8.6% and 6.4% loss in body weight 
respectively. Interestingly, both concentrations of AD; 400mg and 200mg significantly 
prevented weight loss by 17.7% and 15.5% respectively, while glibenclamide reduced weight 
loss by 12.9%.  Both concentrations of AD were able to significantly impede weight loss in 
STZ-induced diabetes better than the reference drug; glibenclamide (Figure 5.3A). In addition 
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to the increased weight loss, the heart to body weight ratio of untreated diabetic rats 
significantly increased by 40% when compared to the normal rats (Figure 5.3B). Administration 
of 400 and 200 mg/kgBW AD significantly ameliorated possible hypertrophy by reducing the 
heart-body weight ratio of diabetic rats by 15% and 11.95% respectively. Treatment with 5 
mg/kgBW of glibenclamide did not reduce relative heart weight in diabetic hearts when 
compared to the untreated diabetic rats (Figure 5.3B). This demonstrated the ability of AD to 
protect against STZ induced organ toxicity. 
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Figure 0.3: Effect of AD administration on (A) Bodyweight change and (B) Heart-body weight ratio. 
Points and bars are indicative of mean values ± SEM of bodyweight change and heart-body weight 
ratio. Bars with different letters are significantly (p<0.05) different from each other.  
 
5.3.2 Effect of AD on antioxidant enzymes and protein synthesis in STZ induced 
diabetes 
Figures 5.4A & 5.4B illustrate the effect of diabetes and administration of AD on catalase and 
SOD activities in the heart of normal and diabetic rats. Administration of AD led to an 
observable increase in the activities of catalase and SOD in the normal rats. Also, induction of 
diabetes by administration of STZ significantly increased the activity of catalase in the hearts 
of untreated diabetic rats (Figure 5.4A). However, treatment with AD attempted to revert the 
abnormally increased levels of catalase, however not significantly. Glibenclamide, reduced the 
catalase levels to near normal. There was no significant difference in the SOD levels in normal 
and diabetic groups (Figure 5.4B). A slight decrease in protein levels was observed in the 
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diabetic rats, the ingestion of AD led to increased protein levels in the treated diabetic rats as 
presented in Figure 5.4C. 400 mg/kgBW of AD was able to enhance protein levels in diabetic 
rats (p>0.05). 
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Figure 0.4: Effect of treatment with AD on the activity of (A) Catalase, (B) SOD and (C) Total protein 
in the heart of normal and diabetic rats. Bars are indicative of mean values ± SEM of group values. 
Bars with different letters are significantly (p<0.05) different from each other. 
 
5.3.3 Effect of treatment with AD on antioxidant indices in the heart of normal 
and diabetic rats 
The oxygen radical absorbing ability was significantly reduced in the hearts of untreated 
diabetic rats when compared to normal rats (Figure 5.5A). ORAC levels in the diabetic rats 
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administered 200mg/kgBW and 5mg/kgBW of AD and glibenclamide respectively were 
comparable to normal. Ferric reducing antioxidant power in the hearts of normal and diabetic 
rats were not significantly different (Figure 5.5B). 
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Figure 0.5: Effect of intervention with AD on the antioxidant capacities; (A) ORAC and (B) FRAP in 
the heart of normal and diabetic rats. Bars are indicative of mean values ± SEM of group values. Bars 
with different letters are significantly (p<0.05) different from each other. 
 
5.3.4 AD modulated hyperglycaemia-induced immune response in the heart in 
T2D model 
STZ injection significantly increased IL-18 in the heart of untreated diabetic rats. However, 
treatment with AD (400mg/kgBW) and glibenclamide (5mg/kgBW) restored it to normal levels 
(Figure 5.6D). Administration of 200mg/kgBW of AD caused a 16.2% reduction in IL-18 levels 
in diabetic hearts but not significantly at p<0.05. The administration of AD increased the 
concentration of IL-10 in the heart of normal rats, while it significantly decreased in the heart 
of untreated diabetic rats when compared to normal rats placed on AD (Figure 5.6C). There 
was no significant difference in the levels of IL-10 in normal controls and diabetic rats treated 
with 400mg/kgBW of AD. IL-6 and IL-1β levels were significantly reduced in the heart of 
diabetic rats (untreated and 200mg/kgBW) when compared with normal rats (Figure 5.6A & 
5.6B). This was restored back to normal levels in diabetic rats treated with 400mg/kgBW of AD 
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and glibenclamide. An increase was observed in the MCP-1 levels in the hearts of untreated 
rats when compared with normal and treated rats, but this was not significant at 5% level of 
significance (Table 5.2). Injection of STZ did not have any significant difference in the TNFα 
concentrations in the diabetic rats compared to normal rats (Table 5.2). 
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Figure 0.6: :  Effect of AD administration on interleukins (IL) (A) IL-1β, (B) IL-6, (C) IL-10 and (D) IL-
18 in the heart of normal and diabetic rats. Bars are indicative of mean values ± SEM of group values. 
Bars with different letters are significantly (p<0.05) different from each other. 
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Table 0.2: The response of TNFα and MCP-1 to treatment with AD in normal and diabetic hearts. 
Experimental Groups TNFα (pg/mL) MCP-1 (pg/mL) 
NC 56.87 ± 3.68 288.8 ± 19.34 
N+AD 200 61.39 ± 2.42 272.1 ± 23.34 
N+AD 400 60.05 ± 3.38 287.4 ± 15.24 
DC 50.40 ± 3.06 306.3 ± 15.03 
D+AD 200 48.50 ± 3.68 280.7 ± 12.25 
D+AD 400 49.72 ± 2.28 301.1 ± 23.00 
D+G 51.52 ± 3.06 313.1 ± 27.05 
 
 
5.3.5 The effect of AD on lipid peroxidation and heart function markers  
Presence of abnormal concentrations of heart fatty acid binding protein (H-FABP) in the serum 
is indicative of cardiomyopathy. H-FABP was measured in the serum of normal and diabetic 
rats. Hyperglycaemia caused a significant increase in the levels of H-FABP in the serum of 
diabetic rats when compared with normal rats (Table 5.3). Treatment with AD did not have any 
effect on the increased H-FABP in the serum of treated, diabetic rats. There was no significant 
difference in the TBARS concentration in normal and diabetic hearts (Table 5.3). 
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Table 0.3: Shows the effect of AD on (A) H-FABP and (B) TBARS levels in the heart of normal and 
diabetic hearts. 
Experimental Groups H-FABP (ng/mL) TBARS (pmole/g) 
NC 0.216 ± 0.011a 2.226 ± 0.15 
N+AD 200 0.2784 ± 0.004 2.080 ± 0.09 
N+AD 400 0.2896 ± 0.003 2.032 ± 0.16 
DC 0.2955 ± 0.002b 1.809 ± 0.10 
D+AD 200 0.2926 ± 0.006b 2.068 ± 0.11 
D+AD 400 0.2918 ± 0.005b 2.371 ± 0.10 
D+G 0.3121 ± 0.003b 1.867 ± 0.12 
Values with different letters are significantly (p<0.05) different from each other. 
 
5.3.6 The regulation of transcription factors by AD in T2D model 
Figure 5.7A (fluorescence micrographs) demonstrates the effect of AD intervention on 
NFkB/p65 and Nrf2 in the hearts of normal and diabetic rats. The expression of Nrf2 and 
NFkB/p65 was significantly enhanced in the hearts of diabetic rats (Figure 5.7B and 5.7C). 
This was significantly reduced in the rats treated with 200 and 400 mg/kgBW of AD in a dose 
dependent manner and comparable to normal rats. 5mg/kgBW of glibenclamide had no effect 
on the Nrf2 expression in the diabetic hearts, but it significantly reduced the NFkB levels in 
treated diabetic hearts when compared to diabetic control hearts. However, the reduction of 
NFkB expressions by glibenclamide was not comparable to normal levels (Figure 5.7). This 
increase in Nrf2 and NFkB/p65 expression is suggestive of increased oxidative stress and 
inflammation in the diabetic rats. 
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Figure 0.7: (A) Representatives of Confocal microscopy image showing the effect of AD on the 
expression of NFkB/p65 (red) and Nrf2 (green) in the heart tissues. Quantitative analysis of (B) 
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NFkB/p65 and (C) Nrf2 expression in the heart tissues. Bars are indicative of mean values ± SEM of 
group values. Bars with different letters are significantly (p<0.05) different from each other. 
 
5.3.7 Anti-apoptotic effect of AD on T2D model 
Caspase 3 is a pro-apoptotic marker, while Bcl2 promotes cell survival and inhibits the action 
of pro-apoptotic markers. The effect of AD administration on caspase 3 and Bcl2 in normal and 
diabetic rats is displayed in Figure 5.8. An increase (85.6%) was observed in the expression 
of caspase 3 in the diabetic hearts which was not significant at p<0.05 (Figure 5.8B). 
Conversely, there was an observable decrease (22.8%) in the levels of Bcl2 in the diabetic 
hearts when compared with normal rats (Figure 5.8C). Intervention with 200 and 400 mg/KgBW 
of AD was able to reduce the expression of Caspase 3 by 7.9%, and 9.4%, Bcl2 expression 
was also upregulated in the diabetic treated rats. 
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Figure 0.8: (A) Fluorescence micrographs showing the effect of AD intervention on apoptotic markers 
in the hearts of normal and diabetic rats. (B) Quantification of the level of expression of caspase 3 and 
(C) Bcl2 in the heart tissues. 
 
5.4 Discussion 
Organ and body weights are essential indices for evaluating the toxicity of a plant or other 
substances. [38]. The administration of STZ and fructose caused a significant body weight loss 
(24.1%), while intervention with AD significantly prevented weight loss. Rats treated with AD 
showed between 6.4%-8.6% weight loss. Although, 5%-10% body weight loss has been 
recommended as an effective strategy for glycemic control in ameliorating diabetes [39], 24.1% 
weight loss in diabetic control is extreme and implicative of decreased cellular metabolism and 
growth [40,41]. Also, the loss of insulin sensitivity prevents the utilization of glucose for energy 
in the cells, body burns fat and muscle as an alternative energy source [42]. Other studies 
have reported severe weight loss in diabetes mellitus [43,44]. An increase in relative organ 
weight is significant of hypertrophy [45]. Hypertrophy combined with other factors; fibrosis, 
oxidative stress and apoptosis in the heart are characteristics of myocardial pathology in 
diabetic conditions [46]. Treatment with AD was able to significantly ameliorate hypertrophy in 
diabetic hearts when compared with the diabetic control which alludes to the cardio-protective 
effect of AD against the organ impairment and related conditions caused by hyperglycemia. 
However, the administration of glibenclamide failed to reduce the hypertrophy in the diabetic 
hearts. 
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Activation of Nrf2 is one of the pathways initiated during oxidative stress and inflammation to 
mitigate the overproduction of free radicals. Increased oxidative stress due to hyperglycemia 
in the diabetic rats resulted in the increased activation and expression of Nrf2 in the diabetic 
hearts. Interestingly, certain studies reported decreased Nrf2 levels in diabetic cardiomyocytes 
and other associated vascular conditions [47,48]. However, the mechanism of operation by 
which Nrf2 is activated showed that it is constitutively expressed in higher amounts in response 
to oxidative stress which corroborates with our findings [18,49,50]. The expression of Nrf2 
which was enhanced in the diabetic hearts was significantly reduced to near normal levels with 
AD therapy when compared with the untreated diabetic rats. The ability of AD to normalize 
Nrf2 levels can be attributed to its inherent antioxidant compounds, which scavenges the free 
radicals, combatting oxidative stress, hence the system has lower need to induce the 
expression of Nrf2. Reports showed that Nrf2 expression enhances the transcription of ARE 
genes thereby elevating CAT, SOD and other antioxidant capacities in the body [51]. The 
observed increase in the activities of CAT and SOD in this study can be related to the increased 
expression of Nrf2.  
 
The insignificant decrease in lipid peroxidation in the untreated diabetic rats compared with the 
treated diabetic and normal rats is indicative of the increased Nrf2 expression. Studies have 
shown that Nrf2 inhibits lipid peroxidation and upregulates the transcription of anti-ferroptotic 
genes, which combats lipid peroxides and prevent ferroptotic cell death [52]. The reduced 
synthesis of protein in diabetic control is typical of diabetic condition and can be as a result of 
an increased supply of amino acids for gluconeogenesis [32,53]. Introduction of STZ altered 
the protein metabolism and led to decreased protein in the diabetic rats. There was no 
significant difference in the ORAC and FRAP levels in the heart of diabetic control, treated and 
normal rats. This implies that the diabetic condition and the treatment do not have significant 
effect on the heart ORAC and FRAP levels. 
NFkB which is activated by increased oxidative stress and hyperglycemia, promotes the 
transcription and expression of pro-inflammatory genes and protein in the heart. These 
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cytokines have been linked to pathological conditions [6,13]. NFkB/p65 protein was 
significantly upregulated in the hearts of diabetic controls, usage of 200 and 400mg/kgBW of 
AD significantly diminished NFkB/p65 expression to normal levels in the diabetic hearts. The 
repressing effect of glibenclamide on NFkB/p65 expression in the diabetic heart is not 
comparable to AD. This supports ethnopharmacological claims and previous scientific findings 
of AD as an anti-inflammatory agent.  
 
A relationship has been shown to exist between catalase activities and pro-inflammatory 
markers such as IL-1β and IL-6. The activity of catalase is inversely proportional to the 
concentrations of IL-1β and IL-6 [54,55]. Therefore, the significant rise in catalase activities in 
the untreated diabetic heart led to significantly diminished levels of IL-1β and IL-6. IL-6 can 
also mediate as an anti-inflammatory agent in local and systemic inflammation [56,57]. Hence, 
the increase in IL-6 levels in normal and diabetic rats placed on AD can suggestively be 
attributed to the anti-inflammatory modulation by AD. However, IL-10 concentration 
significantly declined in the diabetic hearts. Management with AD augments IL-10 in the 
diabetic heart. In addition, treatment with AD significantly abated the production of IL-18 in 
diabetic hearts in reference to the diabetic control. Increase of pro-inflammatory markers in the 
heart has been connected to cardio-dysfunction such as impaired left ventricular function [42]. 
The ability of AD to downregulate IL-18 and upregulate IL-10 signifies its importance in 
mediating cardiac pathologies associated with diabetic complications.  
 
Mitochondrial dysfunction is one of the underlying mechanisms in the progression of DCM, and 
it is triggered chiefly by oxidative stress leading to distortion in the proteins, lipids and DNA in 
the mitochondria [58]. Mitochondrial dysfunction further upregulates pro-apoptotic proteins 
(cytochrome c, caspase 3, -9, -8) and cause increased apoptosis [59]. Increased ROS-
mitochondrial mediated apoptosis in the cardiomyocytes, is an important factor in the 
development of various pathologies in diabetic hearts [60]. Bcl2 impedes mitochondrial-
mediated apoptosis by blocking the activation and release of cytochrome C which in turn 
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initiates caspase cascades of activation that leads to cell death. Diabetic induction enhanced 
caspase 3 expression and led to a decline in Bcl2 expression. Supplementation with AD 
caused an increase in Bcl2 expression and lowered caspase 3 expression in diabetic hearts. 
This suggests that the ability of AD to moderate apoptosis may be one of the contributing 
factors in ameliorating DCM. A proposed mechanism of action for AD in ameliorating DCM by 
modulating apoptosis, inflammation and oxidative stress is summarized in Figure 5.9. AD 
reduced hyperglycemia, hence, inhibited the development of oxidative stress and was able to 
retard inflammation and apoptosis in diabetes by blocking the production of IL-18 and caspase 
3 via the deregulation of NFkB expressions in the treated diabetic rats. 
 
 
Figure 0.9: Proposed mechanism of action of AD in the management of DCM. AD-Anchomanes 
difformis, CAT-catalase, SOD-superoxide dismutase, ROS-reactive oxygen species, AREs- 
antioxidant response elements, Nrf2- nuclear factor E2-related factor 2, NFkB- nuclear factor kappa-
light-chain enhancers of activated B cells 
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5.5 Conclusion 
The ability of AD to protect against toxicity, reduce inflammation and mediate apoptosis in the 
heart present its potentials to mitigate diabetic cardiomyopathy. Hence, the need to consider 
the use of AD as an alternative therapy in the prevention and management of diabetic 
cardiomyopathy. 
 
5.6 Recommendation 
The ameliorating effect of AD in other diabetic complications such as nephropathy and sexual 
dysfunction can be explored. In addition, this study can be taken further into clinical trials to 
assess and validate the therapeutic effect of AD in type 2 diabetes in humans. 
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ABSTRACT  
Background 
Kidney disease in diabetes is one of the common microvascular complications of diabetes 
mellitus implicated in end-stage renal failure. Constant hyperglycemia, oxidative stress, 
damaged β-cells of the pancreas, increased inflammation and apoptosis occur in diabetic 
nephropathy. This study explored the ability of Anchomanes difformis to ameliorate kidney and 
pancreatic damage in type 2 diabetes mellitus. 
Methods 
Two weeks of fructose (10%) administration, followed by single intraperitoneal injection of 
streptozotocin (40mg/kg) were used to induce type 2 diabetes in male Wistar rats. Leaf extract 
(aqueous) of Anchomanes difformis (200mg and 400mg/kgBW) was administered orally for six 
153 
 
weeks. Body weights before and after interventions were monitored. Urea and creatinine were 
measured as markers of kidney function. Interleukins (IL)-1β, IL-6, IL-10, IL-18, and TNFα were 
measured in the kidney lysate as indices of inflammation. CAT, SOD, ORAC, FRAP, and MDA 
levels were also evaluated in the kidney. Expressions of transcription factors (Nrf2 and 
NFkB/p65) and apoptotic markers (Bcl2 and caspase 3) were investigated in the kidney 
tissues. Histological sections of the pancreas and kidney tissues were examined for any visible 
pathology. 
 
Results 
Supplementation with Anchomanes difformis enhanced antioxidant status, modulated 
inflammatory response, and reduced apoptosis in the kidney. It also restored the kidney and 
pancreatic histoarchitecture of the treated diabetic rats. 
Conclusion 
The pathophysiology associated with diabetic nephropathy and pancreatic damage showcase 
the importance of exploring the use of antidiabetic, nephroprotective agents such as 
Anchomanes difformis to prevent or delay the progression of kidney damage in the 
management of type 2 diabetes. 
 
Keywords: Anchomanes difformis, apoptosis, diabetes, glibenclamide, inflammation, 
nephropathy, oxidative stress 
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6.1 Introduction 
Kidney disease in diabetes (refers to as diabetic nephropathy-DN) is a common complication 
of type 2 diabetes mellitus (T2DM) and has become one of the major causes of kidney failure 
1,2. It is widely characterised by abnormalities in the architecture of the renal tissues such as 
expansion of the mesangial matrix, glomerular hypertrophy, thickening of the glomerular and 
tubular basement membrane 3. Abnormal values of urea, creatinine, albumin and other 
proteins in the serum and urine are typical observations in diabetic subjects 2. Administration 
of fructose and low dose of STZ causes partial disruption of the beta cells leading to less 
production of insulin and hence, hyperglycemia with insulin resistance 4,5. Hyperglycemia leads 
to oxidative stress by influencing the generation and overproduction of ROS through the 
increased activation of the polyol pathway, protein kinase C (PKC) and formation of advanced 
glycation end-products (AGEs) 1,6. An imbalance in the production of ROS and the antioxidant 
(such as catalase and superoxide dismutase) results in oxidative stress 7,8. Oxidative stress 
induced by hyperglycemia can further inhibit the production of insulin by the beta cells of the 
pancreas. This occurs through hyperglycemia-mediated activation of uncoupling protein-2 
leading to leakage of protons and reduced ATP/ADP ratio in the beta cells. ROS produced as 
a result of constant hyperglycemia can also occasion lipid peroxidation in the cell membrane 
resulting in beta cell damage 1,9. The excessive production of ROS such as superoxide anion 
in pancreatic beta cells can activate stress-signalling pathways, which further induces 
inflammatory mediators, cytokines and apoptotic transcription factors such as NFkB, this leads 
to beta cell death and reduced insulin production 9.  
 
NFkB is upregulated during oxidative stress in most cells of the kidney including tubular cells, 
mesangial and endothelial cells and the podocytes 10. The activated NFkB causes the 
transcription of proinflammatory genes coding for cytokines (TNFα, IL-1β, IL-2, IL-6, IL-12, and 
IL-18) and chemokines (MCP-1). NFkB also enhances the transcription of profibrotic genes 
responsible for growth factors (TGF-β) and leukocyte adhesion molecules (E-selectin, VCAM1, 
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and ICAM-1). The expression of these proinflammatory and profibrotic proteins triggers 
inflammation, atherosclerosis and vascular dysfunction 11. 
 
Cell death is a key factor in the progression of DN 12. Chronic exposure of tissues to oxidative 
stress sufficiently induces a wide range of pathophysiological events that leads to eventual cell 
death 3. In normal tissues, unwanted cells are removed by apoptosis thereby maintaining tissue 
homestasis, however, in damaged cells, apoptosis is triggered thereby activating cell-death 
receptors such as TNFRs 12–14. As a result of the inappropriate activation of these intracellular 
signalling pathways, an imbalance occurs between cell death and cell proliferation in the 
damaged tissues in diabetes 15,16. The expression of Bcl2; an anti-apoptotic protein, is majorly 
detected in the proximal and distal tubules and in the capsular parietal cells in normal rats and 
humans 17. Interestingly, a loss of balance has been recorded in DN between pro- and anti-
apoptotic markers, such as the decreased expression of anti-apoptotic Bcl2 protein 18. 
Furthermore, increased expression of Growth factors such as TGF-B are induced by 
hyperglycemia and oxidative stress in the glomerulus and other tissues. The upregulation of 
TGF-B promotes further, the generation of ROS by activating NADPH oxidase and 
mitochondrial respiratory process resulting to aggravated TGF-B-induced apoptosis and 
detachment of the podocyte 19,20. 
 
ROS-mediated renal injury finally progresses into chronic kidney disease by evoking 
hemodynamic dysregulation and abnormalities in the structure and function of the nephron 21. 
The damaged glomerulus and its filtration barrier increase permeability of plasma proteins 
such as albumin (albuminuria); a crucial process involved in the etiology of DN 3. Elevated 
proteins (in the tubular ultrafiltrate) in the presence of increased ROS elicit various aberrant 
signaling pathways 3. The increased activation of these impaired signalling mediators which 
includes transcription factors, inflammatory agents, growth factors, and vasoactive molecules 
causes several pathological events in the glomerulus and the tubules promoting renal injury 
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from a progressive state to an end-stage renal failure 3.  Figure 6.1 summarizes the key 
pathways and mediators involved in the progression and pathogenesis of DN. 
 
 
Figure 0.1: Pathogenesis of diabetic nephropathy. 
 
There is a paradigm shift towards the use of medicinal plants in the management of 
pathological conditions and diseases, due to its cost effectiveness, with little or no adverse 
effects when appropriately used. It is also more available when compared with conventional 
drugs 22,23. Anchomanes difformis (AD) has been used traditionally as a treatment against 
varying pathological conditions including diabetes, kidney pains, asthma, pain and wounds, 
microbial infections, and gastrointestinal related problems. Most of these folkloric uses and 
claims have been proven with scientific studies, while others are still indigenous claims 24. We 
carried out a study on the identification and characterization of the bioactive compounds 
present in six different extracts of AD using HPLC and UPLC-MS, antioxidant capacities of 
these extracts were investigated. Aqueous extract exhibited the highest antioxidants ability 25. 
AD extracts especially aqueous, contains phytochemicals such as quercetin, phloridzin, 
kaempferol, rutin, chlorogenic acids amongst others which are active against hyperglycaemia, 
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oxidative stress, inflammation and apoptosis 25,26. The wide range of biological properties of 
compounds present in AD has necessitated the need to further investigates its potentials 
against diabetic complications. Antidiabetic ability of AD has been established and reported 
27,28, however, no study has been conducted to investigate the potency of AD leaves on the 
kidney and pancreas pathology in diabetes mellitus. This study therefore investigates the 
ameliorative potential of AD in hyperglycemia-induced kidney and pancreatic damage using in 
diabetic male Wistar rats. 
 
6.2 Methodology 
6.2.1 Plant preparation 
The leaves of AD were harvested and authenticated at the Herbarium; University of Lagos, 
Nigeria and a specimen was deposited (LUH6623) in the Herbarium. The harvested leaves 
were dried under shade, milled and de-oiled using n-hexane (10%W/V) for 2 days. The aqueous 
extraction was carried out using cold-stirred extraction method, where the defatted leaves were 
soaked in water (5% W/V) for 2 days at 2-8oC. The extract was freeze-dried and stored at -20oC 
for further analysis. 
 
6.2.2 Ethical consideration 
Ethical approval for this study was granted by the Research Ethics Committee (REC) of the 
Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, 
South Africa (CPUT/HW-REC 2016/A4) and the Ethics Committee for Research on Animals at 
the South African Medical Research Council (SAMRC), South Africa (REF.04/17), where the 
animal experiment was conducted. 
 
6.2.3 Animals 
64 male Wistar rats weighing approximately 180 ± 10g were procured for this study from the 
Animal facility in Stellenbosch University, South Africa. The animals were accommodated at 
the Primate Unit & Delft Animal Centre (PUDAC), SAMRC and made to adapt to the 
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environment for 3-4 weeks. Housing conditions were controlled: humidity- 45% to 55%, 
temperature- 22oC to 26oC. They were exposed to normal photo period (12hour dark/12hour 
light) and fed with standard rat chow (SRC). Animal handling, care and other procedures were 
done in accordance with the standard operating procedure of SAMRC PUDAC (SOP No: 2016-
R01) which conforms to the revised South African National Standard for the Care and Use of 
Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008). 
 
6.2.4 Modelling and grouping  
After acclimatization, the rats (with weights between 270g and 300g) were indiscriminately 
grouped into 7 with a minimum of eight rats in each group (Figure 6.2). The diabetic models 
received 10% fructose for 2 weeks followed by intraperitoneal injection of 40mg/KgBW 
streptozotocin (STZ). Water and citrate buffer served as vehicles for fructose and STZ in 
normal rats. Group 1 served as the negative controls (non-diabetics) and received vehicle only 
(NC). Animals in group 2 and 3 served as treatment controls (non-diabetic treated rats) and 
were placed on 200mg and 400mg/KgBW of AD (N+AD 200 and N+AD 400 respectively). 
Group 4 was the positive control (untreated diabetic rats) and were given vehicle only (DC). 
Group 5, 6 and 7 were treated diabetic groups placed on 200mg, 400mg of AD and 5mg 
glibenclamide respectively (D+AD 200, D+AD 400 and D+G). 
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Figure 0.2: Experimental design. Animals were randomly assigned into 7 groups (n≥8). 14 days’ 
administration of 10% fructose preceded a single-dose injection of STZ (40mg/kg). After 5 days, 
animals with fasting blood glucose of 15mmol/L or greater were considered diabetic. OGTT was 
conducted to confirm insulin resistance. Normal rats were administered the vehicle; water and citrate 
buffer (CB) correspondingly. Treatment commenced immediately for 42 days via oral gavage. Animals 
were euthanized on the 43rd day (red bar). 
 
6.2.5 Sample collection  
The rats were euthanised after the treatment period. The rats were anaesthetized prior to 
euthanasia with 2% isoflurane per oxygen (1L/min flow rate) via inhalation. Blood was collected 
from the abdominal vein into the Z-serum clot activator tubes. The kidneys and pancreas were 
immediately harvested, washed in ice-cold phosphate buffer and weighed. Blood samples 
were centrifuged at 4,000 g for 10 min at 4oC for serum yield and aliquoted. The serum and 
tissues were frozen in liquid nitrogen and later stored at -800C for further analysis. 
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6.2.6 Tissue Preparation 
The kidney and pancreas samples for histological examination were immediately fixed in 10% 
buffered formalin solution. Kidney samples that will be used for immunofluorescence assays 
were fixed with a freezing media, froze in the liquid nitrogen and stored at -80 °C. 
Homogenization of kidney tissues (200mg) for other assays was carried out on ice in 2mls of 
50mM phosphate buffer with 0.5% triton and centrifuged at 10,000 g for 15 minutes at 40C. 
The supernatants were aliquoted and stored at -80 °C. 
 
6.2.7 Estimation of organ function and toxicity markers 
Serum levels of urea and creatinine were measured in the normal and diabetic rats as indices 
of organ function. The estimation of urea and creatinine in the serum was done on an ABX 
Pentra 400 Chemistry Analyzer (Horiba) using Horiba kits (Montpellier, France) and performed 
following the manufacturer’s guidelines. The body weight measurements of all the animals 
were recorded every week till euthanasia. Relative kidney or pancreas weight for each rat was 
calculated using the kidney weight or pancreas weight and the weight of the same animal. 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑘𝑖𝑑𝑛𝑒𝑦/𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 =  
𝐾𝑖𝑑𝑛𝑒𝑦/𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 × 100 % 
 
6.2.8 Evaluation of antioxidant status and oxidative stress markers  
The activities of antioxidant enzymes; CAT and SOD was done in the kidney homogenates 
according to the method of Ellerby and Bredesen 29. Other non-enzymic antioxidant indices 
such as ORAC and FRAP were used to also evaluate the antioxidant status in the kidney. 
ORAC assay was carried out following the method of Prior and colleagues 30, while FRAP was 
determined using the method described by Benzie and Strain 31. Lipid peroxidation was 
measured to assess oxidative stress status in the kidney by determining TBARS levels in the 
kidney homogenates using the combined methods of Matsunami et al. and Wasowicz et al. 
32,33.  
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6.2.9 Measurement of inflammatory markers 
The determination of the levels of interleukins (IL)-1β, IL-6, IL-10, IL-18 and TNFα were 
determined in the kidney lysate of normal and diabetic rats. Bioplex Promagnetic bead-based 
assays (Bio-Rad Laboratories, Hercules, USA) were used for the measurement of these 
inflammatory markers. Assays were performed according to the manufacturer’s instructions 
(BioRad and Merck Millipore). Bead acquisition and analysis of median fluorescent intensities 
was done using Bio-Plex Manager software, (version 6.0). 
 
6.2.10 Quantification of the expression of transcription and apoptotic proteins 
Immunofluorescence staining and imaging was done in the kidney tissues to estimate the 
expression of transcription factors (Nrf2 and NFkB) and apoptotic proteins (Caspase-3 and 
Bcl2). Frozen tissues were sectioned (10µm) on a cryostat (Leica CM 1860 UV Cryostat) and 
permeabilized with 1x PBS containing 0.025% Triton X-100 (PBS-T). Blocking of tissues was 
done using 10% normal goat serum in PBS and 5% bovine serum albumin for 2 hours. Tissues 
were incubated with primary antibodies overnight at 4oC and secondary antibodies for 1 hour 
in the dark. Washes were done after each incubation with PBS-T and PBS respectively. The 
slides were mounted (Dako mounting medium, Agilent Technology Inc, South Africa) and 
imaged with a Zeiss LSM780 ELYRA PS1 super-resolution, confocal microscope with a 
10x/0.3 M27 objective (EC “Plan-Neofluar”). The argon multiline laser at 488nm and DPSS 
561-10 laser at 561nm was used to excite the Alexa Fluor 488 (green) and Alexa Fluor 594 
(red) respectively. Zen 2.6 imaging software (blue and black edition, Zeiss Germany) were 
used for image analysis and to obtain mean fluorescent intensities (MFI) on four images 
acquired in each experimental condition of three biological repeats.   
 
6.2.11 Histological examination of the kidney and pancreas 
The fixed tissues were dehydrated using graded series of alcohol, embedded in paraffin wax, 
sectioned (5µm), deparaffinized, rehydrated and stained with haematoxylin and eosin (H&E) 
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dyes. Slides were mounted and examined under a light microscope. Photomicrographs were 
taken using digital camera (Motic software). 
 
6.2.12 Statistical analysis 
Values are expressed as mean ± standard error of mean (SEM). Statistical analysis of the 
results was performed using one-way analysis of variance (ANOVA) to find differences 
between groups. Bonferroni test was used for all pair-wise comparisons. Differences (F values) 
were considered statistically significant at p values less than 0.05. All statistical calculations 
were done using GraphPad Prism Version 5.00 for Windows, GraphPad Inc., San Diego, 
California USA. 
 
6.3 Results 
6.3.1 Effect of treatment with AD on the relative weight of the kidney and 
pancreas  
Figure 6.3 shows the relative weight of the kidney and pancreas in normal and diabetic rats. 
Induction of diabetes using fructose and STZ led to a significant increase in the relative weights 
of the kidney and pancreas in the untreated diabetic rats (positive control). However, 
intervention with 200mg and 400mg/KgBW AD lowered relative kidney weight by 9.1% and 
10.7% respectively (Figure 6.3A). Glibenclamide (5mg/KgBW) also reduced relative kidney 
weight by 6.4% in the treated diabetic rats. Similarly, relative pancreatic weight was 
significantly increased in the positive control when compared with the normal rats (Figure 
6.3B). The relative pancreatic weight was minimized in the treated rats by 15.9% and 14.6% 
following the administration of 200mg and 400mgKgBW AD. This is comparable to the activity 
of glibenclamide which had a 20% reduction on the relative pancreatic weight (Figure 6.3B). 
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Figure 0.3: Effect of AD administration on the (A) relative kidney weight and (B) relative pancreas 
weight of normal and diabetic rats. Bars are indicative of mean values ± SEM of group values. Bars 
with different letters are significantly (p<0.05) different from each other. 
 
6.3.2 Effect of AD administration on kidney function markers 
Hyperglycemia caused by STZ and fructose administration resulted in significant increase (by 
3 folds) in the serum levels of urea in the diabetic rats. Treatment with 400mg/kgBW and 
200mg AD abated the urea concentration by 22.5% and 4.5% in treated diabetic rats when 
compared with untreated diabetic rats (Figure 6.4A). Administration of 5mg/kgBW 
glibenclamide did not reduce urea concentration in diabetic kidneys when compared to the 
untreated diabetic kidneys. Creatinine levels in the serum was not significantly affected by 
either hyperglycemia or treatment with AD (Figure 6.4B). 
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Figure 0.4: Effect of AD administration on the (A) urea and (B) creatinine concentration in the serum 
of normal and diabetic rats. Bars are indicative of mean values ± SEM group values. Bars with different 
letters are significantly (p<0.05) different from each other. 
 
6.3.3 AD enhanced the antioxidant status in the kidney 
The effect of AD and glibenclamide on the antioxidant indices (CAT, SOD, ORAC and FRAP) 
and lipid peroxidation marker (TBARS) is presented in Figure 6.5(A-E). The administration of 
AD significantly increased CAT levels in the normal rats treated with 200 and 400mg of AD 
(Figure 6.5A). Conversely, a significant decrease (20.2%) in the activity of CAT was observed 
in the diabetic control when compared with the normal rats. However, supplementation with 
200mg and 400mg/KgBW of AD led to about 13% increase in the activity of CAT in the treated 
groups when compared with untreated diabetic rats (Figure 6.5A). In addition, the activity of 
SOD was increased by 27% and 25% in the normal rats treated with 200mg and 400mg/KgBW 
respectively when compared with the normal control. There was no significant difference in the 
ORAC, FRAP and TBARS levels in the kidney of diabetic control, treated and normal rats.  
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Figure 0.5: Effect of intervention with AD on the antioxidant capacities; (A) CAT, (B) SOD, (C) ORAC 
(D) FRAP and (E) Lipid peroxidation in the kidney of normal and diabetic rats (TBARS). Bars are 
indicative of mean values ± SEM of group values. Bars with different letters are significantly (p<0.05) 
different from each other. 
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6.3.4 AD modulated hyperglycaemia-induced immune response in the kidney 
Induction of diabetic condition triggered increased inflammatory response in the diabetic rats 
as IL-1β and IL-6 were significantly elevated in untreated diabetic rats (Figure 6.6A & 6.6B). 
Intervention with 400mg AD and 5mg glibenclamide showed a significant reduction in the IL-
1β levels in the treated diabetic kidney. An appreciable decrease (11%) was observed in the 
kidney levels of IL-6 of rats treated with both concentrations of AD and glibenclamide, when 
compared with untreated diabetic rats. There was an 8.6% increase in the kidney levels of IL-
18 in the untreated diabetic rats (Figure 6.6D). However, 200mg and 400mg/KgBW of AD 
significantly abated IL-18 in the kidney of treated diabetic rats by 14.7% and 6.3% respectively 
when compared with the positive control. It is noteworthy that supplementation with 200mg 
and 400mg/KgBW AD decreased IL-18 levels by 12.2% and 10.9% in the normal treated 
kidneys when compared with the normal control rats (Figure 6.6D). This same trend was 
observed in the TNFα levels in the treated normal kidneys (Figure 6.6E). 200mg and 
400mg/KgBW AD curtailed the expression TNFα by 10% and 5% respectively in the non-
diabetic treated rats. Diabetes triggered TNFα response (15%) in untreated diabetic kidney. 
200mg and 400mg/KgBW AD supplementation reduced TNFα by 14.4% and 6.3% respectively 
in treated diabetic rats when compared with diabetic control (Figure 6.6E). IL-10 levels were 
significantly increased in the kidney of diabetic control rats, this was modulated in diabetic rats 
placed on AD extract, when compared to the diabetic control (Figure 6.6C). Similar trend was 
observed in the diabetic rats treated with glibenclamide.  
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Figure 0.6: Effect of AD administration on interleukins (IL) (A) IL-1β, (B) IL-6, (C) IL-10 (D) IL-18 and 
(E) TNF-alpha in the kidney of normal and diabetic rats. Bars are indicative of mean values ± SEM of 
group values. Bars with different letters are significantly (p<0.05) different from each other, while bars 
with *** is significantly different at p<0.0001. 
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6.3.5 Effect of AD supplementation on transcription factors in normal and 
diabetic rats 
NFkB expressions in the kidney of untreated diabetic rats were upregulated as depicted by the 
35% increase in the MFI when compared with the normal control rats (Figure 6.7B). 
Management with 200mg and 400mg/KgBW of AD brought about 50% and 25% reduction in 
the NFkB/p65 levels in the treated diabetic kidney. Treatment with glibenclamide also led to 
43% reduction in the expressions of NFkB/p65. This was comparable to the levels observed 
in the normal rats (Figure 6.7B). The expressions of Nrf2 were significantly enhanced in the 
treated normal rats placed on 200mg and 400mgKgBW of AD (Figure 6.7A). This was 
significantly dwindled (40%) in the untreated diabetic rats. Intervention with 200mg and 
400mg/KgBW AD elevated Nrf2 expressions (40% and 27.3% respectively) in the treated 
diabetic kidney (Figure 6.7C). A similar upregulation (33%) was observed in the groups placed 
on 5mg/KgBW glibenclamide. 
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Figure 0.7: (A) Confocal microscopy image showing the effect of AD on the expression of NFkB/p65 
(red) and Nrf2 (green) in the kidney tissues. Quantitative analysis of (B) NFkB/p65 and (C) Nrf2 
expression in the Kidney tissues. Bars are indicative of mean values ± SEM of group values. Bars with 
different letters are significantly (p<0.05) different from each other. 
 
6.3.6 AD administration upregulated the expressions of Anti-apoptotic proteins 
in diabetic rats 
The induction of diabetes altered Bcl2 expressions in the untreated diabetic kidneys. This led 
to a significant decline in the MFI of Bcl2 in the untreated diabetic rats when compared with 
normal control rats (Figure 6.8A). A regimen of 200mg and 400mg/KgBW of AD significantly 
restored the Bcl2 levels as comparable to the observed levels in the normal control rats (Figure 
6.8B). STZ-induction of diabetes or treatment with AD did not have any significant effects on 
the expressions of caspase 3 (Figure 6.8A & 6.8C). 
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Figure 0.8: (A) Fluorescence micrographs showing the effect of AD intervention on apoptotic markers 
in the kidney tissues of normal and diabetic rats. Quantification of the level of expression of (B) 
caspase 3 and (C) Bcl2 in the kidney tissues. 
 
6.3.7 Intervention with AD improved histoarchitecture of the kidney and 
pancreas in type2 diabetes 
Figures 6.9 & 6.10 are representative micrographs of the histological examination in the kidney 
and pancreas tissues of the normal, treated and untreated diabetic rats. Normal control and 
treated normal rats showed normal kidney architecture. Pathological conditions such as 
disappearing of the glomerular tuft comprising of the glomerular capillaries, podocytes and 
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mesangial cells were observed in the kidney tissues of untreated diabetic rats. This led to 
widened Bowman’s space in the diabetic control rats when compared with the kidney of normal 
rats. Furthermore, endothelial cells were markedly detached from the basement membrane of 
the glomerulus in the untreated diabetic kidneys. Loss of tubular cells especially of the proximal 
tubules (PT) and increased blood flux were revealed in the kidney sections of untreated 
diabetic rats. Treatment with 200mg/KgBW showed mild loss of tubular cells in the PT, while 
glomerular capillaries were clearly restored and less occurrence of glomerular shrinkage. 
400mg/KgBW AD ameliorated glomerular and tubular damage in the kidney of treated diabetic 
rats. 400mg/KgBW prevented loss of tubular cells of the proximal tubules and minimized loss 
of glomerular tuft in the treated diabetic rats as comparable to normal. Administration of 
glibenclamide showed widened bowman’s space due to shrinkage of the glomerular tuft and 
moderate loss of tubular cells of the PT. 
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Figure 0.9: Light photomicrographs of haematoxylin and eosin-stained kidney cortex of normal and 
diabetic rats. Double arrows are pointing to the bowman’s capsule and glomerulus (GM), while single 
thin arrows are showing the cells of the distal convoluted tubule (DT). The thick single arrows reveal 
the cells of the proximal convoluted tubule (PT). the blue arrows points at the bowman’s space. 
Magnification 10x (left) and 40x (right). 
 
The histological examination of the pancreatic tissue in the non-diabetic rats showed a normal 
histology of the pancreas (Figure 6.10). The exocrine region clearly distinct from the endocrine 
region as the basement membrane of the islets of Langerhans is visible and the islet appeared 
lightly stained. The shape and structure of the islets is not distorted, and the pancreatic lobules 
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are intact, separated by interlobular and intralobular spaces. The islet was well vascularized 
(double arrows). STZ induction of diabetes revealed pathological changes in both the 
endocrine and exocrine regions of the pancreas in the positive control rats. The structure and 
shape of the islet of Langerhans were distorted as the basement membrane is not visible 
(single arrow), severe destruction of the islet cells especially the beta cells are also observed. 
Vacuolation of the nucleus is seen in almost all the acinar cells and the islet cells. Distortion of 
the berry-like shaped acini was displayed, the pyramidical shape of the acinar cells were also 
distorted. Treated diabetic rats placed on 200mg/KgBW of AD showed a better structured 
acinus, acinar cells and the islet with restoration of beta cells when compared to the untreated 
diabetic rats (Figure 6.10). However, pathological alterations such as moderate vacuolation of 
the acinar and islet cells were seen. Supplementation with 400mg/KgBW of AD restored the 
architecture of the pancreas to normal when compared with the untreated diabetic rats. The 
islets were well vascularized, the structure and shape of the islet were normal, and the 
basement membrane is clearly visible. There was no observable damage such as vacuolation 
in the acinar and islet cells. Also, the structure and shape of the acinar cells were restored. 
Treatment with glibenclamide improved the histology of the pancreas but not comparable to 
normal. The shape of the acini and its cells were moderately distorted, and the basement 
membrane of the islet not distinct enough. 
 
 
 
 
 
176 
 
 
 
 
 
 
177 
 
 
 
Figure 0.10: Light photomicrographs of haematoxylin and eosin-stained pancreatic tissue of normal 
and diabetic rats. Single arrows points to the basement membrane of the islets, while double thin 
arrows are showing the islet capillaries. Arrow heads show vacuolated nuclei in the acinar and islet 
cells. Magnification 10x (left) and 40x (right). 
 
6.4 Discussion 
The current study exhibits the protective effect of AD against organ toxicity, immunotoxicity 
and oxidative stress exerted by STZ on the kidney and pancreas in T2D. Organ weights have 
been used as important markers in investigating the toxicity of xenobiotics 34 and are indicative 
of hypertrophy if significantly increased 35. Relative weight changes of internal organs are 
indices of pathology in the organs 36.  Introduction of fructose and STZ brought about significant 
increase in the relative weight of the kidney and pancreas of diabetic rats. Renal toxicity, 
tubular hypertrophy is known to be reflective of changes in the kidney weight 37. Also, constant 
hyperglycemia results in the formation of AGEs and hyperfiltration leading to glomerular 
hypertrophy 38,39. Administration of AD apparently reduced kidney toxicity as revealed by its 
ability to decrease relative kidney weight by 10%; an improvement over treatment with 
glibenclamide, which had no effect. Similar trends were observed in the relative weight of the 
pancreas in the diabetic control which increased significantly when compared to normal rats. 
However, AD abated abnormally elevated pancreatic weights in treated diabetic rats 
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comparable to glibenclamide. This depicts that AD may be useful in minimising or preventing 
kidney and pancreas toxicity. 
 
Urea and creatinine are one of the major metabolic waste excreted in the urine 3. Abnormal 
levels of urea in the serum is indicative of kidney dysfunction (Mishra et al., 2015). Serum urea 
levels was significantly increased in the diabetic controls when compared to normal rats. There 
were severe pathological changes seen in the glomerulus of the diabetic control such as 
disappearing glomerulus tuft and capillaries, widened bowman’s space which are essential in 
glomerular filtration. Abnormal glomerular filtration may lead to increased urea and creatinine 
in the serum. Also, tubular damage especially in the proximal tubules was observed in the 
kidney tissues of untreated diabetic rats. Proximal tubules are very crucial in the reabsorption 
process as most essential substances in the filtrate including urea are reabsorbed in the 
proximal tubule 3,40. Therefore, the elevated levels of serum urea were likely due to the 
glomerular and tubular damage. Similar results were revealed by other studies 41,42 where 
serum urea was significantly raised in diabetic subjects. Conversely, the administration of AD, 
diminished serum concentration of urea in treated diabetic rats, especially the 400mg/KgBW 
treatment which reduced serum urea by 22.5%. This is expected as 400mg/KgBW of AD 
restored the architecture of the kidney as comparable to normal rats. It is noteworthy that AD 
was more effective in restoring organ function in the diabetic rats than glibenclamide, as 
glibenclamide did not have any reducing effect on the serum urea. Also, corresponding 
pathologies were seen in the tubules and glomeruli of rats placed on glibenclamide.  
 
Oxidative stress triggered by persistent hyperglycemia, play an important role in the 
progression of diabetic nephropathy 39,43. Oxidative stress occurs as a result of imbalance in 
the production of ROS and antioxidants. AD was shown to induce CAT and SOD activities in 
normal rats, thereby improving the antioxidant status in the rats. The significant decline in the 
CAT activity in the untreated diabetic kidneys is indicative of oxidative stress. Contrarily, AD 
elevated CAT levels in the kidneys of treated diabetic rats.  Increased activities of CAT and 
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SOD by AD, suggestively reduced oxidative stress in the diabetic kidneys thereby ameliorating 
injury to cells and resultant cell death that may have occurred as revealed in Figure 6.9. 
Previous studies on the phytochemical content of AD confirmed the presence of antioxidant 
compounds 25. A slight impaired induction of SOD levels was observed in the diabetic control 
which is likely as a response to the hyperglycaemic-induced oxidative stress. Lim and 
colleagues 44 reported a similar finding of impaired induction of SOD and a corresponding 
reduction in SOD activity in diabetic nephropathy. 
 
Increased Nrf2 levels are known to be enhanced by oxidative stress, however, Nrf2 levels can 
be activated by in the presence of phytochemicals with antioxidant ability 45. Supplementation 
with AD stimulated increased production of Nrf2 in normal and diabetic rats (Figure 6.7C). One 
of the possible mechanisms by which AD exerts its antioxidant ability may be that the 
antioxidant compounds present in AD trigger the dissociation of Nrf2/Keap1, activating Nrf2. 
Activated Nrf2 binds to the promoter region of the AREs gene, enhancing the transcription of 
AREs genes that code for antioxidant enzymes such as CAT and SOD. Figure 6.5A showed 
that there was a corresponding increase in the CAT and SOD activities of rats treated with AD, 
which follows the pattern of Nrf2 induction in the same rats. The significant decrease of Nrf2 
observed in untreated diabetic rats concurs with the reduced CAT activities in the same rats. 
Benipal and co-researchers 46 hypothesized that repetitive ROS production downregulates the 
expression of Nrf2. 
 
NFkB activated by oxidative stress; plays a central role in inflammatory mediation and its 
deregulation is strongly associated with inflammatory diseases, hence its role in the 
progression of renal damage 47,48. NFkB expression was upregulated in the kidney of diabetic 
control rats, which was downregulated in the diabetic rats placed on AD. The activation of 
NFkB usually promotes the expression of pro-inflammatory markers and apoptosis. The 
increased production of the inflammatory markers such as TNFα further activates NFkB 
leading to prolonged and persistent inflammatory response 49,50.  
180 
 
Pro-inflammatory indices; IL-1β and IL-6 were significantly increased in the kidneys of diabetic 
control rats when compared to normal rats. Proinflammatory cytokines; IL-1β, IL-6, IL-18 and 
TNFα which play major roles in the development and progression of DN are triggered by 
hyperglycemia and oxidative stress 51. Increased expression of IL-1β in the glomeruli of STZ-
induced diabetes and significant increase of IL-6 in diabetic subjects especially in the 
mesangium, interstitium and the tubules have been documented 52. The study on kidney 
biopsies of DN subjects carried out by Navarro-Gonzalez and Mora-Fernandez 52, showed a 
positive correlation of IL-6 expression in the mesangium and podocytes with glomerular 
injuries. IL-18; a strong proinflammatory agent that influences the production of other 
proinflammatory cytokines (IL-1β and TNFα) is also elevated in DN, which in turn increases 
urinary albumin excretion thereby increasing kidney susceptibility to renal damage 53–56. High 
levels of TNFα in DN patients is implicated in microalbuminuria 53, it promotes the generation 
of ROS locally in cells such as mesangial cells and activates transcription factors, growth 
factors, receptors and other cytokines 3,52 in the renal cells. TNFα can also alter the glomerular 
filtration rate, cause a dysfunction in endothelial permeability and eventual induction of 
apoptosis 3. However, the administration of AD led to decrease in the levels of these markers, 
as comparable to the glibenclamide in the diabetic treated rats. Similar trends were observed 
in the levels of IL-18 and TNFα. Supplementation with AD is a potential therapy against 
inflammation-induced renal injury in T2D as also supported by its suppression of NFkB and 
reduction of pro-inflammatory cytokines in the normal rats (Figures 6.7(A-B) and 6.6(A-E)). 
The abnormal increase in the levels of IL-10 in the diabetic rats may be due to compensatory 
response, this was significantly repressed in the rats administered AD and glibenclamide. 
 
Bcl2 acts as an anti-apoptotic protein, regulates apoptosis and promotes cell survival by 
inhibiting pro-apoptotic proteins 57. Bcl2 also acts as an anti-inflammatory protein by inhibiting 
NFkB and its controlled genes. The expression of Bcl2 was significantly reduced in the 
untreated diabetic rats. Studies have reported decreased Bcl2 expression in diabetic subjects 
17,46. This is expected as poor glycemic control represses the expression of Bcl2 in diabetes 57. 
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Reduced expression of Bcl2 leads to increased inflammation and apoptosis which contributes 
to the progression of renal pathology in diabetic subjects 57. AD regimen significantly restored 
the expressions of Bcl2 to normal in treated diabetic rats. Lau and co-workers 58 investigated 
the underlying mechanisms through which apoptosis occur in DN. They found out that Bcl2-
modifying factor (Bmf); a pro-apoptotic protein is induced by hyperglycemia via ROS and 
growth factor (TGFβ1) and upregulated in diabetic kidneys of rats and humans. Activated Bmf 
translocates from the cytoskeleton to the mitochondria where it binds and inhibits Bcl2 and 
other apoptotic proteins. This ultimately generates mitochondria transmembrane potential, 
which activates the intrinsic signalling pathway of apoptosis. It was also observed that Bmf can 
activate caspase 3 leading to apoptosis 57. 
 
The major pathological alterations observed in the kidney tissues of untreated diabetic rats 
were disappearing glomerular tuft due to loss of podocytes, mesangial cells and glomerular 
capillaries. Also, loss of tubular cells especially the proximal tubules was observed in diabetic 
controls. This was ameliorated in the diabetic rats treated with AD. Apoptotic cell death plays 
a very crucial role in the loss of mesangial cells and podocytes 59,60. Studies have reported the 
apoptotic death of renal tubular cells across various diabetic models such as mice, rats and 
humans 58. One of the main causes of renal and glomerular apoptosis is increased 
inflammation. NFkB; a pivotal inflammatory factor is activated in the podocytes, mesangial cells 
and tubular cells 10. Increased expression and activation of NFkB in these cells results in the 
production of pro-inflammatory factors and eventually apoptosis 49. Decreased apoptosis was 
reported in NFκB tubular epithelial-specific knockout mice due to less activation of NFκB and 
reduced chemokine expression 50. This supports the central role played by NFkB in the 
apoptosis of the tubular and glomerular cells. A strong correlation has been established 
between NFkB activation and the severity of renal disease 10. In addition, the expression of 
Bcl2 is majorly detected in the proximal and distal tubules and in the capsular parietal cells in 
normal rats and humans 17. In this study Bcl2 expression was significantly reduced in the 
kidney parenchyma of diabetic control rats, thereby aiding apoptosis. Figure 6.11 illustrates 
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the suggested mechanisms and pathways that may be involved in the ameliorative effect of 
AD against kidney damage. 
 
 
Figure 0.11: Proposed mechanisms by which AD ameliorates diabetic nephropathy and pancreatic 
damage. AD-Anchomanes difformis. 
 
6.5 Conclusion 
AD enhanced antioxidant status, reduced apoptosis and modulated inflammatory response in 
diabetic nephropathy. These biological activities of AD in the kidney might be a useful tool in 
the prevention and management of diabetic nephropathy and other associated diabetic 
complications. 
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ABSTRACT 
Background 
Progression of diabetes mellitus has increasingly led to several diabetic complications in the 
body system. Diabetes is one of the major factors implicated in reproductive system damage. 
Recent approaches such as the use of medicinal plants have been explored in the 
management of diabetes and its associated complications. Anchomanes difformis has been 
shown to possess anti-diabetic ability. Therefore, this study seeks to investigate the potency 
of Achomanes difformis to ameliorate diabetes-induced reproductive dysfunction. 
Method 
Type 2 diabetes was induced with 10% fructose administration for 2 weeks and intraperitoneal 
injection of 40mg/kgBW of STZ. The 200mg and 400mg/kgBW aqueous extract of 
Anchomanes difformis (leaves) were administered daily for 6 weeks. The impact of diabetes 
and treatment was investigated by estimating sperm concentration, motility indices, viability 
and morphological parameters in the normal, treated and diabetic rats. Histological 
examination of the testes and epididymis was performed.  
Results 
The administration of Anchomanes difformis significantly (p<0.005) increased sperm 
concentration and sperm viability while it also significantly improved the percentage of 
morphologically normal in diabetic rats. Anchomanes difformis also ameliorated impaired 
testicular damage in the diabetic testes when compared to the diabetic controls. 
Conclusion 
The potency of Anchomanes difformis displayed against diabetic-induced damage in the 
reproductive system might be a new and promising tool in the management of male 
reproductive dysfunctions and associated complications that arise in diabetes mellitus. 
 
Keywords:  Anchomanes difformis, concentration, morphology, motility, reproductive, 
streptozotocin, viability   
192 
 
7.1 Introduction 
Diabetes mellitus is one of the many diseases that contribute to male infertility in the present 
age, as an estimated 51% of diabetic subjects are suffering from different sexual dysfunctions 
(Omolaoye & du Plessis, 2018; Han et al., 2019). Oxidative stress; especially hyperglycemia-
induced, has been implicated in the pathogenesis of reproductive complications arising from 
diabetes (Shoorei et al., 2019). Some of the ways by which oxidative stress results in 
reproductive dysfunction include increased lipid peroxidation of PUFA, damaging the sperm 
membrane which are prone to reactive oxygen species (ROS) attack (Aitken, 2017). Increased 
lipid peroxidation further degenerate to DNA damage in the spermatozoa (Makker et al., 2009). 
Furthermore, oxidative stress leads to damage in the reproductive system through other 
mechanisms such as mitochondrial DNA damage and DNA fragmentation (Omolaoye & du 
Plessis, 2018). Other pathways implicated in the pathogenesis of male infertility in diabetes 
mellitus include the production of advanced glycation end products, the progression of diabetic 
nephropathy and endocrine disorder which affects the hormones (Omolaoye & du Plessis, 
2018). 
 
Hormonal control is an important factor in male fertility as spermatogenesis; the processes 
involved in the production and development of spermatozoa from germ cells (Alves et al., 
2013), are controlled and regulated by the hypothalamic-pituitary-gonadal hormones. The 
hypothalamus produces gonado-tropin-releasing hormone (GnRH) which in turn triggers the 
secretion of follicle stimulating hormone (FSH) and luteinising hormone (LH) from the anterior 
pituitary lobe (Manocha et al., 2018). The release of LH stimulates the production of 
testosterone from the Leydig cells, while FSH prompts the Sertoli cells to supply nutrients to 
the germ cells and activate spermatogenesis (Johnson et al., 2019). Any imbalance or 
impairment in this array of hormones can cause dysfunction in the reproductive system. 
Decreased LH and FSH levels have been reported in diabetic conditions (Ballester et al., 2004; 
Arokoyo et al., 2017). 
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The use of streptozotocin (STZ) to induce hyperglycemia-mediated reproductive toxicity has 
been documented (Navarro-Casado et al., 2010; Omolaoye & du Plessis, 2018); Omolaoye 
and du Plessis, 2019), and has been known to affect the antioxidant status, the spermatogenic 
processes, sperm functions and the reproductive organs (Arokoyo et al., 2018; Johnson et al., 
2019). The contributory role of medicinal plants in combating diabetic-induced reproductive 
impairment have been emphasized in recent times. Anchomanes difformis (AD) has a strong 
ethnopharmacological relevance and it is known for its numerous biological activities such as 
its potency against diabetes, nephropathy, inflammation, microbial activities, and 
gastrointestinal pathologies. These folkloric claims have been scientifically established and 
more investigations to explore its other potentials are ongoing (Ahmed, 2018; Udje et al., 
2018). Agyare and colleagues investigated the potentials of leaves and rhizome extracts of AD 
on histamine and serotonin; mediators of acute inflammation (Agyare et al., 2015). AD 
demonstrated more anti-inflammatory ability when compared with aspirin as reference drug 
(Agyare et al., 2015). Adebayo also reported the anti-inflammatory potentials of AD leaves 
against raw-egg albumin-induced inflammation in chicks (Adebayo et al., 2014). An ethanolic 
extract of AD rhizome displayed hypoglycemic effects in alloxan-induced diabetes using Wistar 
rats (Adeyemi et al., 2015). Egwurugwu and co-workers proposed the effect of AD rhizome 
against uterine fibroid showing its ability to modulate female sex hormones implicated in uterine 
fibroid (Egwurugwu et al., 2016). We carried out previous studies on the antioxidant capacities 
and phytochemical analysis of six different extracts of AD, which revealed that AD is a natural 
source of antioxidant with aqueous leaves extract exhibiting the highest antioxidant ability and 
contained the highest concentration of polyphenols (Alabi et al., 2019). Phytochemical 
characterization of the leaves aqueous extract was also performed using ultra performance 
liquid chromatography mass spectrometry (UPLC-MS) and high performance liquid 
chromatography (HPLC). The results showed the presence of bioactive compounds including 
phloridzin, quercetin, rutin, and kaempferol which are antioxidants and have therapeutic effect 
against diabetes, inflammation and apoptosis (Alabi et al., 2019). The antioxidant, 
hypoglycaemic, anti-inflammatory activities of AD and its impact in modulating female sex 
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hormone indicates its potentials in attenuating reproductive dysfunctions associated with 
diabetes. However, no study has investigated the possible effects of AD leaves extract on 
sperm functional parameters as well as, testicular and epididymal damage in diabetes. This 
paucity in the literature was the major drive that led to this study which focusses on assessing 
the ameliorative effect of Anchomanes difformis on reproductive dysfunction mediated by 
diabetes mellitus in male Wistar rats. 
 
7.2 Methodology 
7.2.1 Plant collection and extraction 
The fresh leaves of AD were from the south-western part of Nigeria and authenticated at the 
University of Lagos Herbarium, Nigeria. A specimen was deposited in the herbarium; 
LUH6623. The harvested leaves were dried under shade, ground into fine particles and 
defatted by soaking in n-hexane (10%W/V) for 48 hours. Following defatting, the leaves were 
subjected to a cold-stirred extraction in water (5% W/V) for 48 hours at 2-8oC. The extract was 
pulverised and stored at -20oC. 
 
7.2.2 Ethical consideration 
Ethical approval for this study was granted by the Research Ethics Committee (REC) of the 
Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, 
South Africa (CPUT/HW-REC 2016/A4) and the Ethics Committee for Research on Animals at 
the South African Medical Research Council (SAMRC), South Africa (REF.04/17), where the 
animal experiment was conducted. 
 
7.2.3 Animal care 
Male Wistar rats (n=64) with approximate weights of 180 ± 10g were secured from the Animal 
facility at Stellenbosch University, South Africa. The animals were accommodated at the 
Primate Unit & Delft Animal Centre (PUDAC), SAMRC and acclimatize for 3-4 weeksbefore 
commencement of the study. Housing conditions were controlled: humidity- 45% to 55%, 
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temperature- 22oC to 26oC. They were exposed to normal photo period (12hour dark/12hour 
light) and fed with standard rat chow (SRC). Animal handling, care and other procedures were 
done in accordance with the standard operating procedure of SAMRC PUDAC (SOP No: 2016-
R01) which conforms to the revised South African National Standard for the Care and Use of 
Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008). 
 
7.2.4 Induction of diabetes  
Type 2 diabetes was induced with 10% fructose and streptozotocin (STZ) according to the 
method of Wilson and Islam (Wilson & Islam, 2012). The diabetic model rats were placed on 
10% fructose water ad libitum for two weeks. A single dose of 40mg/kgBW STZ was 
administered intraperitoneally. After 5 days, animals with fasting blood glucose level above 
15mmol/l were considered diabetic. Oral glucose tolerance test (OGTT) was performed to 
confirm insulin resistance. 
 
7.2.5 Experimental design 
Wistar rats with weights ranging from 270-300g was used for this study. The rats were 
randomly grouped into seven with a minimum of eight rats in each (8 rats in normal groups 
and 10 in diabetic groups) as summarised in Figure 7.1. Water served as the vehicle for 
fructose and AD administration, while citrate buffer was the vehicle for streptozotocin. Animals 
in group 1 served as the normal control (NC) and received vehicle only. Animals in group 2 
and 3 are normal rats who received 200 and 400mg/kgBW of AD aqueous extract only (N+AD 
200 and N+AD 400) and served as the treated control. Group 4-7 consist of animals that were 
placed on 10% fructose for 2 weeks followed by streptozotocin (STZ). Group 4 received vehicle 
only (DC), group 5 and 6 were given 200 and 400mg/kgBW of AD aqueous extract (D+AD 200 
and D+AD 400) respectively while group 7 received 5mg/kgBW of gilbenclamide; an 
antidiabetic drug (D+G).  
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Figure 0.1: Experimental design. Water and citrate buffer served as vehicles of administration, AD- 
Anchomanes difformis leaf extract, Glib-glibenclamide (standard antidiabetic drug), STZ- 
streptozotocin 
 
7.2.6 Sample collection  
Rats were anaesthetized by means of 2% isoflurane (Biofarm, Cape Town, South Africa) per 
oxygen (1L/min) inhalation and thereafter terminated via exsanguination. Both testes, 
epididymis and vas deferens were excised. The dissected male reproductive tract was cleaned 
by carefully trimming off all unnecessary blood vessels and fat tissue until all parts of the 
reproductive tract could be clearly seen and differentiated. The cauda epididymis, comprising 
the larger convoluted tubes, was removed and placed in a pre-warmed petri dish containing 
200µL Ham’s F10 (Invitrogen, Cape Town, South Africa). The testes and epididymis were 
washed and weighed accordingly. The relative weights of the testes and epididymis were 
calculated using the body weight of the same rats against the weight of the testes or 
epididymis. 
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𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑒𝑠𝑡𝑖𝑠/𝑒𝑝𝑖𝑑𝑖𝑑𝑦𝑚𝑖𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 =  
𝑇𝑒𝑠𝑡𝑒𝑠/𝑒𝑝𝑖𝑑𝑖𝑑𝑦𝑚𝑖𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 × 100 % 
 
7.2.7 Sperm isolation (Swim out method) 
The swim-out technique was used to select the motile spermatozoa. Small incisions were 
made at the distal end of the cauda epididymis and the motile spermatozoa could swim out of 
the ducts into the surrounding medium (Ham’s F10 supplemented with 3% bovine serum 
albumin). forming a cloud of spermatozoa.   
 
7.2.8 Measurement of sperm concentration and motility 
Semen samples were taken from the edge of the spermatozoan cloud to measure sperm 
concentration, motility and other related parameters. The semen (5 µL) was pipetted into a 
20µm deep chamber Leja slide; SC 20-01-04B (Leja Products B.V., Nieuw-Vennep, The 
Netherlands). The slide was pre-heated on the microscope’s warming stage at 37oC. For 
assessment of sperm concentration, the semen sample was diluted with Ham’s F10 in the ratio 
1:20. To measure sperm motility, 2-10 fields were captured until a total number of 200 
spermatozoa were analyzed. Other motility parameters evaluated include curved-linear 
velocity (VCL), straight-line velocity (VSL), average-path velocity (VAP), beat-cross frequency 
(BCF), linearity (LIN), straightness (STR), oscillation index; also known as wobble (WOB), and 
amplitude of lateral head displacement (ALH). These measurements are presented as an 
average percentage of all the captured fields. The sperm concentration and motility were 
determined with the Rodent SCA® CASA (sperm class analyser, computed assisted sperm 
analysis) system version 6.2.0.15 (Microptic S.L, Barcelona, Spain). Photomicrographs were 
captured with a Basler A602fc digital camera (Microptic S.L, Barcelona, Spain) that was 
mounted (C-mount) onto a Nikon Eclipse 50i microscope (IMP, Cape Town, South Africa), 
equipped with phase contrast optics and a heated stage. 
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7.2.9 Evaluation of sperm morphology and viability 
7.2.9.1 Preparation of sperm smears 
Sperm smears for morphology and vitality were prepared from the swim-out sperm preparation 
after 10 minutes of incubation to confirm the motility of the selected spermatozoa to be 
smeared. 10µL of swim-up sperm was pipetted to make duplicate smears, making it about 
about 2-10 spermatozoa per field when viewed at a 103x magnification. Smears were allowed 
to dry. 
 
7.2.9.2 Morphology 
Dried smears were stained with Rapid SpermBlue (a combination of fixative and stain) 
following the method described by van der Horst and Maree  (Van Der Horst & Maree, 2010). 
Smears were vertically placed into the staining tray (coplin jar) containing SpermBlue for 40-
50 seconds at room temperature. Excess stain/fixative were drained off by holding the slides 
at an angle between 60 to 80 degrees. Slides were washed by slowly dipping in another coplin 
jar containing distilled water for six seconds, excess fluid was allowed to run off on tissues 
paper. Stained smears were dried at room temperature for 24 hours and mounted with DPX. 
Sperm morphology was assessed using SCA® on a Nikon E200 microscope, with a blue filter 
and phase ‘A’ setting, and 60x magnification. Spermatozoa with background staining or that 
overlap another were excluded and a total of fifty spermatozoa were analyzed per slide. Other 
indices associated with sperm morphology were estimated. These include; area, width, angle 
of the head and midpiece, while perimeter, chord and roughness were assessed in the head 
only. 
 
7.2.9.3 Viability 
BrightVit; a nigrosin-eosin based solution (Sigma Aldrich, Cape Town, South Africa) was used 
to stain the sperm smears for the analysis of sperm viability. Briefly, 40µL of BrightVit was pre-
heated to 37°C and mixed with 10µL of semen for 5 minutes at 37°C. The stained smears were 
left to dry in the dark room at room temperature and mounted with DPX. Spermatozoa were 
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viewed at 20x magnification under a light microscope. Percentage viability was calculated as 
the percentage of live spermatozoa from a total of 100 spermatozoa analyzed per slide. Dead 
spermatozoa appeared pink/red due to the eosin stain while live spermatozoa appeared white 
(unstained) due to the ability of the intact membranes to exclude dyes. 
 
7.2.9.4 Sperm deformity index (SDI) 
Sperm deformity index was estimated following the method described by Ahmad and Tariq 
(2011) (Ahmad & Tariq, 2011). SDI was calculated using the sum of sperm morphological 
deformities observed and the total numbers of sperm randomly selected and counted in a 
sperm population. 
 
𝑆𝑝𝑒𝑟𝑚 𝑑𝑒𝑓𝑜𝑟𝑚𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 =  
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑒𝑟𝑚 𝑑𝑒𝑓𝑒𝑐𝑡𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑒𝑟𝑚 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
  
 
7.2.10 Histological analysis of the gonadal tissues 
The testes and epididymis were excised, washed, weighed and fixed in 10% buffered formalin. 
After fixation, the tissues were passed through ascending series of alcohol for dehydration, 
cleared in xylene and embedded in paraffin. Sections (5 µm) of each tissue were 
deparaffinized, rehydrated and stained with hematoxylin and eosin. The stained tissues were 
mounted and examined under a light microscope. 
 
7.2.11 Statistical analysis 
Values are expressed as mean ± standard error of mean (SEM). Data were analysed using 
GraphPad Prism Version 5.00 for Windows, GraphPad Inc., San Diego, California USA. 
Differences between means of groups were determined using one-way analysis of variance 
(ANOVA). The Bonferroni test was used for all pair-wise comparisons. Differences (F values) 
were considered statistically significant at p values less than 0.05. 
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7.3 Results 
7.3.1 Treatment with AD alleviates organ toxicity in the testis and epididymis 
Figure 7.2 presents the weights of the testis, epididymis and their relative weights. Induction 
of diabetes with STZ and fructose resulted in significant decrease in the weight of the 
epididymis in the diabetic controls (Figure 7.2C), while no significant changes were observed 
in the weight of the testes in the normal, diabetic and treated rats (Figure 7.2A). The relative 
testicular weight of the diabetic controls was significantly increased (54.1%) when compared 
with the weights of the testes in the normal rats. Treatment with 200 and 400mg/kgBW of AD 
reduced relative testis weight by 7.8% and 10.4% respectively, while 5mg/kgBW of 
glibenclamide reduced relative testis weight by 4.2% (Figure 7.2B) when compared with the 
diabetic control. Inversely, induction of diabetes led to a significant decrease in the relative 
weight of the epididymis when compared with the epididymis of the normal rats. However, the 
administration of 200 and 400mg/kgBW of AD and glibenclamide significantly increased the 
relative epididymal weight to be comparable to normal (Figure 7.2D).   
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Figure 0.2: : Effect of AD administration on the (A) testicular weight (B) relative weight of the testis 
(C) weight of the epididymis and (D) the relative epididymal weight of normal and diabetic rats. Bars 
are indicative of mean values ± SEM of group values. Bars with different letters are significantly 
(p<0.05) different from each other. 
 
7.3.2 AD improved sperm function in normal and diabetic rats 
 Sperm concentration was significantly reduced in diabetic control rats when compared with 
the normal rats. Supplementation with 200 and 400mg/kgBW of AD significantly restored 
sperm concentration back to normal in treated diabetic rats (Figure 7.3B). Administration of 
200 and 400mg/kgBW triggered a 10% and 28.5% increase respectively in the sperm 
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concentration of normal rats serving as treatment controls. Figure 7.3A is a representative 
micrograph showing the sperm density in the normal, diabetic and treated rats. The sperm 
population in the normal controls (NC) and treated normal rats were densely packed, while it 
was sparsely populated in the untreated diabetic rats (DC). This is the same trend observed in 
the quantitative measurement of the sperm concentration (Figure 7.3B) where treatment with 
AD increased sperm concentration in the non-diabetic treated rats. 
 
The effect of diabetes, treatment with AD and glibenclamide on indices of sperm function and 
quality is presented in Figure 7.4. Sperm morphology was significantly distorted in the 
untreated diabetic rats when compared with the normal rats (Figure 7.3A). Sperm morphology 
of diabetic rats that received 200 and 400mg/kgBW of AD were restored to normal. In addition, 
there was a significant increase in the sperm deformity index (SDI) in the diabetic controls 
when compared with normal rats (Figure 7.3B). SDI was significantly abated to normal with 
200 and 400mg/kgBW AD treatment in treated diabetic rats as well as the standard drug. 
Induction of diabetes also caused a significant decrease in sperm viability of diabetic controls 
(Figure 7.3C). This was significantly enhanced in diabetic rats treated with both concentrations 
of AD, however, 400mg/kgBW increased sperm viability, as comparable to normal. There was 
no significant difference in the percentage progressive sperm motility in normal, diabetic and 
treated rats (Figure 7.3D).  
 
203 
 
NC N+AD 200 N+AD 400
DC
DC
D+AD 200 D+AD 400 DG
A
 
Sperm Concentration
N
C
N
+A
D
 2
00
N
+A
D
 4
00 D
C
D
+A
D
 2
00
D
+ 
A
D
 4
00
D
+G
0
1
2
3
4
5
a
a
a
b
a
a
a
B
Experimental Groups
C
o
n
c
e
n
tr
a
ti
o
n
m
il
li
o
n
/m
l
 
Figure 0.3: Sperm concentration of normal, diabetic and treated diabetic rats; (A) Representative 
micrographs and (B) quantitative graphical representation. Bars are indicative of mean values ± SEM 
of group values. Bars with different letters are significantly (p<0.05) different from each other. Each 
plate in Figure A comprises of four different fields of the semen sample. 
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Figure 0.4: Effect of AD administration on the sperm function indices (A) sperm morphology (B) sperm 
deformity index (C) sperm viability and (D) sperm motility. Bars are indicative of mean values ± SEM 
of group values. Bars with different letters are significantly (p<0.05) different from each other. 
 
7.3.3 AD enhanced sperm velocities and kinematics in STZ-induced diabetes 
Other parameters associated with motility such as velocities, linearity, straightness and 
oscillation index were measured in the semen of normal, treated and untreated diabetic rats. 
The curved linear velocity (VCL) observed in the semen of diabetic rats was not significantly 
different from the normal controls and the treated rats (Figure 7.5A). The straight-line velocity 
(VSL) was significantly reduced in the diabetic controls when compared with the normal 
controls (Figure 7.5B), while VSL was enhanced in the rats treated with 200 and 400mg/kgBW 
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of AD. Spermatozoa of diabetic controls had a 28.5% reduced average path velocity (VAP) 
when compared with spermatozoa from normal rats. An observable increase of 15.7% and 
23.7% in the VAP was noticed in the sperm of rats treated with 200 and 400mg/kgBW (Figure 
7.5C). Linearity (LIN), straightness and oscillation index (WOB) of the spermatozoa were 
significantly affected and decreased in diabetic control. Administration of both concentrations 
of AD improved the LIN, WOB and straightness of the sperm cell in treated diabetic rats 
(Figures 7.6 (A-C)). 
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Figure 0.5: Effect of AD administration on indices of sperm velocities (A) VCL (B) VSL (C) VAP and 
(D) BCF of spermatozoa in normal and diabetic rats. Bars are indicative of mean values ± SEM of 
group values. Bars with different letters are significantly (p<0.05) different from each other. 
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Figure 0.6: Effect of AD administration on sperm kinematics; (A) LIN (B) STR and (C) WOB of 
spermatozoa in normal and diabetic rats. Bars are indicative of mean values ± SEM of group values. 
Bars with different letters are significantly (p<0.05) different from each other. 
 
The impact of STZ-induction of diabetes and treatment on the factors affecting WOB is 
presented in Figure 7.7. ALH was increased by 20% in the diabetic controls and diabetic rats 
treated with 200mg/kgBW when compared with normal rats. The administration of 
400mg/kgBW led to a 25% reduction in the abnormal ALH values in treated diabetic rats 
comparable to normal and standard drug (Figure 7.7A). There were no significant changes in 
the sperm BCF values in the normal, diabetic and treated rats 
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Figure 0.7: Effect of AD administration on indices of oscillation index; (A) ALH and (B) BCF of sperm 
cells in normal and diabetic rats. Bars are indicative of mean values ± SEM of group values.  
 
7.3.4 The Effect of AD administration on sperm morphometric indices in normal 
and diabetic rats 
To further investigate the effect of diabetes, and treatment with AD and glibenclamide, certain 
parameters relating to morphology of the sperm cell were measured in the normal, diabetic 
and treated rats. The arc, width, area, perimeter, angle, roughness and chord of the sperm 
head, together with the area, width and angle of the sperm midpiece were measured (Table 
7.1). Result showed that there are no significant changes in the spermatozoa head and 
midpiece of normal, diabetic and treated rats. 
 
Table 0.1: Morphology parameters of sperm cells from normal and diabetic rats 
HEAD NC N+AD 200 N+AD 400 DC D+AD 200 D+AD 400 D+G 
Arc 21.36±0.14 21.46±0.16 21.23±0.10 20.86±0.21 20.71±0.14 21.20±0.1 20.89±0.14 
Width 1.415±0.02 1.442±0.03 1.513±0.02 1.518±0.03 1.485±0.03 1.500±0.02 1.474±0.03 
Area 18.01±0.26 18.81±0.22 18.82±0.19 18.52±0.19 17.94±0.31 18.55±0.25 18.44±0.38 
Perimeter  45.48±0.33 45.60±0.3 45.36±0.20 44.52±0.37 44.42±0.26 45.23±0.18 44.64±0.31 
Angle  66.18±1.39 63.26±1.39 62.71±1.61 61.81±1.01 62.75±0.80 63.13±0.92 62.75±0.79 
Roughness 0.110±0.00 0.113±0.00 0.117±0.00 0.116±0.00 0.115±0.00 0.116±0.00 0.117±0.00 
Chord 11.34±0.07 11.36±0.16 10.99±0.10 11.12±0.15 10.91±0.13 11.06±0.16 10.86±0.09 
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MID PIECE        
Area 2.19±0.16 2.68±0.13 2.38±0.14 2.70±0.16 2.17±0.11 2.41±0.11 2.62±0.15 
Width  0.67±0.02 0.69±0.02 0.707±0.02 0.701±0.02 0.675±0.01 0.690±0.02 0.702±0.02 
Angle 11.11±0.56 11.44±0.71 10.78±0.43 13.39±0.49 12.16±0.93 11.42±0.68 10.04±0.64 
 
7.3.5 The effect of intervention with AD on gonadal tissues; testis and 
epididymis in STZ-induced diabetes 
Figures 7.8 and 7.9 present the findings from the microscopic examination of the testes and 
epididymal tissues. The normal and treatment control gonadal tissues showed normal 
architecture, the structure of the germinal epithelium and spermatozoa were intact. Autolytic 
changes characterized with vacuolation within the germinal epithelium and loss of the Sertoli 
and germ cells were observed in the testes of diabetic control rats (Figure 7.8). These 
pathological changes led to a severe disruption in spermatogenesis depicted by degeneration 
of spermatogonia, spermatocytes and spermatids. The testes of the rats administered 
200mg/kgBW of AD revealed moderate vacuolation while the testes of rats treated with 
400mg/kgBW had very mild vacuolation. Treatment with AD repaired the germinal epithelium 
of the treated diabetic rats to near normal when compared with the diabetic control. 
 
The structures of the epithelia lining the tubules of the epididymis were clearly seen with nicely 
arranged cilia and high intraluminal sperm density in the normal controls and treated controls. 
In diabetic controls, several sloughed germ cells were observed in the lumen of the epididymis, 
and a reduced sperm density. Also, the brush border; ciliated epithelium was disrupted (Figure 
7.9). Treatment with 200mg and 400mg/kgBW of AD markedly impede sloughing of germ cells 
and restored the epithelium of the epididymis with the cilia visible and nicely arranged. 
Administration of AD further increased the intraluminal sperm density when compared with 
diabetic control. 
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Figure 0.8: Light micrographs of the testes of normal and diabetic rats stained with hematoxylin–eosin 
(x400). The arrowhead reveals vacuolation within the germinal epithelium, the long arrow shows loss 
of germ cells and distorted spermatogenesis (40x Magnification).  
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Figure 0.9: Light micrographs of the testes of normal and diabetic rats stained with hematoxylin–eosin 
(x400). The double arrows reveal sloughed germ cells within the epididymal lumen, while the red 
rectangle focuses on the cilia and brush border of the epithelium of the epididymis. (4x, 10x and 40x 
Magnification).  
 
7.4 Discussion 
Diabetes mellitus is known to affect sexual behaviour and reproductive tract functions which 
ultimately leads to a reduced fertility (Han et al., 2019). Male reproductive irregularities 
associated with diabetes and the ability of various medicinal plants to ameliorate diabetes and 
testicular dysfunction in diabetic rats have been explored (Suresh et al., 2010; Arokoyo et al., 
2018; Shoorei et al., 2019). The findings from this study established the potency of AD in 
ameliorating diabetes-induced reproductive dysfunction. Persistent hyperglycemia resulted in 
significant increase in the relative testicular weight and a significant decrease in the weight and 
relative weight of the epididymis. Similar findings have been reported in diabetic studies 
involving the use of STZ (Arokoyo et al., 2017; Omolaoye et al., 2018). Progression of diabetic 
condition is known to cause significant changes in the weight of the body and internal organs 
including the gonads (Cintra et al., 2017; Han et al., 2019). Disparity in relative organ weights 
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serve as one of the crucial factors in assessing the presence of toxicity and pathology in an 
organ (Akhigbe, 2014; Al-Malki & El Rabey, 2015). The ability of AD to increase the total and 
relative epididymal weight, and also the reduce relative testicular weight in treated diabetic rats 
comparable to standard drug establishes its potency against diabetes induced testicular and 
epididymal toxicity.  
 
There was no significant difference in the percentage sperm motility of the normal, diabetic 
and treated rats. This was also reported in a study conducted by Arokoyo and colleagues 
(Arokoyo et al., 2017) on diabetic-induced reproductive dysfunction. In the present study, it is 
worthy of note that no tail defects were observed in the morphology assessment across the 
groups, especially seeing that the tails are important structures that drive sperm motility (Lehti 
& Sironen, 2017). The absence of tail defects, especially in the diabetic controls might explain 
the non-disparity in the percentage sperm motility in the normal, diabetic and treated rats. 
Interestingly, a significant decrease was observed in the sperm velocities and kinematics of 
untreated diabetic rats and this was significantly increased with AD supplementation in treated 
diabetic rats (Figure 7.5 & 7.6). A very similar result was documented by Mukhopadhyay and 
colleagues, (Mukhopadhyay et al., 2010), where routine semen analyses from patients 
exposed to heavy metals and cigarette smokes showed normal motility. However, further 
probing on CASA system using the same semen samples, showed that VCL, STR and ALH 
which are sperm velocity parameters were significantly reduced.  This highlights the 
possibilities of impaired sperm motion which may not reflect in the overall percentage motility 
but observed in the significant differences in sperm velocities and kinematics as observed in 
the diabetic control rats. Furthermore, STZ administration can affect sperm velocities and 
kinematics (Omolaoye et al., 2018). However, AD seems to prevent these anomalies in a 
similar manner to the standard drug. 
 
A relationship has been shown to exist between sperm velocities, kinematics and 
concentration (Farooq et al., 2018), sperm concentration is negatively correlated to VCL, VSL 
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and VAP. The reported VAP values were twice the VSL values (Figure 7.5B and 7.5C), and 
these are observed in cases of irregular sperm motion path which have significant effects on 
the WOB, STR, ALH and BCF of sperms (Lu et al., 2014). Sperm velocities directly correlates 
to LIN, STR, WOB, ALH and BCF (Farooq et al., 2018), which further strengthens our findings 
in this study. 
 
Sperm concentration, motility, morphology and viability are important factors to consider when 
assessing the sperm or semen quality (de Villiers, 2018). The significant reduction in the sperm 
concentration, viability, morphology and motility parameters in the diabetic controls may be 
linked to impaired spermatogenesis observed in the seminiferous tubules as it affects the 
quantity and quality of the spermatozoa produced (Bo et al., 2015). Spermatogenesis is usually 
disrupted in diabetes through hyperglycemia-induced oxidative stress (Armstrong et al., 1999). 
Antioxidants have shown to increase sperm viability and reduce sperm defects by alleviating 
oxidative stress (Suresh et al., 2010). Phytochemical characterisation carried out on the 
aqueous extract of AD leaves established the presence of bioactive compounds that have high 
antioxidant and antidiabetic properties such as quercetin, kaempferol, rutin, and phloridzin 
amongst others (Alabi et al., 2019). The significant reduction in sperm concentration 
corresponds with the significantly reduced weight of the epididymis and the relative epididymal 
weight as the epididymis stores spermatozoa until maturation.  The ability of AD to improve 
hyperglycemia-induced sperm functions is most likely due to its possession of these bioactive 
compounds. 
 
Male fertility largely depends on the complete development of spermatozoa in the testis and 
their maturation in the epididymis (Yeung & Cooper, 2002), inferentially, sperm quality is 
compromised in the case of pathological alterations in the testis or epididymis. The severe 
pathological features observed in the testis and epididymis of diabetic controls were associated 
with the decreased sperm functions in the same animals. The germinal cells observed in the 
epididymal lumen of diabetic rats were immature germ cells that were sloughed from the 
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germinal epithelium of the testis and were transported with the spermatozoa into the 
epididymis. It is evident from the findings that the level of damage in the germinal epithelium 
of the testes was commensurate to the proportion of sloughed germ cells observed in the 
epididymal lumen of diabetic control rats. These were noticeably reduced in the diabetic rats 
treated with AD. Sertoli cells are potential targets for toxicants (Monsees et al., 2000), severe 
loss of these cells as noticed in our study is possibly due to the administration of STZ. The loss 
of Sertoli and germ cells in the diabetic controls were accountable for the reduced sperm 
production, as the number of Sertoli cells are strongly related to sperm concentration. Sertoli 
cells play a key role in the attachment, development and sustenance of germ cells, they supply 
the nutrients and hormones required by the germ cells (Monsees et al., 2000). Hence, damage 
or the loss of Sertoli cells results in disrupted spermatogenesis, loss of germ cells, decreased 
sperm production and reproductive dysfunction in the diabetic control which was repaired with 
treatment with AD. The potentials of AD to prevent germinal epithelial loss and improve sperm 
quality and functions provides a natural alternative and therapy in attenuating diabetes related 
sexual dysfunctions.  These findings however provide the basis for further studies that will aim 
at investigating the underlying mechanisms by which AD exerts its pro-fertility abilities in 
diabetic and non-diabetic conditions. 
 
7.5 Conclusion 
The potency of Anchomanes difformis displayed against diabetic-induced damage in the 
reproductive system might be a new and promising tool in the management of sexual 
dysfunctions and associated complications that arise in diabetes mellitus. 
 
Acknowledgement 
We would like to thank Temidayo Omolaoye, Division of Medical Physiology, Faculty of 
Medicine and Health Sciences, Stellenbosch University, for her technical support and 
assistance. We would also like to appreciate Mrs Joritha van Heerden, SAMRC, Cape Town, 
for her constant support and advises during the animal experiment. 
215 
 
Funding 
This research was supported by National Research Foundation, South Africa [NRF 105249] 
and Cape Peninsula University of Technology, South Africa [CPUT-RJ23 and CPUT-NRF 
RO22] granted to Professor OO Oguntibeju. The first author also received financial assistance 
in the form of a bursary from DST-NRF [107580 and 116563]. 
 
Declaration of conflict 
The authors do not have any conflict of interest. 
  
216 
 
References 
Adebayo, A.H., Binda John-Africa, L., Grace Agbafor, A., Elizabeth Omotosho, O. & Olusoji 
Mosaku, T. 2014. Anti-nociceptive and anti-inflammatory activities of extract of 
Anchomanes difformis in rats. Pak. J. Pharm. Sci, 27(2): 265–270. 
Adeyemi, O., Makinwa, T.T. & Uadia, R.N. 2015. Ethanol Extracts of Roots of Anchomanes 
difformis ENGL Roots as an Antihyperglycemic Agent in Diabetic Rats. , 1(3): 68–73. 
Agyare, C., Boakye, Y.D., Apenteng, J.A., Dapaah, S.O., Appiah, T. & Adow, A. 2015. 
Antimicrobial and Anti-Inflammatory Properties of Anchomanes difformis (Bl.) Engl. and 
Colocasia esculenta (L.) Schott. Biochemistry & Pharmacology: Open Access, 05(01). 
http://www.omicsgroup.org/journals/antimicrobial-and-antiinflammatory-properties-of-
anchomanes-difformisbl-engl-and-colocasia-esculenta-l-schott-2167-0501-
1000201.php?aid=67887. 
Ahmad, M.O. & Tariq, M. 2011. A study of sperm deformity index at Islamabad. Pakistan 
Journal of Physiology, 7(1): 1–3. 
Ahmed, H.A. 2018. Anchomanes difformis: A multipurpose Phytomedicine. IOSR Journal of 
Pharmacy and Biological Sciences, 13(2): 62–65. 
Aitken, R.J. 2017. Reactive oxygen species as mediators of sperm capacitation and 
pathological damage. Molecular Reproduction and Development, 84(10): 1039–1052. 
http://doi.wiley.com/10.1002/mrd.22871. 
Akhigbe, R.E. 2014. Discordant Results in Plant Toxicity Studies in Africa: Attempt of 
Standardization. Toxicological Survey of African Medicinal Plants: 53–61. 
https://www.sciencedirect.com/science/article/pii/B9780128000182000042 16 April 
2019. 
Al-Malki, A.L. & El Rabey, H.A. 2015. The Antidiabetic Effect of Low Doses of Moringa oleifera 
Lam. Seeds on Streptozotocin Induced Diabetes and Diabetic Nephropathy in Male 
Rats. BioMed Research International, 2015: 1–13. 
http://www.hindawi.com/journals/bmri/2015/381040/. 
Alabi, T.D., Brooks, N.L. & Oguntibeju, O.O. 2019. Antioxidant Capacity, Phytochemical 
Analysis and Identification of Active Compounds in Anchomanes difformis. The Natural 
Products Journal, 09(1). http://www.eurekaselect.com/171785/article. 
Alves, M.G., Martins, A.D., Rato, L., Moreira, P.I., Socorro, S. & Oliveira, P.F. 2013. Molecular 
mechanisms beyond glucose transport in diabetes-related male infertility. Biochimica 
et Biophysica Acta (BBA) - Molecular Basis of Disease, 1832(5): 626–635. 
https://www.sciencedirect.com/science/article/pii/S0925443913000252 23 October 
2019. 
Armstrong, J.S., Rajasekaran, M., Chamulitrat, W., Gatti, P., Hellstrom, W.. & Sikka, S.C. 1999. 
Characterization of reactive oxygen species induced effects on human spermatozoa 
217 
 
movement and energy metabolism. Free Radical Biology and Medicine, 26(7–8): 869–
880. https://www.sciencedirect.com/science/article/pii/S0891584998002755 29 
October 2019. 
Arokoyo, D.S., Oyeyipo, I.P., Du Plessis, S.S. & Aboua, Y.G. 2018. Antioxidant Activities of 
Basella alba Aqueous Leave Extract In Blood, Pancreas, and Gonadal Tissues of 
Diabetic Male Wistar Rats. Pharmacognosy research, 10(1): 31–36. 
http://www.ncbi.nlm.nih.gov/pubmed/29568184. 
Arokoyo, D.S., Oyeyipo, I.P., Du Plessis, S.S., Chegou, N.N. & Aboua, Y.G. 2017. 
Reproductive parameters in streptozotocin-induced diabetic male wistar rats: 
Beneficial role of basella alba aqueous leave extract. Journal of Kerman University of 
Medical Sciences, 24(6): 467–479. 
Ballester, J., Muñoz, M.C., Domínguez, J., Rigau, T., Guinovart, J.J. & Rodríguez-Gil, J.E. 
2004. Insulin-Dependent Diabetes Affects Testicular Function by FSH- and LH-Linked 
Mechanisms. Journal of Andrology, 25(5): 706–719. 
http://doi.wiley.com/10.1002/j.1939-4640.2004.tb02845.x. 
Bo, C., Zhao, W., Jia, Q., Yang, Z., Sai, L., Zhang, F., Du, Z., Yu, G., Xie, L. & Zhang, Z. 2015. 
Effects of α-zearalanol on spermatogenesis and sex hormone of male mice. 
International Journal of Clinical and Experimental Medicine, 8(11): 1–12. 
Cintra, L.T.A., Samuel, R.O., Prieto, A.K.C., Sumida, D.H., Dezan-Júnior, E. & Gomes-Filho, 
J.E. 2017. Oral health, diabetes, and body weight. Archives of Oral Biology, 73: 94–99. 
https://linkinghub.elsevier.com/retrieve/pii/S0003996916302771. 
Egwurugwu, J., Nwafor, A., Chinko, B., Ugoeze, K., Uchefuna, R., Ohamaeme, M. & Ebuenyi, 
M. 2016. Effects of Extracts of Anchomanes difformis on Female Sex Hormones: 
Preliminary Results. Asian Journal of Medicine and Health, 1(6): 1–9. 
http://www.sciencedomain.org/abstract/17400. 
Farooq, U., Malecki, I.A., Mahmood, M. & Martin, G.B. 2018. Correlation between objective 
semen analysis and fertility in Japanese quail. Theriogenology, 115: 23–29. 
https://www.sciencedirect.com/science/article/pii/S0093691X18301511 29 October 
2019. 
Han, X.X., Jiang, Y.P., Liu, N., Wu, J., Yang, J.M., Li, Y.X., Sun, M., Sun, T., Zheng, P. & Jian-
Qiang Yu. 2019. Protective effects of Astragalin on spermatogenesis in streptozotocin-
induced diabetes in male mice by improving antioxidant activity and inhibiting 
inflammation. Biomedicine and Pharmacotherapy. 
Van Der Horst, G. & Maree, L. 2010. SpermBlue®: A new universal stain for human and animal 
sperm which is also amenable to automated sperm morphology analysis. Biotechnic & 
Hostochemistry, 84(6): 299–308. 
218 
 
Johnson, A., Cheng, S.-C., Tsou, D. & Kong, Z.-L. 2019. Attenuation of reproductive 
dysfunction in diabetic male rats with timber cultured Antrodia cinnamomea ethanol 
extract. Biomedicine & Pharmacotherapy, 112: 108684. 
https://www.sciencedirect.com/science/article/pii/S0753332218386566 29 October 
2019. 
Lehti, M.S. & Sironen, A. 2017. Formation and function of sperm tail structures in association 
with sperm motility defects†. Biology of Reproduction, 97(4): 522–536. 
http://academic.oup.com/biolreprod/article/97/4/522/4097575. 
Lu, J.C., Huang, Y.F. & Lü, N.Q. 2014. Computer-aided sperm analysis: Past, present and 
future. Andrologia, 46(4): 329–338. 
Makker, K., Agarwal, A. & Sharma, R. 2009. Oxidative stress and male infertility. Indian Journal 
of Medical Research, 4: 357–367. 
Manocha, A., Kankra, M., Singla, P., Sharma, A., Ahirwar, A.K. & Bhargava, S. 2018. Clinical 
significance of reproductive hormones. Current Medicine Research and Practice, 8(3): 
100–108. https://www.sciencedirect.com/science/article/pii/S2352081718300692 23 
October 2019. 
Monsees, T.K., Franz, M., Gebhardt, S., Winterstein, U., Schill, W.B. & Hayatpour, J. 2000. 
Sertoli cells as a target for reproductive hazards. Andrologia, 32(4–5): 239–246. 
Mukhopadhyay, D., Varghese, A.C., Nandi, P., Banerjee, S.K. & Bhattacharyya, A.K. 2010. 
CASA-based sperm kinematics of environmental risk factor-exposed human semen 
samples designated as normozoospermic in conventional analysis. Andrologia, 42(4): 
242–246. http://doi.wiley.com/10.1111/j.1439-0272.2009.00984.x. 
Navarro-Casado, L., Juncos-Tobarra, M.A., Chafer-Rudilla, M., de Onzono, L.I., Blazquez-
Cabrera, J.A. & Miralles-Garcia, J.M. 2010. Effect of Experimental Diabetes and STZ 
on Male Fertility Capacity. Study in Rats. Journal of Andrology, 31(6): 584–592. 
http://doi.wiley.com/10.2164/jandrol.108.007260. 
Omolaoye, T.S., Skosana, B.T. & du Plessis, S.S. 2018. Diabetes mellitus- induction: Effect of 
different streptozotocin doses on male reproductive parameters. Acta Histochemica, 
120(2): 103–109.  
https://www.sciencedirect.com/science/article/pii/S0065128117303446 16 October 
2019. 
Omolaoye Temidayo, S. & Du Plessis Stefan, S. 2018. Diabetes mellitus and male infertility. 
Asian Pacific Journal of Reproduction, 7(1): 6–14. 
Shoorei, H., Khaki, A., Khaki, A.A., Hemmati, A.A., Moghimian, M. & Shokoohi, M. 2019. The 
ameliorative effect of carvacrol on oxidative stress and germ cell apoptosis in testicular 
tissue of adult diabetic rats. Biomedicine and Pharmacotherapy, 111: 568–578. 
219 
 
Suresh, S., Prithiviraj, E. & Prakash, S. 2010. Effect of Mucuna pruriens on oxidative stress 
mediated damage in aged rat sperm. International Journal of Andrology, 33(1): 22–32. 
http://doi.wiley.com/10.1111/j.1365-2605.2008.00949.x. 
Udje, T.D., Brooks, N.L. & Oguntibeju Oluwafemi O. 2018. Medicinal Activities of Anchomanes 
difformis and its Potential in the Treatment of Diabetes Mellitus and Other Disease 
Conditions.pdf. In M. R. Goyal & A. O. Ayeleso, eds. Bioactive Compounds of Medicinal 
Plants: Properties and Potential for Human Health. New York: Apple Academic Press: 
219–235. 
de Villiers, C. 2018. A comparison between the semen and sperm parameters from the captive-
bred Vervet monkey (Chlorocebus aethiops) and Rhesus monkey (Macaca mulatta). 
Journal of Medical Primatology, 47(4): 211–216. 
Wilson, R.D. & Islam, M.S. 2012. Fructose-fed streptozotocin-injected rat: an alternative model 
for type 2 diabetes. Pharmacological Reports, 64(1): 129–139. 
Yeung, C.-H. & Cooper, T.G. 2002. Acquisition and Development of Sperm Motility Upon 
Maturation in the Epididymis. In The Epididymis: From Molecules to Clinical Practice. 
Boston, MA: Springer US: 417–434. http://link.springer.com/10.1007/978-1-4615-
0679-9_24. 
 
  
220 
 
CHAPTER EIGHT 
8 GENERAL DISCUSSION AND CONCLUSION 
 
8.1 General discussion  
Natural therapy is a promising approach in the prevention and treatment of several ailments 
and diseases prevalent among humans and animals today. The use of medicinal plants in the 
management of diabetes is getting more attention, especially with the increasing prevalence 
of diabetes, its social and economic significance. The preference of alternative medicine over 
conventional drugs is due to its availability, cost effectiveness and little or no associated 
adverse effect (Wang et al., 2003; Fimognari et al., 2006; Hinterthuer, 2008). Anchomanes 
difformis is one of such medicinal plants with strong ethnopharmacological relevance including 
its use in diabetic conditions (Ahmed, 2018). However, there is paucity of scientific evidence 
on its antidiabetic potentials and the underlying mechanisms. Hinged on these, the 
hypoglycemic, hypolipidemic, anti-inflammatory, anti-apoptotic abilities of Anchomanes 
difformis, and its potentials against reproductive dysfunction was investigated in this study.  
 
Trending reports on the biological activities of Anchomanes difformis, its relation to diabetes 
and oxidative stress was reviewed. The aetiology and pathogenesis of type 2 diabetes and 
diabetic complications were critiqued. The present study was partitioned into two; the in vitro 
analyses on the Anchomanes difformis extracts and the in vivo investigations on the effect of 
Anchomanes difformis in diabetic male Wistar rats. 
 
The in vitro phase of this study focused on the screening and selection of the more effective 
plant-part of Anchomanes difformis and its most efficacious extract. This was carried out by 
evaluating antioxidant capacities; ORAC, FRAP and TEAC on three solvent extracts (aqueous, 
ethanol and ethyl acetate) each from the leaves and the rhizome of Anchomanes difformis. 
Quantitative phytochemical analyses of the polyphenolic content, flavonol and flavanol content 
were also conducted on these extracts. HPLC and UP-LCMS was used for identification and 
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characterization of bioactive compounds present in these various extracts. All the six extracts 
demonstrated antioxidant properties and contain polyphenols, flavonol and flavanols. 
However, aqueous extract exhibited the highest antioxidant ability in ORAC, FRAP and TEAC 
assays that were evaluated. This is likely attributed to its polyphenolic content as it contained 
the highest polyphenols. Polyphenols have been positively and strongly correlated with 
antioxidant power (Locatelli et al., 2017) and reported for its biological activities which include 
anti-inflammatory, antidiabetic, antioxidant, anticancer, profertility potentials (Li et al., 2014; 
Abbas et al., 2017). Hence, aqueous extract was selected to further investigate the potentials 
of Anchomanes difformis in diabetes using male Wistar rats.  
 
The in vivo experiment of this study centered on the ameliorative potentials of Anchomanes 
difformis in type 2 diabetes and associated complications in the liver, heart, kidney and 
reproductive system. Fructose and STZ was used to induce type 2 diabetes in male Wistar 
rats (Wilson and Islam, 2012). Treatment with two doses of Anchomanes difformis; 200 and 
400 mg/kgBW was administered in comparison with a standard drug; glibenclamide (5 
mg/kgBW). The ethanolic extract from the rhizome of Anchomanes difformis has been shown 
to exhibit hypoglycemic ability in alloxan-induced diabetes in wistar rats (Adeyemi et al., 2015) 
The results from the in vivo diabetic experiment validated the hypoglycemic activity and 
unveiled the hypolipidemic properties of Anchomanes difformis over the reference drug; 
glibenclamide. Both doses of aqueous leaves extract of Anchomanes difformis significantly 
reduced the blood glucose concentration in the treated diabetic rats, and this was more 
effective than glibenclamide. Constant hyperglycemia led to significant weight loss in the 
diabetic rats. Intervention with both doses of Anchomanes difformis significantly prevented 
weight loss in the treated diabetic rats. 200 and 400 mg/kgBW of Anchomanes difformis 
demonstrated greater capacity to prevent weight loss than glibenclamide. Significant changes 
in the weights and relative weights of organs are reflective of organ toxicity (Tanna et al., 2015). 
Induction of diabetes caused significant increase in the weights of the heart, kidney pancreas 
and testes, while a significant decrease was observed in the epididymis in the diabetic controls.  
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Treatment with Anchomanes difformis reduced the relative weights of the heart, kidney 
pancreas and testes while it increased the relative weight of the epididymis to normal in treated 
diabetic rats.  
 
Oxidative stress plays a pivotal role in the pathogenesis and progression of diabetes (Pan, 
2008). For this study, the oxidative stress level and the antioxidant status in the serum and the 
organs were measured. Lipid peroxidation (TBARS) and GSH-GSSG ratio were measured in 
the serum and the liver respectively, in addition, ORAC and FRAP levels were determined in 
the serum and the liver of normal, diabetic and treated rats. Treatment with Anchomanes 
difformis significantly reduced lipid peroxidation in diabetic rats, while glibenclamide did not 
exhibit any reducing effect. Antioxidant status was also restored to normal in the serum and 
the liver of diabetic rats placed on Anchomanes difformis, as observed by ORAC levels which 
were restored to normal and increased GSH-GSSG ratio. Furthermore, the administration of 
Anchomanes difformis increased tGSH in a dose-dependent manner when compared to the 
normal control rats. Anchomanes difformis also increased ORAC and FRAP levels and 
reduced TBARS levels in non-diabetic rats thereby enhancing antioxidant status and 
diminishing oxidative stress. This suggests that Anchomanes difformis has preventive ability 
against increased oxidative stress. More investigations on the impact of Anchomanes difformis 
in attenuating diabetic hepatopathy, revealed the ability of Anchomanes difformis to 
significantly reduce the leakage of ALP, AST and ALT from the hepatocytes in diabetic treated 
rats. Anchomanes difformis displayed its protective role on the liver by increasing the 
antioxidant status and reducing oxidative stress and prevented further oxidative damage to the 
liver.  The glycemic control displayed by Anchomanes difformis can be attributed to its 
antioxidant and lipid-lowering ability, as these are important factors in persistent hyperglycemia 
(Adeyemi et al., 2015).  
 
The investigations on the impact of Anchomanes difformis in diabetes extended to its 
ameliorative potentials in complications associated with diabetes such as cardiomyopathy, 
223 
 
nephropathy and sexual dysfunctions. Increased oxidative stress, inflammation, and apoptosis 
are implicated in the development of diabetic complications (Miranda-Díaz et al., 2016), 
therefore, the effect of Anchomanes difformis on these factors were assessed in the heart and 
kidney. As a result of the increased oxidative stress, Nrf2; a transcription factor that triggers 
the transcription of antioxidant enzymes was significantly expressed in the heart of diabetic 
controls. This led to the significant, increased production of catalase and SOD in the diabetic 
controls.  An inverse relationship has been established between antioxidant enzymes and 
some inflammatory markers, especially between catalase, IL-1β and IL-6 (Mathy-Hartert et al., 
2008; Gutierrez-Ruiz et al., 2001). The increasing activities of catalase led to a decrease in the 
production of IL-1β and IL-6, this was modulated by intervention with Anchomanes difformis in 
the diabetic treated rats. NFkB; a chief player in the inflammatory response was significantly 
elevated in the heart of diabetic controls which led to a corresponding increase in the 
production of IL-18 in the diabetic hearts. IL-10 levels were also decreased in the diabetic 
controls. NFkB and IL-18 expressions were significantly reduced and IL-10 increased following 
treatment with Anchomanes difformis. NFkB has also been implicated in increased apoptosis 
(Jin et al., 2018), an observable increase in caspase 3 expression and decrease in Bcl2 
expression was seen in the diabetic control. The effect of the administration of Anchomanes 
difformis was also observed on apoptosis, as Bcl2 expression was increased and Caspase 3 
expression was downregulated in the treated diabetic rats. Anchomanes difformis attenuated 
pathological conditions in the heart by down-regulating inflammation and reducing apoptosis 
in the heart tissues.  
 
Furthermore, the effect of Anchomanes difformis in the diabetic kidney damage was assessed. 
The results obtained revealed significant increase in markers of kidney injury and toxicity such 
as urea and relative kidney weight in the diabetic controls. This was reduced in the diabetic 
rats treated with Anchomanes difformis, especially 400 mg/kgBW. Anchomanes difformis 
enhanced the expression of Nrf2 and the activities of catalase in the treatment controls (non-
diabetic rats). The expression of Bcl2 was significantly downregulated in diabetic controls, 
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management with Anchomanes difformis markedly restored Bcl2 to normal levels in diabetic 
treated rats. Increased proinflammatory markers (IL-1β and IL-6), were reduced in diabetic rats 
following treatment with Anchomanes difformis. Anchomanes difformis ameliorated kidney 
damage through antioxidant-mediated roles such as up-regulation of transcription factor Nrf2 
which articulates the expression of antioxidant enzymes. Also, Anchomanes difformis 
modulated inflammatory response and repressed apoptosis in the kidney tissues.  
 
The prevalence of male infertility in prolonged diabetes mellitus prompted the exploration of 
the impact of Anchomanes difformis on sperm function in diabetes (Han et al., 2019). The 
induction of diabetes mellitus led to significant reductions in sperm concentration, viability and 
morphology in the diabetic controls. This was completely reversed to normal level with the 
administration of Anchomanes difformis in the treated diabetic rats. There was no significant 
difference in the percentage motility of the sperm cells in normal, diabetic and treated rats. 
However, further investigations on the velocities and kinematics of the sperm cells revealed a 
significant decrease in the sperm velocities and kinetics in the diabetic rats. This was also 
observed by Mukhopadhyay and colleagues, (Mukhopadhyay et al., 2010), where semen 
routine analyses of sperm cells from patients exposed to heavy metals and cigarette smokes 
showed normal motility. However, further probing on CASA system using the same semen 
samples, showed that VCL, STR and ALH which are sperm velocity parameters were 
significantly reduced. Anchomanes difformis administration had a positive effect on sperm 
velocities and kinematics in the treated diabetic rats. It is interesting to note that Anchomanes 
difformis may possess pro-fertility abilities as depicted by its capacity to increase sperm 
concentration in normal rats administered 200 and 400 mg/kgBW in a dose-dependent 
manner. 
 
Histological examination for any visible pathological changes was conducted in the liver, 
kidney, pancreas, testis and epididymis in normal, treated and diabetic rats.  Histology of the 
liver; the main organ involved in drug metabolism and most affected by it revealed some 
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pathological changes in the diabetic rats such as portal inflammation, steatosis, sinusoidal 
dilatation and centrilobular necrosis. Treatment with 400 mg/kgBW of Anchomanes difformis 
reversed these pathological conditions, while it was significantly reduced in the liver of rats 
placed on 200 mg/kgBW of Anchomanes difformis and this was more effective than 
glibenclamide.  Persistent hyperglycemia resulted in the shrinkage and loss of glomerulus tuft, 
loss of tubular cells, prominently in the proximal tubules, and increased blood flux in the renal 
parenchyma. Treatment with 200 mg/KgBW showed mild loss of tubular cells in the PT, while 
glomerular capillaries were clearly restored and less occurrence of glomerular shrinkage. 400 
mg/KgBW AD ameliorated glomerular and tubular damage in the kidney of treated diabetic 
rats. 400 mg/KgBW prevented loss of tubular cells of the proximal tubules and minimized loss 
of glomerular tuft in the treated diabetic rats as comparable to normal. In the pancreas, STZ 
administration led to distortion in the shape and loss of pancreatic islets, severe destruction of 
the beta cells in the islets and vacuolation in the acinar and islet cells. Intervention with 
Anchomanes difformis improved the structure of the islets of Langerhans and the surrounding 
acinar cells and minimized vacuolation in the treated diabetic rats in a similar manner as 
glibenclamide.  
Prolonged hyperglycemia affected the structure of the testes in diabetic rats as evident by loss 
of Sertoli cells and different spermatogenic phases. The brush border of the epididymis was 
also distorted in the diabetic controls. The administration of Anchomanes difformis enhanced 
spermatogenesis and impeded germinal cell loss in the testes thereby boosting sperm 
functions; sperm concentration, viability, and morphology and repaired the brush border in the 
epididymis. 
 
Summarily, findings from this study revealed that Anchomanes difformis exerts its antidiabetic 
potentials by combating oxidative stress, hyperlipidemia, inflammation and apoptosis which 
are key factors in the aetiology of diabetes and its complications. It is noteworthy that 
Anchomanes difformis displayed preventive roles against oxidative stress, inflammation and 
apoptosis in non-diabetic rats (treated controls) and enhanced antioxidant status and sperm 
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functions. Interestingly, Anchomanes difformis exhibited more ameliorative potentials in this 
model than the reference antidiabetic drug; glibenclamide. 
 
8.2 Conclusion 
This study focused on the medicinal activities of Anchomanes difformis in type 2 diabetes and 
diabetic complications. This study was able to establish the antidiabetic and hypolipidemic 
potentials of Anchomanes difformis. Furthermore, this study was able to demonstrate the 
ability of Anchomanes difformis to ameliorate and delay the progression of diabetic 
complication with its novelty in showcasing the mode of action and mechanisms of 
Anchomanes difformis in type 2 diabetes. This discovery will be a useful tool in the 
management of diabetes and its associated complications. 
 
8.3 Recommendation 
The therapeutic competency of Anchomanes difformis has been established in this study using 
Wistar rats, however, there is the need to consider its efficacy in humans through clinical 
studies. Further research is recommended in this regard. The possible effect of Anchomanes 
difformis on other diabetic complications such as retinopathy, neuropathy and wound healing 
can be explored, especially those related to its folklore. Studies involving the isolation, 
characterization and the biological activities of the bioactive compounds present in 
Anchomanes difformis can be designed, this will help identify the compounds responsible for 
the medicinal properties and if they work in synergy or isolation. 
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 Toyin D. Alabi, Nicole L. Brooks, Oluwafemi O. Oguntibeju (2019). Antioxidant 
Capacity, Phytochemical Screening, and Identification of Active Compounds in 
Anchomanes difformis. The Natural Products Journal, 9(1).  
 Alabi TD, Chegou NN, Brooks NL, Oguntibeju OO (2020). Effects of Anchomanes 
difformis on Inflammation, Apoptosis, and Organ Toxicity in STZ-Induced Diabetic 
Cardiomyopathy. Biomedicines, 8(2):1-22 
 
ARTICLES UNDER REVIEW 
 Toyin D. Alabi, Nicole L. Brooks, Oluwafemi O. Oguntibeju. Improved antioxidant status 
and hepato-protective role of Anchomanes difformis in streptozotocin-induced diabetes 
in male Wistar rats. Journal of Ethnopharmacology 
 Toyin D. Alabi, Nicole L. Brooks, Oluwafemi O. Oguntibeju. Anchomanes difformis 
ameliorated kidney and pancreatic damage in type 2 diabetes? European Journal of 
Integrative Medicine  
 Toyin D. Alabi, Nicole L. Brooks, Oluwafemi O. Oguntibeju. The beneficial role of 
Anchomanes difformis in STZ-induced reproductive dysfunction. Andrologia 
 
CONFERENCES ATTENDED 
 6th Annual Meeting of the International Cytokine and Interferon Society (ICIS); 
“Cytokines 2018”. 27-30 October 2018, Boston, USA. “Anchomanes difformis; a 
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potential solution to increased inflammation in type 2 diabetes and complications” 
Toyin D Alabi, Nicole L Brooks, Oluwafemi O Oguntibeju (poster presentation). 
 6th U6-International Conference; “Research, Innovation and Technology for African 
Development”. 4th-6th September 2018, Cape Town, South Africa. “Improved 
antioxidant status and Protective role of Anchomanes difformis on the liver in type 2 
diabetes” Toyin D Alabi, Nicole L Brooks, Oluwafemi O Oguntibeju (oral presentation). 
 The South African Annual Pharmacology (SAPHARM) Conference; “Advances in 
Pharmacological Sciences”. 1st-4th October 2017, Bloemfontein, South Africa.  
“Antioxidant Capacity, Phytochemical Screening and Identification of active 
compounds in Anchomanes difformis” Toyin D Alabi, Nicole L Brooks, Oluwafemi O 
Oguntibeju (oral presentation). 
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ADDENDUM 3: CHROMATOGRAMS 
Chromatograms of compounds identified in AD, showing the unfragmented, the 
fragmented spectra, the elemental analysis and the UV spectra. 
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Unknown 737 m/z at 5.99 minutes 
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4-Vinylsyringol 
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Chrysoeriol 7-O-glucoside 
Isorhamnetin 3-O-rutinoside 
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Luteolin 
Scutellarein 
Kaempferol 
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Phloridzin  
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Apigenin 6,8-di-C-glucoside 
Chrysoeriol 7-O-apiosyl-glucoside  
Luteolin 7-O-rutinoside  
Kaempferol 3-O-galactoside 7-O-rhamnoside  
Kaempferol 3-O-rutinoside  
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Hispidulin  
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Kaempferol 3,7-O-diglucoside
Kaempferol 3-O-sophoroside
Quercetin 3-O-galactoside 7-O-rhamnoside
Quercetin 3-O-rhamnosyl-galactoside
Quercetin 3-O-rutinoside
254 
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m-Coumaric acid 
o-Coumaric acid  
255 
 
p-Coumaric acid  
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593 m/z at 14.40 minutes: C27H30O15 
 
Sesamol
Protocatechuic aldehyde
2-Hydroxybenzoic acid
3-Hydroxybenzoic acid
4-Hydroxybenzoic acid
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Apigenin   
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Aqueous Leaves 
 
 
Ethanol Leaves 
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Ethyl Acetate Leaves 
 
 
Aqueous Rhizome 
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Ethanol Rhizome 
 
 
Ethyl Acetate Rhizome  
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Combined chromatogram for the six extracts from leaves and rhizome of AD 
 
 
Chromatogram for other compounds likely present in AD 
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ADDENDUM 4: OVERVIEW OF THE IN VITRO AND IN VIVO ACTIVITIES ANCHOMANES 
DIFFORMIS  
Table 1: Phytochemical characterization and antioxidant capacities of AD extracts 
 ORAC FRAP TEAC Polyphenols Flavonols Flavanols Compounds 
Aq 
Leaves 
H* H* H* H* I I 19 
Aq 
Rhizome 
L L* L L L* L 19 
E-OH 
Leaves 
L* I I H H H* 19 
E-OH 
Rhizome  
I L I L I L* 20 
Ethyl-A 
Leaves 
I L L* I I I 16 
Ethyl-A 
Rhizome 
I I I I H I 15 
Aq - aqueous, E-OH - ethanol, Ethyl-A - ethyl acetate, H- high, H*-highest, L-low, L*-lowest 
 
Table 2: The effect of STZ and treatment with AD on antioxidant defense system, oxidative 
stress status and blood glucose in diabetes control and diabetes treated rats 
 Nrf2 CAT SOD ORAC FRAP TBARS tGSH Blood 
glucose 
Liver  _ ↓ NS ↓ NS _ ↓ _ 
Heart ↑ ↑ NS ↓ NS NS _ _ 
Kidney NS NS NS NS NS NS _ _ 
Serum _ _ _ ↓ ↓ ↑ _ ↑ 
After treatment with AD 
Liver  _ ↑ NS ↑ NS _ ↑ _ 
Heart Norm NS NS NS NS NS _ _ 
Kidney NS NS NS NS NS NS _ _ 
Serum _ _ _ Norm NS ↓ _ ↓ 
NS- not significant, Norm-normalized, ↓-decrease, ↑-increase 
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Table 3: The effect of STZ and treatment with AD on the immune response in diabetes control 
and diabetes treated rats 
 NFkB IL-1β IL-6 IL-10 IL-18 MCP-1 TNF-α 
Heart ↑ ↓ ↓ ↓ ↑ NS NS 
Kidney NS ↑ ↑ ↑ ↑ _ ↑ 
After treatment with AD 
Heart Norm Norm Norm Norm Norm NS NS 
Kidney NS ↓ ↓ ↓ NS ↓ NS 
NS- not significant, Norm-normalized, ↓-decrease, ↑-increase 
 
Table 4: The effect of STZ and treatment with AD on apoptosis in diabetes control and diabetes 
treated rats 
 NFkB Bcl2 Caspase-3 
Heart ↑ NS ↑ 
Kidney NS ↓ NS 
After treatment with AD 
Heart ↓ NS ↓ 
Kidney NS Norm NS 
NS- not significant, Norm-normalized, ↓-decrease, ↑-increase 
 
Table 5: The effect of STZ and treatment with AD on sperm functions in diabetes control and 
diabetes treated rats 
 Sperm  
Conc  
Sperm 
Viability  
Sperm 
Morphology 
Sperm Motility Indices 
% motility Velocity/kinematics 
Diabetic 
control 
↓ ↓ ↓ NS ↓ 
Diabetic 
treated 
Norm Norm Norm NS ↑ 
NS- not significant, Norm-normalized, ↓-decrease, ↑-increase 
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Table 6: The effect of STZ and treatment with AD on organ function in diabetes control and 
diabetes treated rats 
 Liver Kidney Heart Testis Epididymis 
 ALP AST ALT TChol Urea Creat Rwt HFABP Rwt Rwt Rwt 
DC ↑ ↑ ↑ ↑ ↑  ↑ ↑ ↑ ↑ ↓ 
DT ↓ Norm Norm Norm ↓ NS NS NS ↓ NS Norm 
NS- not significant, Norm-normalized, ↓-decrease, ↑-increase 
 
 
